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Abstract 
 
Saudi Arabia has amongst the highest incidence of type 2 diabetes in the world, with 
nearly 20 percent of the adult population suffering from the condition. The prevalence 
of vitamin D deficiency in type 2 diabetics has been shown to be twice that of non-
diabetic individuals. Recent studies have shown, over 95 percent of the Saudi 
adolescent population are vitamin D deficient. Pancreatic beta-cells express vitamin D 
receptors, as well as the vitamin-D3–activating enzyme 1-alpha-hydroxylase. Vitamin D 
plays a key role in both insulin production and glucose homeostasis. Supplementation 
with vitamin D could help tackle morbidity in diabetes by decreasing insulin resistance 
and reducing levels of advanced glycation endproducts (AGEs) which contribute to the 
onset and progression of diabetic complications. Despite vitamin D deficiency and 
diabetes being highly prevalent amongst the female Saudi population, the effect of 
vitamin D3 supplementation on improving diabetic outcomes is an area that is currently 
understudied.  
This was a double-blind randomized control study of 156 overweight Saudi females 
with poorly controlled type 2 diabetes mellitus recruited from Al-Noor Hospital in 
Saudi Arabia. Each subject was randomly allocated to either a placebo, 2000 IU/day or 
4000 IU/day vitamin D3 intervention group for 16 weeks. Serum measurements were 
analysed using routine laboratory procedures. Oxidative stress biomarkers, including 
total antioxidant levels, were measured using a colorimetric method. AGEs were 
measured using an AGE reader at baseline and 16 weeks.  
Significant improvements in vitamin D status, HbA1c, LDL and total cholesterol were 
demonstrated after 16 weeks of supplementation (p < 0.001), (p = 0.001), (p = 0.028) 
and (p = 0.049) respectively. There were no statistically significant changes in HOMA-
IR, AGE concentrations, fasting insulin, fasting glucose, HDL-cholesterol and 
triglyceride levels.  
This study suggests vitamin D may have a role in improving outcomes for type 2 
diabetics and slowing the natural progression of the disease. Further research however is 
needed to determine the optimum dose, duration and form of delivery of 
supplementation in order to achieve these effects.  
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Chapter 1. Introduction 
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1.1 General Introduction 
Diabetes Mellitus is a group of metabolic disorders characterised by defects in insulin 
secretion and insulin sensitivity resulting in chronic hyperglycaemia (WHO 2016). 
According to World Health Organisation (2016) statistics, there are over 422 million 
people suffering from diabetes mellitus worldwide. It is the sixth leading cause of 
death globally and the mortality rates amongst diabetic patients are almost double that 
of healthy individuals of the same age (WHO 2014). Furthermore, the long-term health 
complications of diabetes are numerous and include neuropathy, retinopathy and 
nephropathy, as well as atherosclerosis and cardiovascular disease (Alberti and 
Zimmet 1998; Rother 2007).  
1.2 Type 2 Diabetes Mellitus 
Type 2 Diabetes Mellitus (T2DM), also known as non-insulin-dependent diabetes 
(NIDDM), accounts for approximately 90–95% of all diabetic cases (American 
Diabetes Association 2010). Modern sedentary lifestyles containing high calorie diets 
have contributed to a global epidemic of the disease, with global prevalence nearly 
doubling since 1980 (WHO 2016). Saudi Arabia has the fourth highest incidence of 
type 2 diabetes in the Middle East and the seventh highest in the world, with 
approximately 19% of adults aged between 20 and 79 suffering from the condition 
(International Diabetes Federation 2012). Mirroring the global trend, type 2 diabetes in 
Saudi Arabia is also on the rise and the prevalence amongst the population is predicted 
to increase by 39.5% by 2022 (Al-Quwaidhi et al., 2014). 
1.3 Pathophysiology of Type 2 Diabetes 
Type 2 diabetes results from a combination of insulin resistance and inadequate 
secretion (Cersosimo et al., 2014). The pathophysiology is complex, involving an 
interplay between genetic and environmental risk factors that contribute to beta-cell 
failure and the development of insulin resistance (DeFronzo 2009). The results are 
decreased peripheral glucose uptake, utilisation and storage, leading to a state of 
chronic hyperglycaemia (Kahn et al., 1993; Leahy 2005). The length of exposure to 
hyperglycaemia and its severity has been shown to be directly proportional to the 
development of vascular wall impairment and subsequent diabetic complications in 
patients with type 2 diabetes (Fuller et al., 1979; Balkau et al., 1998; UKPDS 1998).  
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Hyperglycaemia disturbs endothelial cell homeostasis, prompting modifications to the 
macro- and microvasculature, including increased generation of reactive oxygen 
species (ROS), enhanced oxidative stress and increased cell membrane permeability 
(Popov 2010). 
1.4 Complications of Diabetes 
The complications associated with diabetes are grouped in to two subsets: 
microvascular disease (damage to small blood vessels) and macrovascular disease 
(damage to larger arteries) and are shown in Figure 1.1. Microvascular complications 
include nephropathy, retinopathy and neuropathy. Macrovascular complications 
include cardiovascular disease, resulting in strokes and myocardial infarction (Fuller et 
al., 1979; Balkau et al., 1998; UKPDS 1998).  
 
1.4.1 Retinopathy 
Diabetic retinopathy occurs in 90% of diabetic patients after approximately 20 to 30 
years from onset of the condition. The most advanced form of the disease affects 60% 
of diabetic individuals (Fong et al., 2003) and it is the leading cause of new diagnoses 
of adult blindness worldwide (Aiello et al., 1998; Frank 2004).  One study has found 
an incidence of 36.1% of diabetic retinopathy in Saudi Arabian patients with a mean 
Figure 1.1: Diagram representing the long-term complications of Type 2 Diabetes 
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duration of diabetes of 13 years (El-Bab et al., 2012). Diabetic retinopathy is a result 
of microvascular damage to the retina and can be classified in two stages: non-
proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) 
(Miura et al., 2004).  NPDR is characterised by thickening of the basement membrane 
of the retina. Eventually this leads to a reduction in pericytes in the retinal blood 
vessels, resulting in haemorrhages and microaneurysms, as shown in Figure 1.2 (Al-
Mesallamy et al., 2011). Pericytes are contractile mesenchymal cells that wrap around 
the endothelial cells of capillaries. They regulate retinal blood flow by controlling 
vascular tone and the lumen size of retinal capillaries (Beltramo and Porta 2013; Wu et 
al., 2003; Kelley et al., 1987). A key histopathological change in diabetic retinopathy 
is the selective loss of pericytes. The exact mechanism by which this occurs is not fully 
understood, however it is thought that basement membrane thickening, systemic and 
local hypertension and the formation of advance glycation end-products contribute to 
pericyte apoptosis and the breaking of the tight structural connections between 
pericytes and endothelial cells (Beltramo and Porta 2013). It has been shown that in 
proliferative diabetic retinopathy, microaneurysms development following pericyte 
loss (Hirschi et al., 1998; Antonelli-Orlidge et al., 1989).  
PDR is characterised by neovascularisation as blood vessels with reduced pericytes 
become more vulnerable to angiogenic factors (Motiejunaite and Kazlauskas 2008). It 
has been shown that a longer duration and increased degree of hyperglycaemia is 
associated with PDR (Park et al., 2008). 
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                                (Adapted from Latter 2014) 
 
1.4.2 Nephropathy 
Diabetes is the most common cause of end-stage renal disease in the developed world 
and 40 to 50% of diabetics will develop nephropathy (Mauer and Chavers 1985). 
Diabetic nephropathy is characterised by glomerular hyper-filtration which leads to 
basement membrane thickening in the renal glomerulus and tubule. Initially, this is 
evidenced by microalbuminuria which advances to proteinuria, a reduced glomerular 
filtration rate and end-stage renal failure as the disease progresses, as shown in Figure 
1.3 (Hong and Chia 1998; Wolf et al., 2003; Coughlan et al., 2005). 
Figure 1.2: Pathogenesis of diabetic retinopathy 
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(Wright 2015) 
1.4.3 Neuropathy 
Diabetic neuropathy is classified as damage to the nervous system and is a common 
complication of diabetes. More than one third of diabetics report experiencing 
neuropathic problems including diabetic ulcers, impotence, pain and incontinence 
(Young et al., 1993). A study of 375 Saudi Arabian diabetic patients with diabetes for 
nine years or more found symptoms of nerve dysfunction in 38% of the study 
population (Nielsen 1998b).  
1.4.4 Macrovascular complications 
Damage caused to the larger arteries in diabetes results in an increased risk of 
cardiovascular disease, peripheral vascular disease and cerebrovascular disease 
(Johansen and Birkeland 2003). The risk of developing cardiovascular disease is 
increased two- to four fold in diabetic patients (Poornima et al., 2006) and is the 
leading cause of diabetic morbidity and mortality (Bucala et al., 1994). Macrovascular 
disease is characterised by endothelial dysfunction and accelerated atherosclerosis 
which develops due to a multitude of factors, including hyperglycaemia, 
hyperlipidaemia, oxidative stress and insulin resistance (Laakso and Lehto 1998; 
Donnelly and Davis 2000; Candido et al., 2003). 
1.5 Pathogenesis of Diabetic Complications  
Several studies have demonstrated chronic hyperglycaemia to be the principal factor in 
the onset and progression of diabetic complications (Stratton et al., 2000; Reusch 
Figure 1.3: Differences between the healthy and diabetic glomerulus 
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2003; Wong et al., 2004). Several biological pathways are initiated by the presence of 
elevated glucose levels and have been implicated in the development of macrovascular 
and microvascular diabetic complications (see Figure 1.4). These include:   
• Polyol pathway 
• Activation of protein kinase C (PKC)  
• AGE formation pathway 
• Oxidative stress   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        (Adapted from Hadi and Suwaidi 2007)                
Decreased antioxidant 
activity 
 
Figure 1.4: Biological pathways resulting in diabetic complications 
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1.5.1 Oxidative stress 
Biological processes in the body create reactive oxygen species (ROS) that are 
damaging to cells and tissues (Skrha 2003). The production of ROS is limited by 
antioxidant defences comprising both endogenous and exogenous elements. Oxidative 
stress is defined as the imbalance between the formation of these reactive oxygen 
species and antioxidant defences (Betteridge 2000). In healthy individuals both the 
generation and inhibition of ROS are balanced, however oxidative stress may arise if 
either the formation of ROS increases or the body’s defensive mechanisms are not 
fully effective (West 2000). Both of these may exist in diabetes where higher ROS 
formation is accompanied by insufficient antioxidant defences (West 2000).  
It has been suggested that diabetes contributes to the production of reactive oxygen 
species through different pathways, which will be discussed in greater detail in this 
chapter. High concentrations of intracellular glucose in endothelial cells have been 
shown to activate ROS production in mitochondria, accelerating glycation and cellular 
damage (Lorenzi 2007). A major target of oxidative stress is the vascular endothelium, 
which plays a vital role in the pathophysiology of diabetic complications (Hadi and 
Suwaidi 2007). Speciﬁcally, oxidative stress increases vascular endothelial 
permeability and promotes leucocyte adhesion, initiating the early stages of diabetic 
microangiopathy (Lum and Roebuck 2001).   
ROS production in healthy individuals is usually balanced by a system of endogenous 
and exogenous scavenger enzymes and antioxidants. Exogenous sources of antioxidant 
scavengers, such as vitamins A, C and E, lipoic acid and carotenoids, can be derived 
from a healthy diet (Jakus 2000). Several potent endogenous antioxidants, including 
superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and 
glutathione reductase (GRed) have been studied both in vivo and in vitro in acute and 
chronic hyperglycaemic conditions (Skrha 2003). These enzymes have been shown to 
work either directly or indirectly to catalyse the removal of ROS, preventing further 
oxidative stress (Maritim et al., 2003). Numerous studies have demonstrated 
significantly reduced antioxidant activity in patients with type 2 diabetes (Illing et al., 
1951; Sundaram et al., 1996; Maxwell et al., 1997; Opara et al., 1999). Furthermore, 
research has shown that in those patients with severely reduced antioxidant levels, the 
incidence of diabetic complications was far greater (Reunanen et al., 1998; Opara et 
al., 1999). 
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1.5.2 Polyol pathway  
The polyol (or sorbitol) pathway explains how glucose is metabolised when 
intracellular levels are elevated (Gabbay et al., 1973; Oates 2002). In states of 
hyperglycaemia, glucose is reduced to sorbitol via aldose reductase (AR) and NADPH 
and then further metabolised to fructose by sorbitol dehydrogenase (Lorenzi 2007). 
This has many implications for diabetic patients. Firstly, the fructose produced can be 
phosphorylated to fructose-3-phosphate which is broken down to 3-deoxyglucosone, 
both of which are powerful glycating agents involved in the formation of advanced 
glycation endproducts (AGEs) (Gonzalez et al., 1988; Szwergold et al., 1990). 
Secondly, the use of NADPH by AR results in less co-enzyme availability for 
glutathione reductase. This enzyme is vital for the maintenance of the intracellular pool 
of reduced glutathione (GSH), a potent antioxidant, lessening the cells capability to 
balance ROS (Barnett et al., 1986). Chronic hyperglycaemia therefore exposes cells to 
oxidative stress, lessens antioxidant defences and increases AGE formation, resulting 
in amplified rates of cellular damage and advancing diabetic vascular complications.   
1.5.3 Activation of protein kinase C 
Many studies have shown activation of the DAG-PKC pathway to be linked to the 
development of diabetic complications (Koya and King 1998). The DAG-PKC 
pathway is one of the most studied of the cellular signalling pathways initiated in 
diabetes. Hyperglycaemia promotes diacylglycerol (DAG) accumulation within cells 
due to an increase in glycolytic intermediate dihydroxyacetone phosphate. This is 
reduced to glycerol-3-phosphate which subsequently increases synthesis of DAG. In 
diabetics, increased levels of DAG have been demonstrated in vascular tissues 
including the retina, aorta, heart and renal glomeruli (Craven et al., 1990; Shiba et al., 
1993).  
DAG is a physiological activator of protein kinase C (PKC), a family of enzymes 
responsible for regulating the function of other intracellular proteins (Inoguchi et al., 
1992; Xia et al., 1994). PKC has been associated with vascular dysfunction, including 
increased permeability and contractility, synthesis of extracellular matrix, cell growth 
and apoptosis, angiogenesis, leucocyte adhesion and superoxide production (Geraldes 
and King 2010). 
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1.5.4 AGE formation pathways 
The formation of advanced glycation endproducts (AGEs) is a major biochemical 
abnormality dominant in diabetes mellitus (Hadi and Suwaidi 2007). In healthy 
individuals, AGEs form at a continuous rate, beginning in early embryonic 
development. In diabetics, however, the increased availability of glucose means AGEs 
form and accumulate at an accelerated rate (Peppa et al., 2003). AGEs have been 
strongly linked to a number of diabetic complications due to their ability to form 
covalent crosslinks between proteins, such as the cellular matrix, basement membranes 
and vascular endothelium, altering their structure and function (Peppa et al., 2003). 
Examination of post mortem aorta samples have, for example, demonstrated aortic 
stiffness to directly correlate with AGE accumulation in the tissue (Sims et al., 1996). 
Other pathogenic features of AGEs involve their interaction with a variety of cell-
surface binding receptors for advanced glycation endproducts (RAGE), initiating cell 
degradation or activation and pro-oxidant, pro-inflammatory actions (Peppa et al., 
2003). 
1.5.4.1 Glycation 
AGEs form through a succession of chemical reactions first described by Maillard 
(Litchfield et al., 1999) in which reducing sugars covalently bind to the free amino 
groups of proteins (Ahmed 2005). The Maillard reaction, as shown in Figure 1.5, 
begins with the nucleophilic addition of the carbonyl group of a reducing sugar to the 
amino group of a protein, producing a glycosylamine, known as the Schiff base. The 
Schiff base is a highly labile compound and therefore undergoes rearrangement to 
form the more stable Amadori product (a ketoamine), of which glycated haemoglobin 
(HbA1c) is the best known (Monnier et al., 1981; Watkins et al., 1985; Yaylayan and 
Huyghues-Despointes 1994; Boel et al., 1995). These initial reactions are 
concentration-dependent and in the presence of low glucose levels, the sugars will 
become detached from the amino groups. Conversely, in chronic hyperglycaemic 
states, the opposite is true and these glycated proteins will undergo further 
fragmentation, creating dicarbonyl intermediates, which eventually give rise to AGEs 
(Monnier 2003; Peppa et al., 2003; Ahmed 2005). 
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(Adapted from Ahmed, 2005) 
1.5.4.2 Autoxidative glycation 
In addition to glycation, autoxidation of glucose also contributes to the production of 
AGEs, as well as free radicals (Wolff et al., 1989). In the presence of transition metals, 
glucose undergoes autoxidation to form an enediol radical (Ahmed 2005). This enediol 
radical then reduces oxygen to form a superoxide radical which itself becomes 
oxidised to a dicarbonyl ketoaldehyde (see Figure 1.6). In turn, the dicarbonyl 
ketoaldehyde can react with protein amino groups to form a ketoimine (a compound 
involved in AGE production), similar to an Amadori product but far more reactive 
(Wolff and Dean 1988). Superoxide radicals combine in a reaction catalysed by 
superoxide dismutase (SOD) to form hydrogen peroxide. When in contact with 
Figure 1.5: Glycation and formation of AGEs  
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transition metals, hydrogen peroxide produces the extremely toxic hydroxyl radical, 
inducing further oxidative damage (Baynes 1991). Whilst glucose autoxidation directly 
increases the formation of ROS, the generation of AGEs by autoxidative glycation is 
also accelerated by the presence of ROS (Stehouwer and Schaper 1996). 
   (Adapted from Ahmed, 2005) 
1.5.4.3 AGE receptors 
Whilst there are many proven AGE receptors, the best characterised and most studied 
of the AGE receptors is the RAGE receptor (see Figure 1.7) (Mackic et al., 1998; 
Schmidt et al., 1999). In diabetes mellitus, the expression of RAGE is increased and 
the interaction between AGEs and their receptor is now considered fundamental in the 
pathogenesis of AGE-induced diabetic complications (Hudson et al., 2002; Ahmed 
2005). These pathological consequences are driven through cellular activation and 
subsequent induction of oxidative stress and other broad signalling mechanisms when 
AGEs bind with RAGE. AGE-RAGE interaction in macrophages has been shown to 
induce the generation of intracellular free radicals and oxidative stress and subsequent 
Ketoimine 
Protein 
H2O2 OH• 
Ketoaldehyde 
Enediol radical 
anion 
Glucose 
Enediol 
AGEs 
O2• + 
O2• 
Figure 1.6: Autoxidative glycation in the presence of transition metals, leading to the 
production of free radicals and AGEs  
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activation of the transcription factor NF-κB (Schmidt et al., 1994; Yan et al., 1994; 
Lander et al., 1997). NF- κB  controls the gene transcription of endothelin-1, tissue 
factor and thrombomodulin and the generation of pro-inflammatory cytokines such as 
interleukin-1 α (IL-1α), interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) 
(Neumann et al., 1999). In addition, there is the enhanced expression of adhesion 
molecules, which lead to increased vascular permeability amongst other effects (Singh 
et al., 2014). AGE interaction with RAGE also triggers the activation of NADPH 
oxidase leading to generation of reactive oxygen species (ROS) and further oxidative 
stress (Wautier et al., 2001). There is also evidence to show that RAGE may be 
directly involved in mediating inflammatory cell recruitment (Chavakis et al., 2003). 
Together, the effects of RAGE activation in endothelial cells, macrophages and smooth 
muscle cells contribute to the pathogenesis of diabetic macrovascular and 
microvascular complications (Ramasamy et al., 2011). 
1.5.4.4 Role of AGEs in pathogenesis of diabetic complications  
A growing body of evidence has demonstrated that AGEs are significant pathogenic 
mediators of nearly all micro- and macro-vascular diabetic complications (Peppa et al., 
2003). The ability of AGEs to alter the structure and function of key proteins in the 
cellular matrix, basement membrane and vascular endothelium is key to their role in 
the pathogenesis of diabetic microangiopathies (Peppa et al., 2003). Furthermore, their 
interaction with RAGE receptors alters intracellular signalling, gene expression, 
release of pro-inflammatory molecules and free radicals that all contribute to the 
pathology of diabetic complications (Ahmed 2005). For example, AGEs have been 
found in the retinal blood vessel walls of diabetic patients and are believed to 
contribute to increased permeability of retinal endothelial cells and vascular occlusion, 
resulting in vascular leakage (Stitt 2003). Furthermore, the severity of retinopathy has 
been shown to directly correlate with serum AGE levels (Peppa et al., 2003). 
In diabetic patients, levels of AGEs were also found to be increased in the axons and 
Schwann cells of peripheral neurones (Sugimoto et al., 1997). In vitro, Schwann cells 
and neuronal cells undergo apoptosis when incubated with AGEs (Takeuchi et al., 
2000; Sekido et al., 2004). This may be due to AGE-induced hypoxia as a result of 
vasoconstriction. Whilst AGEs promote nitric oxide synthase expression leading to an 
increase in available nitric oxide, they have also been shown to directly react with and 
quench nitric oxide. As a result, vasoconstriction occurs and there is consequently 
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reduced blood flow to peripheral nerves (Amore et al., 1997; Bucala et al., 1991; 
Chakravarthy et al., 1995; Amore et al., 1997). AGEs also modify neurofilaments and 
tubulin, which are structures involved in nerve signalling along axons. This causes a 
disturbance in axonal transport, which contributes to the development of atrophy and 
degeneration of neurone fibres typical of diabetic neuropathies (Wada and Yagihashi 
2005; Vlassara et al., 1981).   
Several studies have demonstrated AGE levels in the kidney to be higher in diabetic 
patients compared to healthy subjects (Miyata et al., 1997; Monnier et al., 1999; Weiss 
et al., 2000; Miura et al., 2003; Monnier et al., 2005; Yoshida et al., 2005). The 
characteristic structural changes of diabetic nephropathy, including thickening of the 
glomerular basement membrane and mesangial expansion, can all be attributed to the 
action of AGEs in the nephron (Peppa et al., 2003). AGEs accumulate on collagen in 
the basement membrane, trapping plasma proteins and contributing to basement 
membrane thickening. This leads to altered filtration and ultimately loss of glomerular 
function (Monnier et al., 1992). Mesangial cells, which modulate glomerular filtration, 
express RAGE on their cell surface. In vitro, AGE-RAGE interaction can stimulate 
mesangial cells to produce matrix proteins (Dworkin et al., 1983; Schlondorff 1987; 
Skolnik et al., 1991). This results in expansion of the mesangial matrix and is thought 
to be one of the main factors in diabetic renal impairment due to the effect on 
glomerular filtration (Steffes et al., 1989).   
AGEs have been identified in atheromatous plaques in the coronary arteries of diabetic 
subjects, implicating a role for AGEs in the formation of atherosclerosis and 
cardiovascular disease (Obayashi et al., 1996). Endothelial cells, smooth muscle cells 
and monocytes have been shown to express RAGE receptors. The interaction of AGE 
with RAGE receptors within these cells induce inflammatory response pathways, 
atherogenesis and vasoconstriction. Eventually, this leads to atherosclerosis, 
thrombosis and coronary dysfunction as demonstrated in the macrovascular 
complications of diabetes (Hartog et al., 2007).  
1.5.5 Dyslipidaemia 
Dyslipidaemia is one of the major causes of cardiovascular disease in diabetes mellitus 
(Mooradian 2009). Type 2 diabetes is associated with characteristically high plasma 
triglyceride concentrations, low high density lipoprotein (HDL) concentrations, and 
15 
 
increased small dense low density lipoprotein concentrations (sdLDL) (American 
Diabetes Association 2003). The exact mechanisms of diabetic dyslipidaemia are still 
poorly understood, however growing evidence suggests that insulin resistance has a 
crucial role in the pathogenesis of the condition (Mooradian 2009).  
1.5.5.1 Pathogenesis of diabetic dyslipidaemia 
The fundamental features of diabetic dyslipidaemia can be explained by increased free 
fatty-acid release from insulin-resistant adipose tissues (Taskinen 2003; Krauss and 
Siri 2004; Del Pilar Solano and Goldberg 2005; Chahil and Ginsberg 2006). In a 
healthy individual, when insulin binds to the insulin receptors on adipocytes, the 
activity of hormone-sensitive lipase (HSL) within the cell is suppressed (Frayn and 
Coppack 1992; Kershaw et al., 2006). In the presence of insulin resistance, HSL is not 
suppressed, leading to the hydrolysis of triglycerides to free fatty acids and glycerol 
(Frayn and Coppack 1992). Free fatty acids are released into the circulation and travel 
to the liver. In the state of insulin resistance, the increased flux of free fatty acids into 
the liver stimulates triglyceride production, which in turn promotes the secretion of 
apolipoprotein B (ApoB). Apolipoprotein B is a large protein which is the major 
component of very-low density lipoprotein (VLDL) cholesterol (Mooradian 2009). 
When the ability of insulin to inhibit free fatty-acid release is impaired, VLDL 
cholesterol production increases, leading to enhanced hepatic fat accumulation (Frayn 
2001; Adiels et al., 2007). 
The increased numbers of VLDL cholesterol particles and increased plasma 
triglyceride levels decrease the level of HDL cholesterol and increase the concentration 
of small dense LDL-cholesterol particles via several processes (see Figure 1.8). Firstly, 
cholesteryl ester transfer protein (CETP) acts on VLDL-transported triglyceride, 
substituting it for HDL-transported cholesteryl ester. This results in increased amounts 
of both atherogenic cholesterol-rich VLDL remnant particles and triglyceride-rich, 
cholesterol-depleted HDL particles. The triglyceride-enriched HDL is subsequently 
hydrolyzed by hepatic lipase in the liver and readily absorbed by hepatocytes, lowering 
circulating concentrations of HDL cholesterol in the blood (Mooradian et al., 2004; 
Mooradian et al., 2008). 
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The increased concentration of sdLDL cholesterol can also be explained by a similar 
lipid exchange process. CETP once again facilitates the transfer of triglyceride to LDL 
and cholesteryl ester to VLDL, resulting in increased levels of triglyceride-rich LDL. 
Triglyceride-rich LDL then undergoes hydrolysis by hepatic lipase in the liver, 
producing sdLDL. The sdLDL particles have a lower affinity for hepatocyte receptors 
and therefore there is reduced hepatocyte clearance and increased circulating levels of 
sdLDL in the blood (Mooradian 2009).   
LPL = lipoprotein lipase; TG = triglycerides; ApoB = apolipoprotein B; VLDL = very low density 
lipoprotein; CE = cholesteryl ester; CETP = cholesteryl ester transfer protein; HL = hepatic lipase; LDL 
= low density lipoprotein; SD LDL = small density low density lipoprotein; FFA = free fatty acids                                                                                             
(Mooradian 2009) 
1.5.5.2 Complications of diabetic dyslipidaemia 
Atherosclerosis is the most severe consequence of diabetic dyslipidaemia and is the 
leading cause of death in diabetic patients (Ahmed 2005). It is characterised by 
formation of atherosclerotic plaques within the arterial endothelium, leading to 
occlusion of blood flow and hypertension, and eventual myocardial cell death. Raised 
concentrations of LDL leads to accelerated atherosclerosis through several 
mechanisms. In healthy individuals, circulating levels of LDL are recognised by 
receptors on hepatocytes in the liver and cleared from the bloodstream. However, in 
diabetic patients there is increased glycation and oxidation of LDL particles (Ahmed 
2005). This impairs hepatic clearance as glycated and oxidised LDL (ox-LDL) 
particles are not recognised by the native LDL receptor (Skrha 2003). Instead, the 
Figure 1.7: The role of insulin resistance in diabetic dyslipidaemia  
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modified LDL molecules are bound by scavenger receptors on macrophages and their 
subsequent transformation into foam cells is accelerated (Skrha 2003). The deposition 
of these foam cells within the arterial endothelium provides the basis for the formation 
of atherosclerotic plaques and the initial manifestations of cardiovascular disease 
(Ahmed 2005).   
1.6 Prevention of Diabetic Complications 
Complications of diabetes are a significant public health burden leading to increased 
morbidity and a decrease in life expectancy (Gu et al., 1998). Diabetic patients with 
low fasting plasma glucose (FPG) have been found to have a significantly decreased 
risk of both microvascular and macrovascular complications when compared with 
those with a higher FPG (Colagiuri et al., 2002). In order to diagnose diabetes a FPG 
of 126 mg/dl or a 2-hour postprandial plasma glucose level of 200 mg/dl is required 
(WHO, 2006). In type 2 diabetes there is an increase in glycaemic levels as the disease 
progresses and studies have shown that patients who present with a lower HbA1c at 
diagnosis experience fewer diabetic complications (Colagiuri et al., 2002). 
Consequently, intensive glycaemic control is vital in the prevention and delayed 
progression of diabetic retinopathy, neuropathy and nephropathy, as well as 
cardiovascular disease (Keen 1994; Molyneaux et al., 1998; Stratton et al., 2000). 
Whilst maintaining adequate glycaemic control will remain the mainstay of diabetic 
treatment, research has begun to consider developing alternative therapies for halting 
the progression of diabetic complications (Bonnefont-Rousselot 2001). One such 
therapy is the use of certain dietary antioxidants aimed at inhibiting AGE formation 
alongside reducing oxidative stress and dyslipidaemia (Golbidi et al., 2011). 
1.6.1 Exogenous antioxidants 
Many studies have established that oxidative stress, facilitated by hyerglycaemia-
induced free radical production, worsens the progression of diabetes and its related 
complications. It has therefore been suggested that diabetic patients may benefit from 
supplementation with exogenous antioxidants to ameliorate free radical oxidation and 
the subsequent development of micro- and macrovascular complications (Aruoma 
1998). Antioxidant supplementation has also been shown to improve hyperglycaemia 
and insulin efficiency, as well as limiting the oxidation of low-density lipoproteins 
vital to the atherogenesis process (Bonnefont-Rousselot 2001). Furthermore, some 
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antioxidants are able to fight against the harmful effects of AGEs either by preventing 
their cellular action or by inhibiting AGE formation altogether (Ahmed 2005). These 
findings have prompted several clinical trials using antioxidant supplements in diabetic 
patients to limit the long-term complications of the disease. To date the antioxidant 
properties of vitamins E and C, and more recently vitamin D, have been studied with 
thus far inconclusive results (Golbidi et al., 2011).  
1.7 Vitamin D   
Whilst the regulation of calcium homeostasis and bone metabolism are the most 
widely recognised functions of vitamin D, there is an increasing appreciation for its 
non-calcaemic properties; one of the least studied of which is its use as an antioxidant 
(Halicka et al., 2012). Numerous cross-sectional studies have demonstrated low serum 
concentrations of vitamin D to be associated with higher fasting blood glucose levels, 
increased insulin resistance and a greater risk of developing type 2 diabetes 
(Saedisomeolia et al., 2013). Initial interventional studies investigating the effect of 
vitamin D supplementation on diabetic outcomes have to date provided inconsistent 
results (Raghuramulu et al., 1992; Orwoll et al., 1994; Taylor and Wise 1998; De Boer 
et al., 2008; Bonakdaran and Afkhami Zadeh 2011; Nikooyeh et al., 2011; Al-Daghri 
et al., 2012; Tayebinejad et al., 2012; Nikooyeh et al., 2014; Tabesh et al., 2014; 
Mohamad et al., 2015). 
1.7.1 Structure and function  
Vitamin D (calciferol) is a group of steroids which are fat-soluble and regulate many 
biological functions including calcium homeostasis, cell proliferation and 
differentiation and immune function (Holick 2007; Tsiaras and Weinstock 2011). The 
two most important compounds of vitamin D are vitamin D2 (ergocalciferol) and 
vitamin D3 (cholecalciferol). The structure of these two compounds is very similar as 
demonstrated in Figure 1.9. Studies have shown vitamin D2 to be less biologically 
active than vitamin D3 (Lehmann et al., 2013). 
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                                               (Holick 2007) 
There are two main sources of vitamin D: diet and sunlight. However, very few 
naturally occurring foods contain either vitamin D2 or vitamin D3 and therefore in 
many countries foods such as cereals, milk and butter are often fortified with an 
artificial form of the vitamin (Holick 2004; Holick 2007). The majority of vitamin D 
comes from ultraviolet B radiation from sunlight (Holick 1994). 
Cholecalciferol (D3) is synthesised in the skin layers from 7-dehydrocholesterol when 
exposed to ultraviolet (UV) light in the wavelength range 280-320nm (Neyestani 
2013). This form of vitamin D is biologically inactive and cannot be utilised by cells 
until converted to 1,25-dihydroxycholecalciferol (1,25(OH)2D3) (see Figure 1.10) 
(Jones et al., 1998; Holick 2007; Holick 2009). This process of vitamin D metabolism 
occurs through two hydroxylation reactions in the liver and kidneys to produce 
25(OH)D3 and 1,25(OH)2D respectively. Cytochrome P450 mixed-function oxidases 
(CYPs) are responsible for these reactions. CYP2R1, found in the endoplasmic 
reticulum of hepatocytes, is the key enzyme for 25-hydroxylation and produces 
25(OH)D3. 25(OH)D3 is then transported to the proximal tubules of the kidneys where 
CYP27B1, the sole enzyme for 1α-hydroxylation, found in the mitochondria converts 
it to 1,25(OH)2D. Another important CYP is CYP24A1, which is responsible for 
catabolizing both 25(OH)D3 and 1,25(OH)2D (Bikle 2013). 
Active vitamin D is an unstable molecule and will rapidly degrade unless bound to the 
vitamin D binding protein (VDBP) in the bloodstream. It is the high affinity of active 
vitamin D for this binding protein that gives it many of its biological properties 
(Andress 2005). Once the active vitamin D-VDBP complex reaches a target cell, it 
must be released from the binding protein. Most tissues of the body have a vitamin D 
receptor (VDR) (located on chromosome 12q13.11) which uptakes the active vitamin 
Figure 1.8: The chemical structure of vitamin D2 and D3 
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D once released in the target cell (Institute of Medicine Committee to Review Dietary 
Reference Intakes for Vitamin 2011; Lee et al., 2011). Once bound to the VDR, active 
vitamin D can interact with other transcriptional factors within the target cell nucleus, 
affecting gene transcription. One such factor is the retinoid X receptor which allows 
recognition of, and binding to, vitamin D responsive elements in the regulatory 
sequences of genes under the control of vitamin D (Haussler et al., 2013). This in turn 
alters gene expression and cellular activities within the target cell, including protein 
synthesis and secretion (Neyestani 2013). 
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Figure 1.9: The conversion of inactive vitamin D to its biologically active form  
                                                     (Holick 2007) 
1.7.2 Factors affecting vitamin D status 
In 2008 it was estimated one billion people were diagnosed with vitamin D deficiency 
(James 2008). One recent study concluded that serum vitamin D concentrations were 
below satisfactory (30 ng/ml) in every region of the world, however severe deficiency 
(concentration below 10 ng/ml) was found to be most prevalent in South Asia and the 
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Middle East (Mithal et al., 2009).  Lower concentrations of circulating 25(OH)D have 
been associated with increasing age, gender, dietary customs, latitude, exposure to 
sunlight and skin pigmentation (Holick 2004). In Saudi Arabia, the prevalence of 
vitamin D deficiency (defined as less than 20 ng/ml) in females has been estimated to 
be between 30% and 85% depending on the study size, age group, season and region 
studied, as shown in Table 1.1.  
 
Table 1.1: Prevalence of low vitamin D status amongst the Saudi population 
  
 
 
 
 
 
 
 
 
 
 
 
Low concentrations of vitamin D in the Saudi population have been noted since the 
1980s (Sedrani et al., 1983; Fonseca et al., 1984), and this may in part be due to 
cultural attitudes, religious observances and dietary habits. Saudi Arabia is a Muslim 
country where women adopt religious dress such as the niqab (full-face veil) and hijab 
(head scarf) and clothing which only exposes the hands and occasionally face. One 
study has found no difference in the serum concentrations of vitamin D between veiled 
and non-veiled women; this is likely due to the face and hands contributing little to the 
cutaneous synthesis of vitamin D (Ardawi et al., 2011).  
Study paper Study 
Population 
N= sample 
size 
Study Design 
 
Percentage of vitamin 
D deficiency 
(<20 ng/ml) 
AlBuhairan et 
al., (2015) 
Saudi 
adolescents 
(n=12,575) 
Cross-sectional 95.6% 
Kanan et al., 
(2013) 
Saudi 
females 
(n=1556) 
Retrospective Premenopausal (80%-
summer, 85%-winter) 
Postmenopausal (60%-
summer, 76% winter) 
Ardawi et al., 
(2011) 
Saudi 
Females 
=1172 
Cross-sectional 80% 
Siddiqui and 
Kamfar, 
(2007) 
Saudi female 
adolescents 
N=43 
Cross-sectional 81% 
Al-Turki et al., 
(2008) 
Saudi 
Females  
N=100 
Cross-sectional 25-35yrs (30%) 
>50 yrs (55%) 
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Sun exposure in Saudi Arabia may be avoided in part due to the cultural attitude to 
favour pale skin colour, along with increased urbanisation (Kanan et al., 2013). In 
addition to this, melanin in the skin reduces vitamin D synthesis and therefore the 
darker the skin pigmentation, the lower the production of vitamin D for the equivalent 
sun exposure (Menon et al., 2013). Dietary intake of vitamin D is dictated by two main 
factors: dietary preference and concentration of vitamin D fortification in processed 
foods. One study comparing the levels of vitamin D fortification in certain foods such 
as cereals or orange juice in America and Saudi Arabia concluded that many of the 
Saudi Arabian versions were not fortified at all, and even those that were contained 
less fortified vitamin D than the recommended levels in the USA (Sadat-Ali et al., 
2013). 
1.7.3 Vitamin D and diabetes 
The prevalence of vitamin D deficiency in type 2 diabetics has been found to be almost 
double that in non-diabetic subjects (Scragg et al., 1995; Isaia et al., 2001; Scragg et 
al., 2004; Al-Zahrani 2013).  The risk factors for vitamin D deficiency and type 2 
diabetes are often shared and include greater BMI, increasing age, and lack of physical 
activity (Brancati et al., 2000; Saintonge et al., 2009). Seasonal fluctuations in glucose 
and insulin concentrations have also been demonstrated (Desouza and Meier 1987). 
This may, at least in part, be due to variations in 25(OH)D concentrations resulting 
from shorter durations of sun exposure in cold seasons (Pittas et al., 2007b). 
Furthermore, research has demonstrated that when accompanied by vitamin D 
deficiency, type 2 diabetes is associated with a greater risk of cardiovascular mortality 
(Cigolini et al., 2006; Joergensen et al., 2010).  
These observations have led to a need for randomised clinical trials to investigate the 
actual effects of vitamin D intake on the glycaemic status of type 2 diabetics. From 
such studies, several theories for the mechanisms of action of vitamin D in diabetes 
have been established. Firstly, vitamin D has been shown to improve markers of 
glycaemia via increased insulin secretion and reduced peripheral insulin resistance (Al-
Daghri et al., 2012; Soric et al., 2012; Talaei et al., 2013; Labban 2014; Nasri et al., 
2014; Tabesh et al., 2014; Yousefi Rad et al., 2014; Mohamad et al., 2015). Secondly, 
an improvement in the lipid profiles of type 2 diabetics has been demonstrated when 
supplemented with dietary vitamin D (Raghuramulu et al., 1992; Bonakdaran and 
Afkhami Zadeh 2011; Al-Daghri et al., 2012; Tabesh et al., 2014; Mohamad et al., 
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2015). Finally, vitamin D has been shown to upregulate endogenous antioxidants and 
therefore may have the potential to attenuate oxidative stress in diabetic individuals 
(Bao et al., 2008). 
1.7.3.1 Vitamin D and glycaemia 
Several mechanisms have been proposed to explain how vitamin D may improve 
markers of glycaemia in diabetic patients. The discovery of the vitamin D receptor on 
pancreatic beta cells, as well as the presence of a vitamin D response element (VDRE) 
within the promoter region of the insulin gene, have provided robust evidence for a 
causal relationship between the vitamin and insulin production (Johnson et al., 1994; 
Bland et al., 2004). Furthermore, 1,25(OH)2D has been shown to directly activate 
transcription and regulate the expression of the insulin receptor, suggesting vitamin D 
has a role in insulin resistance as well as production (Maestro et al., 2000; Maestro et 
al., 2002).  
Pancreatic beta cells are known to express the vitamin D receptor (VDR). One 
hypothesis is that circulating 1,25(OH)2D binds to the VDR on pancreatic beta cells, 
initiating a direct cellular response from the vitamin D response element in the 
promoter region of the insulin gene. This in turn increases the transcription of the 
insulin gene, and therefore the secretion of insulin from the cell (Maestro et al., 2003), 
as shown in Figure 1.11 (Pittas et al., 2007b). Pancreatic beta cells have also been 
found to express the 25-hydroxyvitamin D-1α-hydroxylase enzyme which converts 
25(OH)D to active 1,25(OH)2D within the pancreatic beta cells (Bland et al., 2004).  
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(Adapted from Chiang et al., 2011) 
The indirect role of vitamin D in type 2 diabetes is proposed to be through its role in 
calcium homeostasis. Vitamin D is known to regulate the concentration of extracellular 
calcium and its influx through pancreatic beta cell membranes (Pittas et al., 2007b). 
Insulin secretion is a calcium-dependant process and therefore any alteration in 
calcium concentrations within pancreatic beta cells caused by low circulating vitamin 
D concentrations may negatively influence insulin secretion (Milner and Hales 1967; 
Pittas et al., 2007b). 
1,25(OH)2D is known to directly activate transcription of the insulin receptor gene 
within target cells, increasing the number of peripheral insulin receptors (Maestro et 
al., 2002). In turn, this increases cellular insulin responsiveness and decreases overall 
insulin resistance (Maestro et al., 2000). The indirect role of vitamin D is likely once 
again to be mediated via calcium homeostasis. As previously mentioned, calcium is 
essential in certain tissues in order to effectively execute insulin-mediated cellular 
processes (Williams et al., 1990; Ojuka 2004) The optimum range of intracellular 
calcium that allows for these insulin-mediated cellular functions to work is very 
narrow. Therefore any small changes in the intracellular concentration of calcium may 
lead to peripheral insulin resistance (Draznin et al., 1987; Draznin et al., 1989). 
Studies have however indicated that the effect of vitamin D on insulin resistance is 
likely to be less than its effect on pancreatic beta cell function (Orwoll et al., 1994; 
Pittas et al., 2007a; Mitri et al., 2011).     
Figure 1.10: The proposed direct effect of vitamin D on insulin secretion in a 
pancreatic beta cell 
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1.7.3.2 Vitamin D and dyslipidaemia 
Whilst vitamin D has been demonstrated to improve the lipid profile in diabetic 
patients, the exact mechanisms by which this occurs remain uncertain (Raghuramulu et 
al., 1992; Bonakdaran and Afkhami Zadeh 2011; Al-Daghri et al., 2012; Tabesh et al., 
2014; Mohamad et al., 2015). Several hypotheses have however been proposed. 
Firstly, it has been suggested that vitamin D increases absorption of intestinal calcium 
which in turn reduces the amount of fat absorbed by the gut. Calcium binds to fatty 
acids and bile acids, forming calcium-fatty acid soaps which are excreted in the faeces, 
decreasing the absorption of fat from the gut (Boon et al., 2007). As a result serum 
total and LDL-cholesterol, as well as triglyceride concentrations are reduced (Saunders 
et al., 1988; Grundy and Denke 1990; Van der meer et al., 1990; Vaskonen et al., 
2002; Vaskonen 2003; Cho et al., 2005; Zittermann et al., 2009). A second hypothesis 
is through the action of vitamin D on serum parathyroid hormone (PTH) 
concentrations. PTH has been shown to reduce lipolysis in vitro. As vitamin D 
suppresses PTH secretion in the body it may reduce serum lipids via increased 
peripheral removal (Zemel et al., 2000).  
HDL cholesterol is comprised of 70% apolipoprotein A-1 (Apo-A1) and an increase in 
serum concentrations of this protein is known to lead to a direct increase in HDL 
particle formation and increased reverse cholesterol transport (Vacek et al., 2012; 
Teixeira et al., 2014). Apolipoprotein A1 has been demonstrated to persistently 
correlate with vitamin D concentrations (Satin 2000; Gagnon et al., 2012; Salum et al., 
2012; Vacek et al., 2012). Furthermore, the expression of the apolipoprotein gene in 
hepatocytes (HepG2) and intestinal (CaCo-2) cells, responsible for production of the 
apolipoproteins A-1 and B, is known to be regulated by vitamin D receptor modulators 
(Wehmeier et al., 2008).  
1.7.3.3 Vitamin D and oxidative stress 
It is only in recent years that a possible relationship between vitamin D and oxidative 
stress has gained attention. Current animal studies have shown vitamin D deficiency to 
promote oxidative stress, whilst supplementation with the vitamin has been shown to 
upregulate the antioxidant enzymes superoxide dismutase (SOD), catalase and 
glutathione peroxidase (GSH-Px) by up to 200% in diabetic rats (Kallay et al., 2002; 
Hamden et al., 2009; Argacha et al., 2011). However, the antioxidant properties of 
vitamin D in improving markers of diabetes are only recently coming to light and data 
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remains scarce (Nikooyeh et al., 2011; Tayebinejad et al., 2012; Nikooyeh et al., 
2014). As previously demonstrated, chronic hyperglycaemia can induce oxidative 
stress via several mechanisms. In one recent cross sectional study on diabetic subjects 
a significant inverse relationship was demonstrated between vitamin D and markers of 
oxidative stress, including LDL susceptibility to oxidation and AGEs (Gradinaru et al., 
2012).  
There are multiple possible mechanisms by which vitamin D may influence oxidative 
stress levels. In vitro studies have shown calcitriol to have an inhibitory effect on 
RAGE expression and protein glycation, indicating that vitamin D may protect against 
AGE formation (Yamagishi et al., 2008). In vitamin D deficient subjects, PTH levels 
are known to be raised, leading to activation of 1a-hydroxylation of 25(OH)D in the 
kidneys to produce 1,25(OH)2D. This in turn increases intracellular calcium and the 
promotion of reactive oxygen species (Vidal et al., 2006; Sun and Zemel 2007). 
Furthermore, some experimental findings have demonstrated vitamin D to upregulate 
endogenous antioxidants, most notably glutathione (Neyestani 2013). However, other 
studies have found 25(OH)D to have no beneficial effect on antioxidant defenses  
(Noyan et al., 2005; Eftekhari et al., 2013; Yiu et al., 2013).  The mechanisms by 
which vitamin D may play a role in limiting the progression of diabetic complications 
are summarised in Figure 1.12. 
 
 
 
 
 
 
28 
 
                                                 (Neyestani 2013) 
1.7.4 Previous related research 
The exact mechanism by which vitamin D plays a role in the development and 
progression of type 2 diabetes remains controversial. The earliest studies appear to 
demonstrate no improvement in glycaemic control following supplementation with 
vitamin D (Orwoll et al., 1994). More recently however, many trials have found a 
positive association between vitamin D supplementation and improved markers of 
glycaemic control (Al-Daghri et al., 2012; Soric et al., 2012; Talaei et al., 2013; 
Labban 2014; Nasri et al., 2014; Tabesh et al., 2014; Yousefi Rad et al., 2014; 
Mohamad et al., 2015). Similarly, the existing literature has yielded inconsistent 
results on the role of vitamin D in improving the lipid profile in type 2 diabetics. The 
majority of studies have demonstrated no improvement in dyslipidaemia when vitamin 
D supplements are given (Jorde and Figenschau 2009; Patel et al., 2010; Witham et al., 
2010; Breslavsky et al., 2013; Eftekhari et al., 2013; Talaei et al., 2013; Yiu et al., 
2013; Al-Zahrani et al., 2014; Kampmann et al., 2014; Yousefi Rad et al., 2014; Al-
Figure 1.11: Direct and indirect effects of vitamin D on antioxidant/ pro-oxidant 
balance in diabetes 
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↑ Insulin function 
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Shahwan et al., 2015; Al-Sofiani et al., 2015; Sadiya et al., 2015). However several 
studies exist which contradict this and have displayed significant improvements in the 
lipid profile following supplementation (Raghuramulu et al., 1992; Bonakdaran and 
Afkhami Zadeh 2011; Al-Daghri et al., 2012; Tabesh et al., 2014; Mohamad et al., 
2015). 
Few studies exist which have analysed the effect of vitamin D on oxidative stress and 
AGEs in human subjects (Tayebinejad et al., 2012; Yiu et al., 2013; Nikooyeh et al., 
2014; Krul-Poel et al., 2015; Shab-Bidar et al., 2015). However, of those one-third 
have demonstrated a significant reduction in AGEs following vitamin D 
supplementation (Tayebinejad et al., 2012; Nikooyeh et al., 2014). To the best of the 
researcher’s knowledge, only one study exists demonstrating a reduction in oxidative 
stress following vitamin D supplementation (Shab-Bidar et al., 2015). The findings of 
these studies are summarised in Table 1.2.  
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Table 1.2: Vitamin D intervention studies in diabetic and obese patients.  
  Study   paper Study Population 
N= sample size 
Inclusion 
Criteria 
Study 
design 
Length 
of 
interven
tion 
Type and 
Dose of 
Vitamin D 
Outcome measures Association 
 (+ p value) 
serum 
25(OH)D,  
at baseline 
serum 
25(OH)D,  
at end of 
study  
 
(Raghuramulu 
et al., 1992) 
 
N=42 
30-60 yrs 
 
T2DM (India) 
 
Intervention 
 
1 month 
 
25(OH)D3 
300,000 IU 
IM injection 
 
Cholesterol 
 
Calcium 
Fasting serum insulin 
 
Yes (p <0.02) 
 
Yes (p <0.01) 
Increased but not 
significantly 
 
N/A 
 
N/A 
 
(Orwoll et al., 
1994) 
 
N=20 
40-70 yrs 
 
 
T2DM (USA) 
 
Double-
blind RCT 
 
4 days 
 
1, 25(OH)D2 
200 IU/day 
 
 
1,25-
Dihydroxyvitamin D 
 
FBS, Insulin 
secretion, Calcium 
 
No significant change 
 
 
No significant change 
 
N/A 
 
N/A 
 
(Taylor and 
Wise 1998) 
 
N= 3 
Male=1 
Female=2 
 
 
T2DM (UK) 
 
Case study 
 
3 months 
 
Ergocalciferol 
300,000 IU 
stat 
IM injection 
 
serum 25(OH)D, 
FBS, TG, fasting 
inulin 
 
HbA1c 
 
 
Increase in all, not 
significant 
 
 
Decreased significantly 
 
Patient 1= 
5.2 ng/ml 
Patient 2= 
5.2 ng/ml 
Patient 3= 
3.2 ng/ml 
 
Patient 1= 
20.4 ng/ml 
Patient 2= 
18.8 ng/ml 
Patient 3= 
13.2 ng/ml 
31 
 
 
(Borissova et 
al., 2003) 
 
 
N= 10 
Female=10 
17 yrs 
 
 
T2DM 
(Bulgaria) 
 
Intervention 
 
1 month 
 
25(OH)D3 
1332 IU/day 
 
 
 
serum 25(OH)D 
 
HOMA-IR 
 
Yes (p<0.05) & achieved 
sufficient level 
 
No significant change 
 
14.12 ng/ml 
 
N/A 
 
(De Boer et al., 
2008) 
 
N= 2291 
Females 
50 –79 yrs 
 
T2DM (USA) 
 
Double-
blind RCT 
 
7 years 
 
25(OH)D3 
400 IU/day 
 
serum 25(OH)D 
HOMA-IR , insulin 
level 
FBS, BMI 
 
 
No significant change 
 
< 32 ng/ml 
for 89% of 
participants 
And  
< 20 ng/ml 
for 61%. 
participants 
 
N/A 
 
(Sugden et al., 
2008) 
 
N= 34 
Female= 16 
 
 
T2DM (UK) 
 
Double-
blind RCT 
 
2 months 
 
25(OH)D2 
100,000 IU 
stat dose 
 
serum 25(OH)D 
 
 
FBS, HbA1c, 
calcium, insulin 
 
Yes (p <0.02) but not did 
not achieve the sufficient 
level. 
 
No significant change 
 
 
16 ng/ml 
 
25.16 
ng/ml 
 
(Jorde and 
Figenschau 
2009) 
 
N= 36 
21–75 yrs 
 
 
T2DM 
(Norway) 
 
RCT 
 
6 months 
 
25(OH)D3 
40,000 
IU/week 
 
 
serum 25(OH)D 
FBS, serum insulin, 
HbA1c, HOMA-B, 
HOMA-IR , calcium, 
lipid profile, BMI 
 
Yes (p <0.001) and did 
achieve the sufficient 
level. 
No significant change 
 
24 ng/ml 
 
47.32 
ng/ml 
32 
 
 
(Witham et al., 
2010) 
 
N= 61 
18 years+ 
 
 
T2DM 
(Scotland) 
 
Double-
blind RCT 
 
4 months 
 
25(OH)D3 
100,000 IU , 
or 
200,000 IU 
stat oral dose 
 
 
serum 25(OH)D 
 
 
HbA1c, HOMA-IR, 
cholesterol 
 
Yes (p =0.003) only 
sufficient in the 200,000 
IU group 
 
No significant change 
 
N/A 
 
100,000 IU 
group = 
23.6 ng/ml 
 
200,000 IU 
group = 
30.4 ng/ml 
 
 
Patel, 2010 
 
N= 24 
Male=7 
Female=17 
 
 
T2DM (Israel) 
 
Pilot 
prospective 
randomized 
trial no 
control 
 
4 months 
 
25(OH)D3 
400 IU/day 
or 
1200 IU/day 
 
serum 25(OH)D 
 
 
 
HbA1c, FBS, lipid 
profile, BMI, calcium 
 
Yes (p<0.001) but did 
not achieve the sufficient 
level at either dose 
 
 
No significant change 
 
 
400 IU/day 
group = 17.6 
ng/ml 
 
 
1200 IU/day 
group = 15.6 
ng/ml  
 
400 IU/day 
group = 
25.5 ng/ml 
 
 
1200 
IU/day 
group = 
27.4 ng/ml 
 
(Bonakdaran 
and Afkhami 
Zadeh 2011) 
 
N= 58 
 
 
T2DM (Iran) 
 
Intervention 
study 
 
2 months 
 
1,25(OH)2D3 
(calcitriol) 
0.5 microgram 
per day 
 
 
FBS, HbA1c, 
cholesterol, TG, 
HOMA-IR, 
 
LDL 
 
 
Decrease but not 
significantly 
 
 
Significant decrease 
 
N/A  
 
N/A 
33 
 
 
(Al-Daghri et 
al., 2012) 
 
 
 
N= 92 
Male=34 
Female=58 
30-70 yrs 
 
 
T2DM (Saudi) 
 
Non-RCT, 
Intervention 
 
18 
months 
 
25(OH)D3 
2000 IU/day 
 
 
serum 25(OH)D 
 
 
 
Corrected calcium 
 
LDL 
 
TC 
 
HOMA-B 
 
HOMA-IR, Insulin 
 
 
 
Yes (p < 0.001) but did 
not achieve the sufficient 
level. 
 
 
Yes (p =0.003) 
 
Yes (p =0.004) 
 
Yes (p <0.001) 
 
Yes (p =0.002) 
 
Yes (p <0.0001) 
 
Summary: improved 
lipid profile more 
significant in females 
 
12.88 ng/ml 
 
21.88 
ng/ml 
 
Soric, 2012 
 
N= 37 
Female = 22 21–
75 yrs 
 
T2DM (USA) 
 
Single-blind 
RCT 
 
3 months 
 
25(OH)D3 
2000 IU/day 
 
HbA1c 
 
 
Significant decrease (p < 
0.013) in patients with 
baseline HbA1c >9% 
 
N/A 
 
N/A 
34 
 
 
Heshmat, 2012 
 
N= 42 
Male=15 
Female=27 
37-79 years 
 
T2DM (Iran) 
 
Double-
blind RCT 
 
3 months 
 
25(OH)D3 
300,000 IU 
stat IM 
injection 
 
serum 25(OH)D 
 
 
HbA1c, HOMA-IR, 
BMI, FBS 
 
Yes (p = 0.009) and did 
achieve the sufficient 
level 
 
No significant change 
 
46.9 ng/ml 
 
69.3 ng/ml 
 
Tayebinejad, 
2012 
 
N= 60 
Males and 
females 
30-60 years 
 
T2DM 
(Iran) 
 
RCT 
 
3 months 
 
25(OH)D3 
fortiﬁed 
yogurt drink 
1000IU/day 
vitamin D 
 
 
 
 
25(OH)D 
 
 
Serum of AGEs 
 
FBS 
HbA1c 
HOMA-IR 
 
 
Yes (p<0.001) and 
achieve the sufficient 
level. 
 
Yes (p = 0.029) 
 
Yes (p = 0.016) 
Yes (p = 0.001) 
Yes (p < 0.001) 
 
16.24 ng/ml 
 
30.72 
ng/ml 
 
Breslavsky, 
2013 
N= 47 
Male=22 
Female=25 
 
T2DM (Israel) 
 
Double-
blind RCT 
 
12 
months 
 
25(OH)D3 
1000 IU/day 
serum 25(OH)D 
FBS, serum insulin, 
HbA1c, HOMA-B, 
HOMA-IR, lipid 
profile 
 
 
No significant change 
 
11.8 ng/ml 
 
17.6 ng/ml 
35 
 
 
Yiu, 2013 
 
N= 100 
Male = 50 
Female = 50 
 
 
 
T2DM (Hong 
Kong) 
 
Double-
blind RCT 
 
3 months 
 
25(OH)D3 
5000 IU/day 
 
 
 
serum 25(OH)D 
 
 
 
Oxidative stress, 
FBS,HbA1c,  
lipid profile 
 
Yes (p <0.001)  and 
achieved  the sufficient 
level 
 
 
No significant change 
 
 
 
21.1 ng/ml 
 
58.6 ng/ml 
 
Talaei, 2013 
 
N= 100 
70% women 
30%men 
30 to 70 years 
 
T2DM (Iran) 
 
Single blind 
study 
 
2 months 
 
25(OH)D3 
50,000 
IU/week 
 
 
 
serum 25(OH)D 
 
 
lipid profile 
 
serum insulin 
 
HOMA-IR 
 
FBS 
 
 
Yes (p =0.02) but were 
already sufficient at 
baseline 
 
No significant change 
 
Yes (p =0.02) 
 
Yes (p =0.008) 
 
Yes (p =0.02) 
 
43.03 ng/ml 
 
60.12 
ng/ml 
36 
 
 
Alkharfy, 2013 
 
N= 499 
Male=267 
Female=232 
21-60 years 
 
T2DM (Saudi) 
 
RCT 
 
12 
months 
 
25(OH)D3 
2000 IU/day 
 
 
serum 25(OH)D 
 
 
BMI, FBS 
 
TG, LDL, Total 
cholesterol, HDL 
 
 
Yes (p =0.04) but did not 
achieve sufficient levels 
 
No significant change 
 
Yes (p <0.001 )  
 
13.64 ng/ml 
 
19.24 
ng/ml 
 
Eftekhari, 2013 
 
 
N= 70 
Male=35 
le=35 
30-75 years 
 
T2DM (Iran) 
 
Double-
blind RCT 
 
3 months 
 
2 x capsules of 
calcitriol (0.25 
µg 
1,25dihydroxy
cholecalciferol 
per capsule) 
per day 
 
HDL,  oxidative 
stress 
 
LDL, Total 
cholesterol, TG 
 
No significant change 
 
No significant change 
 
N/A 
 
N/A 
 
Ryu, 2014 
 
 
N= 62 
47 to 63 years 
 
T2DM 
(Korea) 
 
RCT 
 
6 months 
 
2000 IU/day + 
calcium 
 
25(OH)D 
 
 
HOMA-IR, FBS,  
Total cholesterol, 
HDL, TG , HbA1c, 
BMI 
 
Yes (p < 0.001) and 
achieve the sufficient 
level 
 
 
No significant change 
 
12.3 ng/ml 
 
35.4 ng/ml 
37 
 
 
Yousefi RAD, 
2014 
 
N= 58 
Male=36 
Female=22 
30-60 years 
 
T2DM (Iran) 
 
Double-
blind RCT 
 
2 months 
 
25(OH)D3 
4000 IU/day 
 
 
 
serum 25(OH)D 
 
 
HbA1c 
 
insulin concentration 
 
HDL 
 
LDL, Total 
cholesterol, TG 
 
Yes (p <0.001) but did 
not achieve sufficient 
level 
 
Yes (p =0.001) 
 
Yes (p =0.027) 
 
Significantly increased 
 
No significant change 
 
15.55 ng/ml 
 
27.50 
ng/ml 
 
Labban, 2014 
 
N= 722 
Male= 360 
Female= 362 
36 to 61 years 
 
T2DM 
(Morocco) 
 
RCT 
 
2 months 
 
25(OH)D3 
2000 IU/day 
 
 
 
serum 25(OH)D 
 
 
HbA1c 
 
 
 
 
 
Increased significantly 
(p<0.001) but did not 
achieve the sufficient 
level 
 
yes (p=0.02) 
 
14.23 ng/ml 
 
23.89 
ng/ml 
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Alzahrani, 2014 
 
N= 248 
 
 
T2DM (Saudi) 
 
RCT 
 
3 months 
 
25(OH)D3 
45000 IU/day 
for 2 months 
 
Stat dose 
45,000 IU in 
the last month 
 
serum 25(OH)D 
 
 
 
HbA1c, FBS, lipid 
profile,  
BMI 
 
Yes (p =0.01) and 
achieved the sufficient 
level 
 
 
No significant change 
 
10.12 ng/ml 
 
33.12 
ng/ml 
 
Kampmann, 
2014 
 
N= 16 
Male=8 
Female=8 
18 years+ 
 
T2DM 
(Denmark) 
 
Double-
blind RCT 
 
3 months 
 
25(OH)D3 
11,200 IU/day 
for 2 weeks 
 
5,600 IU/day 
for 10 weeks 
 
serum 25(OH)D 
 
 
HbA1c, HOMA, 
BMI, lipid profile, 
calcium, FBS, serum 
insulin 
 
 
Insulin secretion 
 
 
 
 
Yes (p =0.02) and 
achieve the sufficient 
level 
 
 
No significant change 
 
 
Increased but not 
significantly 
 
12.4 ng/ml 
 
41.96 
ng/ml 
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Tabesh, 2014 
 
N= 118 
Female=60 
30 years + 
 
T2DM (Iran) 
 
Double-
blind RCT 
 
2 months 
 
25(OH)D3 
50,000 
IU/week 
vitamin D + 
1,000 mg/day 
calcium 
 
Serum 25(OH)D 
 
 
Serum insulin, 
HbA1c, HOMA-IR, 
LDL, Total 
cholesterol, 
 
HOMA-B, HDL 
 
BMI 
 
Yes (p <0.001) but not 
did not achieve the 
sufficient level 
 
Reduced significantly 
 
 
Significant increase 
 
No significant 
change 
 
11.2 ng/ml 
 
N/A 
 
Nikooyeh, 2014 
 
N= 90 
Males and 
females 
30-60 years 
 
T2DM 
(Iran) 
 
RCT 
 
3 months 
 
25(OH)D3 
fortiﬁed 
yogurt drink 
1000IU/day 
vitamin D 
 
 
25(OH)D 
 
 
Serum of AGEs 
HbA1c 
Markers of oxidative 
stress 
 
 
 
Yes (p<0.001) but 
already had sufficient 
levels at baseline 
 
Yes (p <0.001) 
Yes (p < 0.001) 
No significant change 
 
44.5 ng/ml 
 
74.6 ng/ml 
40 
 
 
Nasri, 2014 
 
N= 60 
Male=17 
Female = 43 
 
 
T2DM (Iran) 
 
Double-
blind RCT 
 
3 months 
 
25(OH)D3 
50,000 
IU/week 
 
 
serum 25(OH)D 
 
 
HbA1c 
 
FBS 
 
Yes (p =0.001) but 
already had sufficient 
levels at baseline 
 
Significant reduction in 
males 
 
No significant change 
 
33.56 ng/ml 
 
65.6 ng/ml 
 
Krul-poel, 2015 
 
N= 245 
Male = 156 
Female = 89 
18 years + 
 
 
T2DM 
(Netherlands) 
 
Double-
blind RCT 
 
6 months 
 
25(OH)D3 
50,000 
IU/month 
 
 
 
serum 25(OH)D 
 
 
 
HbA1c, AGEs 
 
Yes (p < 0.01) and 
achieved sufficient levels 
 
 
No significant change 
 
24.32 ng/ml 
 
41.44 
ng/ml 
 
Mohamad, 2015 
 
 
N= 100 
 
 
T2DM 
(Egypt) 
 
Intervention 
 
2 months 
 
25(OH)D3 
4500 IU/day 
 
serum 25(OH)D 
 
FBS, HbA1c, LDL, 
Total cholesterol 
 
HDL 
TG 
Yes (p < 0.05) and 
achieved sufficient level 
 
Decreased significantly 
 
Increased significantly 
Significantly decreased 
in females 
 
16 ng/ml 
 
49.2 ng/ml 
41 
 
 
Alsofiani, 2015 
 
N= 20 
Male=15 
Female=5 
21 to 75 years 
 
T2DM (Saudi) 
 
Double-
blind RCT 
 
3 months 
 
25(OH)D3 
5000 IU/day 
 
 
 
serum 25(OH)D 
 
 
HbA1c,  HOMA-IR, 
FBS, insulin level, 
BMI, corrected 
calcium, lipid profile 
 
HOMA-B 
 
Yes (p < 0.0001) and 
achieve the sufficient 
level. 
 
No significant change 
 
 
Significant improvement 
within vitamin D group, 
not compared to placebo 
 
11.56 ng/ml 
 
39.72 
ng/ml 
 
Sadiya, 2015 
 
N= 87 
All males 
30-60 years 
 
T2DM (UAE) 
 
Double-
blind RCT 
 
6 months 
(2 phase 
of 3 
months 
each) 
 
25(OH)D3 
Phase 1= 6000 
IU/day 
Phase 2= 3000 
IU/day 
 
serum 25(OH)D 
 
 
 
HbA1c, FBS, lipid 
profile 
 
Peaked in phase 1 and 
achieved sufficient levels 
and then decrease in 
phase 2 significantly 
 
No significant change 
 
 
Phase 1= 
6000 IU/day 
= 11.4 ng/ml 
 
 
Phase 1= 
6000 
IU/day = 
30.88 
ng/ml 
Phase 2= 
3000 
IU/day = 
24.92 
ng/ml 
 
Al-shahwan, 
2015 
 
N= 45 
Male=21 
Female=24 
21 years + 
 
T2DM (Saudi) 
 
Intervention 
study 
 
1 year 
 
25(OH)D3 
2000 IU/day 
 
 
serum 25(OH)D 
 
HOMA-IR 
BMI, FBS, Total 
cholesterol, HDL, 
TG, calcium 
Yes (p  <0.05) but did 
not achieve the sufficient 
level 
Yes (p  <0.05) 
No significant change 
 
10.64 ng/ml 
 
12.84 
ng/ml 
42 
 
 
Shab Bidar, 
2015  
 
N= 100 
Male=43 
Female=57 
40-60 years 
 
T2DM 
(Iran) 
 
RCT 
 
3 months 
 
25(OH)D3 
fortiﬁed 
yogurt drink 
1000IU/day 
vitamin D 
 
 
25(OH)D 
 
 
FBS 
 
HbA1c 
 
Markers of oxidative 
stress including Total 
antioxidant 
 
Yes (p<0.001) but did 
not achieve the sufficient 
level 
 
Yes (p<0.001) 
 
Yes (p<0.001) 
 
Yes (p<0.001) 
 
 
15.4 ng/ml 
 
28.8 ng/ml 
43 
 
As shown in Table 1.2, evidence from recent experimental and observation studies has 
highlighted a potential role for vitamin D in improving glycaemic control, 
dyslipidaemia and markers of oxidative damage in diabetic patients. Vitamin D has 
been demonstrated to improve pancreatic beta cell function and decrease insulin 
resistance, reduce serum LDL-cholesterol and triglyceride levels and to upregulate 
potent endogenous antioxidants to combat oxidative stress. Despite these encouraging 
developments, the role of vitamin D supplementation in diabetes remains controversial 
and there are still many questions that need to be answered. In the Saudi population 
where both type 2 diabetes and vitamin D deficiency are so prevalent, the potential for 
vitamin D as an adjuvant to conventional diabetic therapies is all the more exciting.  
1.8 Aims and objectives 
The aim of this study was to understand glycaemia, dyslipdaemia and oxidative stress 
in Saudi Arabian women who were vitamin D deficient with poorly controlled type 2 
diabetes. 
The objectives were as follows: 
• To assess the effect of vitamin D3 supplementation on markers of glycaemia, 
including fasting serum glucose level, insulin resistance and secretion, and 
glycated haemoglobin in Saudi adult females 
• To assess the effect of vitamin D3 supplementation on diabetic dyslipidaemia, 
including serum low density lipoprotein (LDL), high density lipoprotein 
(HDL), triglycerides (TG) and total cholesterol in Saudi adult females 
• To assess the effect of vitamin D3 supplementation on oxidative stress, 
including total serum antioxidant levels and advanced glycation endproducts 
(AGEs) in Saudi adult females 
• To establish whether different doses of vitamin D3 elicit different responses in 
relation to markers of glycaemia, dyslipidaemia and oxidative stress  
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Chapter 2.  Materials & Methods 
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2.1 Materials, equipment and software  
2.1.1 Materials   
❖ Microcrystalline cellulose placebo; 2000 IU vitamin D3; 4000 IU vitamin D3  
(Metabolics Ltd, UK) 
❖ 96-well microtiter plate format (Eppendorf company, German) 
❖ Uric acid standard 100mg; reaction buffer 400uL; copper ion reagent 1.0mL; 
stop solution 1.5mL (Cell Biolabs, USA) 
❖ 1N NaOH (Sigma Aldrich, USA)  
❖ Albumin colorimetric assay kit (Cobas Albumin Gen.2, Roche Diagnostics, 
USA) 
❖ Tina-quant Haemogblon A1c Gen.3 turbidimetric inhibition immunoassay kit 
(Cobas A1C-3, Roche Diagnostics, USA) 
❖ Calcium Gen. 2 assay kit (Roche Diagnostics, USA) 
❖ Glucose HK GLUC3 enzymatic assay kit (Roche Diagnostics, USA) 
❖ Cholesterol Gen. 2 colorimetric assay kit (Roche Diagnostics, USA) 
❖ Triglycerides  enzymatic colorimetric assay kit (Roche Diagnostics, USA) 
❖ HDL-Cholesterol plus 3rd generation enzymatic colorimetric assay kit (Roche 
Diagnostics, USA) 
❖ LDL-Cholesterol plus 2nd generation enzymatic colorimetric assay kit (Roche 
Diagnostics, USA) 
❖ Insulin immunoassay kit (Roche Diagnostics, USA) 
❖ Vitamin D total 25-hydroxyvitamin D immunoassay kit (Roche Diagnostics, 
USA) 
❖ Eppendorf tubes (Eppendorf company, German) 
❖ Sterile Gloves (Ansell, Canada) 
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❖ Deionized water (Local store, Saudi Arabia) 
2.1.2 Equipment  
❖ Automated electrochemiluminescence assays (Roche Cobas E601, USA) 
❖ Automated electrochemiluminescence assays (Roche Cobas E501, USA) 
❖ OxiSelect TAC assay kit (Cell Biolabs, USA) 
❖ Pipettes (Eppendorf company, German) 
❖ Spectrophotometric microplate reader (BioTek, USA) 
❖ AGE reader (Diagnoptics Technologies B.V., Groningen, the Netherlands) 
❖ 50uL to 300uL adjustable single and multichannel micropipettes (Eppendorf 
company, German) 
❖ Standard tape measure (Seca, Germany) 
❖ Free-standing stadiometer (Seca, Germany)  
❖ Weighing scales (Seca, Germany) 
❖ 21G needle (BD, USA) 
❖ EDTA, serum and lithium heparin tubes for blood collection (BD Vacutainer®, 
USA) 
❖ Centrifuge 5702 (Eppendorf, Germany) 
❖ Laboratory freezer minus 20 (Philip Kirsch, German) 
❖ Laboratory freezer at minus 80 (Philip Kirsch, German) 
❖ Laboratory fridge (Philip Kirsch, German) 
❖ Orbital shaker (Lab tech, Korea) 
❖ Informed consent form (see appendices)  
❖ Pre-screening questionnaire (see appendices) 
❖ Supplement recording calendar (see appendices) 
❖ Debriefing questionnaire (see appendices) 
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❖ Blood analysis flow chart (see appendices) 
2.1.3 Software   
❖ Microsoft office 2013 (Microsoft, USA) 
❖ Statistics Package for Social Sciences (SPSS, version 20 for Windows) (SPSS 
Inc., Chicago, USA) 
❖ Microsoft excel 2013 (Microsoft, USA) 
❖ Powerful statistical software (Minitab 17) (Minitab Inc, USA) 
❖ Microsoft Paint (Microsoft, USA) 
❖ BMI calculator (NHS Tools, UK) 
2.2 Ethical approval 
Ethical approval was granted on the 8th August 2013 by the Manchester Metropolitan 
Ethics Committee. Authorisation from Al-Noor Specialist Hospital, Saudi Arabia, was 
received on the 9th December 2013, and submitted to the Manchester Metropolitan 
Ethics Committee. Ethical approval was also granted from the Ethics committee at Al-
Noor Specialist Hospital, Saudi Arabia, following receipt of the research proposal.  
Funding has been granted through the Saudi Arabian Government Scholarship scheme 
by the Saudi Arabian Culture Bureau.  
2.3 Study overview 
In this study, 156 poorly-controlled T2DM Saudi female patients were recruited from 
Al-Noor hospital (Saudi Arabia), between December 2013 and January 2014. Subjects 
who met the inclusion criteria (Figure 2.1) were randomly allocated to one of three test 
groups: placebo, 2000 IU vitamin D3 daily and 4000 IU vitamin D3 daily. 
Participants were referred to the study by the consultant overseeing their care. If the 
participant met the inclusion criteria they were invited for an initial meeting between 
the participant and researcher where the objectives and expectations were outlined and 
informed consent obtained and documented clearly. Anthropometric measurements 
were taken, along with blood samples for analysis and a 16-week course of 
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supplements were allocated. A follow-up appointment was made at 16 weeks where 
repeat blood samples and anthropometric measurements were taken, a debriefing 
questionnaire completed and any remaining supplements collected. The general outline 
of the study is shown in Figure 2.1. 
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*see 3.3 Reasons for attrition 
Figure 2.1: Study design and progression flow chart. 
Enrolment after meeting 
the inclusion criteria  
Screened for eligibility (n≈3750) 
• Screening questionnaire  
 
Inclusion Criteria 
• age 18-60 years  
• overweight (BMI  25 
kg/m2)  
• type 2 diabetic  
• no renal / 
gastrointestinal  disease  
• not taking vitamin  
supplements  up to 3 
months before or during 
study  
• not pregnant   
• not hypercalcaemia  
 
 
 
 
Randomised allocation 
n=156 
4000 IU vitamin D 
(group A) 
    n=52 
 
Placebo group (group C) 
     n=52 
 
 
 
2000 IU vitamin D 
(group B) 
     n=52 
 
Baseline - Meeting 1 
• Communicate vit D regimen 
• Informed written consent 
• Blood samples and anthropometric 
measurements taken  
• Supplements and pill calendar 
supplied 
Week 16 – Follow-up  
• Debriefing questionnaire and interview on 
compliance 
• Repeat blood samples and anthropometric 
measurements taken 
• Remainder of supplements collected and 
counted 
 
Excluded from analysis* 
Group A (n=6) 
Group B (n=6) 
Group C (n=7) 
Analysed (n=128) 
Via SPSS 
 
Lost to follow-up: 
Group A (n=4) 
Group B (n=3) 
Group C (n=2) 
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2.4 Interventions  
Participants were randomly allocated one of three groups, 4000 IU per day (Group A), 
2000 IU per day (Group B) or placebo (Group C). Both these supplement doses have 
been shown to be effective in raising serum vitamin D concentrations in a number of 
previous studies (Von Hurst et al., 2008; Mitri et al., 2011; Al-Daghri et al., 2012). 
The placebo contained only microcrystalline cellulose as used in previous similar 
studies (Pittas et al., 2007a) and was chosen as it cannot be readily absorbed by the 
body (Grossmann and Tangpricha 2010; Kaptchuk et al., 2010).  
The random allocation of patients to one of the three study groups was also imperative 
to minimize bias and ensure a balanced distribution of important variables between 
groups (Practice Committee of American Society for Reproductive 2008). In this 
study, patients were randomly allocated one of the three groups depending on the order 
in which they presented for their scheduled follow-up appointment with the doctor. 
These appointments had already been allocated by an impartial third party prior to this 
study commencing. For example, the patient attending appointment one was allocated 
group A, patient attending appointment two was allocated group B and so on. This use 
of third party randomisation enabled the order of allocation to the groups to be 
concealed to the researcher, thus eliminating bias. Furthermore, the researcher and the 
patient were both blind to which group would be assigned which supplement dose or 
placebo. In order to maintain the blinding, all tablets and packaging looked the same. 
Blinding has been a key facet of trials analysing vitamin D3 supplementation on 
markers of diabetic control in order to minimise bias (Pittas et al., 2007a; De Boer et 
al., 2008; Von Hurst et al., 2008; Nagpal et al., 2009; Mitri et al., 2011). 
2.5 Safety margins 
Vitamin D intoxication is an uncommon but avoidable issue, which would result in 
hypercalcaemia. Safety is paramount in research on human subjects and thus the upper 
limit of safe vitamin D supplementation had to be determined prior to study initiation. 
The current consensus is that 10,000 IU/day is the recommended highest daily intake 
to be sure of no adverse outcomes (Hathcock et al., 2007). As this study used 2000 IU 
and 4000 IU vitamin D3 supplementation, it can be assured that all supplementation 
was within safe parameters.   
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In order to prevent hypercalcaemia as a result of vitamin D intervention, levels of 
corrected calcium were measured prior to inclusion in the study. Any patient found to 
have higher than acceptable levels of corrected calcium became ineligible for further 
participation in the study.  
2.6 Recruitment and sittings 
The target population was specifically Saudi females with poorly controlled type 2 
diabetes between the ages of 18 and 60 years. Al-Noor hospital is the hub for 
outpatient diabetes clinics in the Makkah area. The researcher first determined eligible 
women for the study by reviewing around 125 files daily of Saudi diabetic females at 
the Diabetic Centre, looking for patients who met the inclusion criteria using the 
screening questionnaire for recruiting participants. A list of suitable patients was 
compiled for the attention of the specialist conducting the diabetic clinic to refer the 
patients on after their appointment. The women referred by the consultants were 
between 18 and 60 years of age and had poorly controlled T2DM. Participants who 
met the eligibility criteria were then invited to take part in the study via phone call. 
Participants were also sent flyers about the benefit of vitamin D and invited by 
What’sapp (if they use the app) to attend a meeting with the researcher after their next 
appointment with the specialist. During the appointment the study researcher explained 
the possible benefits of vitamin D in diabetic patients and what would be expected of 
them if they were to participate in the study. If they chose to participate it was also 
explained how to fill in a supplement recording calendar, the vitamin D3 supplements 
were given out, and blood samples taken for baseline measurements and initial AGE 
measurements taken.  
All patient appointments and biological tests were carried out in Saudi Arabia. Patient 
appointments were conducted at the Al-Noor hospital. Laboratory tests were carried 
out by trained laboratory staff at the Al-Noor clinical laboratory.  Study coordination, 
analysis and subsequent work were all undertaken at the Manchester Metropolitan 
University, Manchester, UK.   
2.7 Inclusion and exclusion criteria 
Inclusion criteria for the study as shown in Figure 7 was as follows: Saudi Arabian 
women, whose parents were both Saudi Arabian, between the ages of 18 and 60 years 
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with poorly controlled type 2 diabetes (defined as glycated haemoglobin > 8%) (Kuo 
et al., 2006; Wolff-McDonagh et al., 2010) and BMI above 25 kg/m2 with no prior 
history of renal, liver or gastrointestinal disease.  
Patients with renal, liver or gastrointestinal disease, pregnancy or prior use of vitamin 
D supplements (three months prior to or during the study time) were excluded from the 
study as seen in Table 2.1. Vitamin D has a circulating half-life of 15 days and 
turnover in the body of two months (Jones 2008) and therefore excluding patients who 
had taken supplements within the past three months negated any confounding results 
from previous supplementation.  Vitamin D3 is absorbed by the gut and then activated 
in the liver and kidneys. Previous studies have shown that renal or liver disease and 
gastrointestinal disease limits the activation or absorption of vitamin D3, thus rendering 
the intervention less effective (Ritz et al., 1979; Farraye et al., 2011; Vavricka and 
Rogler 2012; Stokes et al., 2013). Pregnancy has been linked to vitamin D deficiency 
and resulting clinical outcomes such as gestational diabetes (Barrett and McElduff 
2010). Pregnancy can further complicate the measurement of diabetes as diabetic 
control is more difficult as glucose levels change according to hormonal factors (Rafat 
and Ahmad 2012). Due to the added complications that pregnancy could bring to 
diabetic control, pregnant women were excluded from the study. 
Table 2.1: Study Inclusion and exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
✓ Females aged 18-60 years ➢ Renal, liver or gastrointestinal disease 
e.g. Crohn’s disease or liver failure 
✓ BMI ≥ 25 ➢ Those taking supplements that include 
vitamin D 
✓ Glycated haemoglobin > 8% (Poorly 
controlled type 2 diabetics) 
➢ Pregnancy 
✓ Participant and their parents are both 
Saudi Arabian 
➢ Hypoglycaemic changes 
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2.8 Sample size calculation 
ANCOVA was used to assess changes in outcomes after intervention, but the 
limitation of ANCOVA is that the statistical interpretations based on the F tests are 
sensitive to sample size. When the sample size is too small, there is inadequate power 
to calculate the F statistic and the hypothesis cannot be appropriately tested. The use of 
sample sizes which are inadequate can lead to misrepresentative results which may 
have profoundly negative clinical outcomes (Bailar et al., 1992).  
Specific power calculations for this study were therefore undertaken using G*Power 3 
(Faul et al., 2007) and the recommendations of a statistician to ensure that the sample 
size was sufficient to detect the effect of vitamin D3 supplementation on biological 
outcomes. A power level of 80% was assumed, an effect size explaining 25% of the 
variance in vitamin D concentrations, with three groups to the study, a minimum 
sample size of N=128 was calculated to obtain significance at the p=0.05 level. 
Inevitably, some patients were lost to follow up. To compensate for this the number 
recruited was increased by 20%. If loss to follow up was greater than this, the analysis 
might be unsound and may not be publishable (Schulz and Grimes 2002). Consultation 
on the power calculations was taken with Dr M Sullivan, a Senior Lecturer at 
Manchester Metropolitan University. On consultation of similar previous 
interventional studies, it was noted that sample sizes ranging from between 37 and 92 
participants had achieved significant validated results over various durations of one to 
18 months (Raghuramulu et al., 1992; Sugden et al., 2008; Witham et al., 2010; Al-
Daghri et al., 2012; Soric et al., 2012). 
2.9 Informed consent form 
Written information sheets contribute to patient understanding of a trial more than 
verbal discussion of the information (Langdon et al., 2002; Shukla et al., 2012). It has 
also been shown that such information sheets are often overly complicated in the 
language that they use, especially if the target audience is young or has low literacy 
levels (Franck and Winter 2004). The optimum design for an informed consent form 
has been shown to be brief and to the point (Epstein and Lasagna 1969). In this study, 
an informed consent sheet was given to the participants which explained what was 
expected of them during the study and what would happen at each stage. The language 
used in the form was simple and easy to understand. The participant was asked to 
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confirm in writing that they understood the information presented to them and to 
accept or decline the offer to take part in the study. Contact information for the 
researcher was included on the information sheet so that participants could raise any 
questions directly and at any time. The researcher also spent a one-to-one session with 
each participant, which has been shown to increase participant understanding in 
previous studies (Flory and Emanuel 2004). 
2.10 Pre-study screening questionnaire 
Potential participants attended a meeting with the researcher where their eligibility for 
the study was assessed. The researcher first checked that the potential participants met 
the inclusion criteria and did not breach the exclusion criteria. Those participants that 
met the inclusion criteria and agreed to participate in the study then went on to 
complete the pre-screening questionnaire which is discussed below.  
In order to produce an effective questionnaire, the language used must be simple, 
understandable and precise. The language used should not be too formal or scientific in 
order to minimise confusion and misunderstanding (McLeod 2008; Gould 2011). The 
questionnaire for this study was developed in English and then translated to Arabic. 
The responses were then translated back in to English for analysis. The questions 
asked in this questionnaire fell in to two categories: personal information and medical 
information. These were arranged in a logical order, with the personal information 
questions first (Berdie et al., 1986; Hague 1993). The questions were closed where 
possible, with a minimum number of open ended questions as these are more difficult 
to analyse (Oppenheim 1992). For closed questions, a set number of responses were 
provided, and the subject prompted to circle the most appropriate answer.  
The questionnaire was given out in a face-to-face meeting with the study researcher. 
This ensures that any misunderstanding is rectified and the errors or unanswered 
questions kept to a minimum and so response rates improved (Oppenheim 1992). A 
number of background questions were used to determine patients’ gender, age, marital 
status, education level, employment history, ethnic origin and smoking status. The 
questionnaire also indicated whether the participants were currently taking daily 
vitamin supplements, or whether they were taking vitamin D supplements three 
months prior to inclusion in the study. Specific medical conditions were checked, 
together with listing the prescribed medications that the participants were taking. This 
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section of the questionnaire aimed to identify factors that potentially confound the 
data.  
2.11 Anthropometric measurements 
Body mass index (BMI) is known to be a strong indicator of diabetes risk (Schulze et 
al., 2012). Participants’ height and weight were measured and recorded by the study 
researcher. Height (in centimetres) was recorded whilst the subject was standing erect 
and barefoot using a free-standing stadiometer. Weight (in kilograms) was measured 
using a hospital grade scale (Jack et al., 1994). BMI was calculated as weight (kg) / 
height (m)2. 
2.12 Blood collection  
10 mL of blood was collected at baseline and at 16 weeks. It was drawn by a trained 
phlebotomist from the medial cubital vein using aseptic technique and a 21G needle. 
Blood was taken to fill a 4 mL vacutainer plain tube (to test vitamin D3 and insulin), 2 
mL vacutainer EDTA tube (to test HbA1c) and 4 mL vacutainer lithium heparin tube 
(to test lipids, fasting glucose, calcium, albumin and antioxidant). The patient’s 
information was recorded on the blood bottles as Name, Date of Birth and Hospital 
number (or equivalent) for identification. In order to test fasting glucose levels, 
participants were asked to fast (no food or beverages except water) for a minimum of 
ten hours prior to the phlebotomy appointment (Nagpal et al., 2009). This is due to the 
fact that test results could be affected by consuming food and beverages. This can lead 
to imprecise results as during fasting, glucagon is activated which raises plasma 
glucose levels (The global diabetes community 2013).  
The withdrawn blood was taken to the hospital lab to be centrifuged and kept in the 
freezer at minus 20°C until the end of the recruitment period. The only exception to 
this was the sample of total antioxidant levels which had to be stored off-site at King 
Abulaziz Research Centre at a temperature of -80°C. Once all the data had been 
collated at baseline and following the 16-week trial, the researcher went to the lab to 
run the tests with the technicians.  
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2.13 Supplement compliance  
In this study, the aim was to quantify compliance and employ methods which increase 
compliance to optimal levels. A calendar and pill counting were used to assess 
compliance by Talaei et al. (2013) and von Hurst et al. (2010). Subject interview can 
be particularly useful as it provides qualitative details on why the subject may not have 
complied, not solely whether they complied or not. In the case of von Hurst et al. 
(2010), subjects reported difficulty in taking four capsules per day for six months. This 
was taken into account in the present study to reduce the number of capsules required 
as this could negatively affect compliance. 
Pill counting of the surplus supply by weight or number is a proven method of 
obtaining an objective figure for compliance during the study period (Al-Sofiani et al., 
2015). This method has been employed in a number of studies (De Boer et al., 2008; 
Dong et al., 2010; Talaei et al., 2013).  
Other aids for improving compliance involve calendar charts, which enable the subject 
to record days when the pill was taken and thus highlights to the researcher the days 
when it was missed. In a meta-analysis of the success of compliance methods in 153 
studies showed that no particular intervention had a clear advantage over another 
(Roter et al., 1998). However, methods that encompassed cognitive and behavioural 
components improved compliance substantially.  
Whilst there is no gold standard for compliance assessment, this study incorporated a 
calendar for recording pill usage, along with a debriefing questionnaire and interview 
on compliance issues during the study period and counting remaining supply at 16 
weeks. In addition, the researcher contacted each participant daily via What’sapp 
asking them to reply that they had taken their supplement that day. This method of 
contacting participants via SMS has been shown to improve medication adherence by 
17.8% (Strandbygaard et al., 2010).  
2.14 Debriefing Questionnaire 
At the end of the 16-week trial, an appointment was made for every participant to meet 
with the researcher. Again, participants were reminded via phone one week in advance 
to attend their appointment. At this final appointment, any leftover tablets were 
collected, along with the calendars and the left over pills counted. A debriefing 
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questionnaire was administered to ensure that no changes had occurred during the 
study that would inadvertently affect the results. These included changes to prescribed 
medicines, onset of new medical conditions and use of any additional vitamins. The 
baseline anthropometric measurements were re-recorded, along with the AGEs 
measured and blood samples taken for the previous parameters. 
2.15 Blood analysis 
All blood sampling methods are in accordance with the procedures in place at the Al-
Noor clinical laboratory and information received from Roche (Roche 2013). Storage 
and deposition of blood samples were in line with the Human Tissue Act and 
Manchester Metropolitan University guidelines.  
2.15.1 Measurement of the concentration of vitamin D  
Analysis was carried out using the Roche Cobas E601 analyser. This is a competitive 
electrochemiluminescent protein binding assay designed to measure total 25-OH 
vitamin D in serum or plasma, using vitamin D binding protein (VDBP) as capture 
protein to bind vitamin D3 and vitamin D2. 16µl of serum was incubated with pre-
treatment reagent, releasing the vitamin D from its binding partner Vitamin D Binding 
Protein (VDBP).  
The sample was then incubated with ruthenium labelled VDBP, forming vitamin D- 
ruthenium labelled VDBP complexes. Finally, streptavidin-coated micro-particles were 
added which occupy any free sites in the ruthenium labelled VDBP. The sample was 
then aspirated into the measuring cell, and the microparticles magnetically attach to the 
surface of the electrode. A voltage was applied to the electrode, inducing 
chemiluminescent emission, which was measured by a photomultiplier. Results were 
determined via a calibration curve that was generated by the analysis system. 
Calibration was performed once every 24 hours. The control interval was set with the 
lower limit value between 13.180- 20.620 ng/ml and the upper limit value of 25.200- 
37.800 ng/ml using PreciControl Varia.   
Previous studies have looked at this method of vitamin D measurement and compared 
to other methods of measurement and found high concordance (Abdel-Wareth et al., 
2013). According to the classification of The Endocrine Society, vitamin D deficiency 
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is defined using the serum concentrations shown in Table 2.2 (Holick 2004; Holick 
and Chen 2008; Holick et al, 2011). 
Table 2.2: Classification of vitamin D deficiency according to The Endocrine 
Society, using blood serum concentration of vitamin D.  
         (Holick 2004; Holick and Chen 2008; Holick et al, 2011) 
Classification of vitamin D deficiency Concentration of vitamin D  
Deficiency <   20 ng/ml (< 50 nmol/L) 
Insufficient 21-29 ng/ml (51-74 nmol/L) 
Adequate or sufficient > 30 ng/ml (> 75 nmol/L) 
2.15.2 Measurement of insulin  
Insulin levels were measured using the electrochemiluminescent immunoassay, as used 
in (Nagpal et al., 2009; Tarcin et al., 2009; Shab-Bidar et al., 2011). The Roche 
electrochemiluminescent immunoassay was used and analysed using the Cobas e601 
analysis system. The assay was designed to measure insulin in 20µl of serum in the 
same method as above, using a biotinylated monoclonal insulin-specific antibody, and 
a monoclonal insulin-specific antibody labelled with ruthenium. Results were 
determined via a calibration curve, which was generated by the analysis system. 
Calibration was performed once every 24 hours. The control interval was set with the 
lower limit value between 18.980- 26.22 µU/mL and the upper limit value of 59.140- 
81.660 µU/mL Using PreciControl Multimarker/ Universal. 
2.15.3 Measurement of the concentration of glycated haemoglobin  
This study used the Roche turbidimetric inhibition immunoassay (TINIA). This is a 
two-step assay where the sample and an anti-HbA1c antibody are mixed, causing 
glycohaemoglobin (HbA1c) to form soluble antigen-antibody complexes. The addition 
of polyhaptens then react with excess anti-HbA1c antibodies to form an insoluble 
antibody-polyhapten complex which can be quantified turbidimetrically using the 
Cobas e501 analyser. A blood volume of 2 µl was diluted with 180 µl Hemolyzing 
Reagent. The control interval was set with the lower limit value between 4.80-6.12% 
using PreciControl HbA1c norm (normal) and the upper limit value of 9.3-11.7% using 
PreciControl HbA1c path (Pathogenic).  
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A diagnosis of diabetes is made with HbA1c levels of 6.5% or greater (WHO 2011; 
American Diabetes Association 2012). This study was interested in patients with 
poorly controlled T2DM, defined as HbA1c levels of greater than 8%, as used in 
previous studies (Rotchford et al., 2002; Kuo et al., 2006; Wolff-McDonagh et al., 
2010).  
2.15.4 Measurement of the concentration of lipids 
This study used an enzymatic method to measure high-density lipoprotein (HDL), low 
density lipoprotein (LDL), triglycerides (TG) and total cholesterol (TC). HDL and 
LDL was measured using the Roche enzymatic colorimetric assay system. The 
concentration of HDL- and LDL- cholesterol is determined enzymatically by 
cholesterol esterase and cholesterol oxidase. Cholesterol esters are broken down into 
free cholesterol and fatty acids by cholesterol esterase. In the presence of oxygen, 
cholesterol is oxidized by cholesterol oxidase to 4-cholestenone and hydrogen 
peroxide. In the presence of peroxidase, the hydrogen peroxide generated reacts with 
4-amino-antipyrine and HSDA to form a purple-blue dye. The colour intensity of this 
dye is directly proportional to the cholesterol concentration and is measured 
photometrically using the Cobas analyser e501. A volume of 2.5µl of serum was used 
to measure HDL and 2µl of serum for LDL. The control intervals for HDL- cholesterol 
were set as 23.7-32.5 mg/dL for the lower limit using PreciControl ClinChem Multi 1 
and 53.2-73.6 mg/dL for the upper limit using PreciControl ClinChem Multi 2. The 
control intervals for LDL- cholesterol were set 44.6-61.4 mg/dL for the lower limit and 
80.3-110.7 mg/dL for the upper limit, again using PreciControl Multi 1 & 2 
respectively.  
Triglycerides (TG) were measured using a Roche assay that uses a lipoprotein lipase 
for the rapid and complete hydrolysis of triglycerides to glycerol followed by oxidation 
to dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide 
produced then reacts with 4-aminophenazone and 4-chlorophenol under the catalytic 
action of peroxidase to form a red dyestuff. The colour intensity of the red dyestuff 
formed is directly proportional to the triglyceride concentration and can be measured 
photometrically. A sample size of 2 µl was used and the control intervals set as 93-113 
mg/dL for the lower limit using PreciControl ClinChem Multi 1 and 184-224 mg/dL 
for the upper limit using PreciControl ClinChem Multi 2.     
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Total cholesterol (TC) was measured using a Roche assay. Cholesterol esters are 
cleaved by the action of cholesterol esterase to yield free cholesterol and fatty acids. 
Cholesterol oxidase then catalyzes the oxidation of cholesterol to cholest-4-en-3-one 
and hydrogen peroxide. In the presence of peroxidase, the hydrogen peroxide formed 
effects the oxidative coupling of phenol and 4-aminophenazone to form a red quinone-
imine dye. The colour intensity of the dye formed is directly proportional to the 
cholesterol concentration. It is determined by measuring the increase in absorbance 
using the Cobas e501 analyser. A volume of 2µl of serum was sampled and the control 
intervals set as 74.1-90.5 mg/dL for the lower limit using PreciControl ClinChem 
Multi 1 and 155-191 mg/dL for the upper limit using PreciControl ClinChem Multi 2. 
Table 2.3 shows the desirable, low, borderline high, high and very high cut off points 
for lipid measurements, as defined by the American Heart Association (The American 
Heart Association 2013). These cut offs were used to compare the lipid levels pre-
intervention and post-intervention to assess whether vitamin D3 has significantly 
altered lipid values.  
The American Diabetes Association published guidelines in 2012 on desirable lipid 
levels for diabetic patients, whilst adding a limit for a low HDL cut-off (American 
Diabetes Association 2012). These are in agreement with the optimal levels shown in 
Table 2.3.  
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Table 2.3: Defining the cut offs for lipid measurements. 
 (Adapted from The American Heart Association 2013). 
 
 
2.15.5 Measurement of the concentration of fasting Glucose 
Fasting glucose levels were determined using the Roche enzymatic reference method 
combining 2µl of serum with hexokinase. 4,5 Hexokinase catalyzes the 
phosphorylation of glucose to glucose-6-phosphate by ATP. Glucose‑6‑phosphate 
dehydrogenase oxidizes glucose-6-phosphate in the presence of NADP to gluconate-6-
phosphate. No other carbohydrate is oxidized. The rate of NADPH formation during 
the reaction is directly proportional to the glucose concentration and is measured 
photometrically using the Cobas e501 analyser. The control intervals were set as 92-
112 mg/dL for the lower limit using PreciControl ClinChem Multi 1 and 212-260 
mg/dL for the upper limit using PreciControl ClinChem Multi 2. 
2.15.6 Measurement of the concentration of corrected calcium 
The most popular method of calcium analysis in the previous studies is 
chemilumiescence (Orwoll et al., 1994; Mitri et al., 2011; Shab-Bidar et al., 2011; 
Talaei et al., 2013). Calcium ions in 3 µl of serum react with 5-nitro-5’methyl-BAPTA 
(NM-BAPTA) under alkaline conditions, forming a complex. This complex reacts in 
the second step with EDTA to form a calcium EDTA complex + NM-BAPTA. The 
 Desirable Low Border line high High Very high 
HDL ≥40 mg/dL for men 
≥50 mg/dL for women 
< 35 mg/dL N/A N/A N/A 
LDL <100 mg/dL N/A 130 to 159 mg/dL 160 to 189 
mg/dL 
≥190 mg/dL  
TG <150 mg/dL N/A 150–199 mg/dL 200–499 
mg/dL 
≥500 mg/dL  
TC <200 mg/dL N/A 200 to 239 mg/dL ≥240 
mg/dL  
N/A 
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change in absorbance is directly proportional to the calcium concentration and is 
measured photometrically. The control intervals were set as 8.00-9.40 mg/dL for the 
lower limit using PreciControl ClinChem Multi 1 and 12.6-15.0 mg/dL for the upper 
limit using PreciControl ClinChem Multi 2. 
About 45% of calcium in the blood is normally transported partly bound to plasma 
proteins, notably albumin. When albumin concentrations fluctuate substantially, total 
calcium levels may vary (Goltzman 2000). Such discrepancies can be ‘corrected’ using 
the formula: 
Corrected calcium (mM) = measured total Ca (mM) + [40 - serum albumin (g/L)] X 
0.02 
Albumin was measured using the Roche cobas c 501 colorimetric assay. A buffer 
solution is added to 3µl of serum to give a pH value of 4.1. At this concentration, 
albumin is able to bind with bromcresol green (BCG), an anionic dye, to form a blue- 
green complex. The colour intensity of the blue-green colour is directly proportional to 
the albumin concentration in the sample and is measured photometrically. The control 
intervals were set as 2.83-3.59 gm/dL for the lower limit using PreciControl ClinChem 
Multi 1 and 4.45-5.65 gm/dL for the upper limit using and PreciControl ClinChem 
Multi 2.  
2.15.7 Measurement of Oxidative Stress (Total Antioxidant Capacity) 
Total antioxidant capacity (TAC) has been demonstrated to be a reliable method for 
measuring oxidative stress, with a lower TAC representing higher levels of oxidative 
stress (Ceriello et al., 1997). TAC was assessed using a colorimetric method with the 
commercially available Cell Biolabs’ OXiSelect TAC assay kit (Antibodies online 
2013). This method utilises a standard against which to measure the total antioxidant 
capacity (ascorbic acid; bovine serum albumin [BSA]; glutathione [GSH]; vitamin E; 
uric acid; butylated hydroxytoulene [BHT]). 20µl of plasma was collected with heparin 
and then centrifuged at 4°C for 10 minutes. To measure total antioxidant capacity in 
the samples, the samples were compared to a known concentration of uric acid 
standard within a 96-well microtiter plate format. Samples and standards were diluted 
with a reaction buffer and a reading obtained using a standard 96-well 
spectrophotometric microplate reader at 490nm. Upon addition of the copper ion 
reagent into each well the reaction proceeded for a few minutes. The reaction was then 
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stopped and once again read with the spectrophotometric microplate reader at 490nm. 
Quality control solutions of a fixed concentration of total antioxidants were ran in 
duplicate and the absorbance of the control sample measured as with the plasma 
samples. 
2.16 Homeostasis Model Assessment 
Insulin resistance and progressive pancreatic β-cell dysfunction have been shown to be 
paramount in the pathogenesis of type 2 diabetes (Song et al., 2007). There have been 
various methods employed to assess these factors, including fasting insulin level, 
fasting glucose/insulin ratio (FGIR), homeostasis model assessment for insulin 
resistance (HOMA-IR) and quantitative insulin-sensitivity check index (QUICKI) 
(Matthews et al., 1985; Bergman 1989; Katz et al., 2000; Cutfield et al., 2003; 
Kurtoglu et al., 2010). HOMA-IR, however has been found to be far superior to FGIR 
and QUICKI in accurately determining insulin resistance (Keskin et al., 2005). 
Therefore, HOMA-IR is a frequently used marker in clinical research studies (Wallace 
and Matthews 2002; Cutfield et al., 2003). The Homeostasis Model Assessment 
(HOMA) estimates both beta cell function (%B) insulin resistance (%IR), as 
percentages of a normal reference population. It is derived from calculating the balance 
between hepatic glucose secretion and insulin secretion from fasting levels of glucose 
and insulin using the following formulas: (Matthews et al., 1985; Wallace et al., 2004). 
HOMA-B = Fasting insulin level/ fasting glucose concentrations – 3.5 (Wallace et al., 
2004). 
HOMA-IR= Fasting insulin (μU/mL) x Fasting glucose (mg/dL) /405 (Matthews et al., 
1985). 
As the HOMA model uses only a single measurement of fasting insulin and glucose it 
is seen to be an easy, cheap and reliable alternative to large-scale epidemiologic 
studies.  
2.17 Advanced Glycation Endproducts (AGE) measurement 
An AGE reader was used. This can assess AGE levels within the skin in less than 30 
seconds and is a non-invasive procedure. Some AGEs have auto-fluorescence 
capabilities. The AGE reader has a UV light source which penetrates the skin to a 
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depth of 1 mm. The AGEs become excited, and emit auto-fluorescence at particular 
wavelengths. The detector within the AGE reader can assess the wavelengths of auto-
fluorescence produced by the AGEs, and its intensity, which correlate to the quantity 
of AGEs present within the skin tissue (Diagnoptics 2012).   
2.18 Data protection  
The researcher obtained an MRC data protection certificate prior to commencing the 
study and the study followed data protection 1998 guidelines to ensure that only those 
involved in the study had access to data and that all computers that store this data are 
encrypted with a password (Smith and Harding 2013). The study was anonymised and 
all subjects given a unique study number. A key linking patient names and their study 
number was held by the study supervisor.  
2.19 Data handling and cleaning  
All data was entered in to and maintained in Microsoft Excel. All entries were double 
checked to minimise data entry errors. Before statistical analysis, data was cleaned and 
checked for mistakes. If during the course of the study, changes had occurred that 
would inadvertently affect the results, these subjects were excluded from the study. 
This included non-compliance with taking vitamin, changes to prescribed medicines, 
onset of new medical conditions, use of any additional vitamins and not returning after 
16 weeks. Adherence to medication was calculated by taking the worst outcome from 
either the pill calendar, debriefing questionnaire or returned supplements. This value 
for the number of pills not taken during the study period was used to calculate 
percentage adherence (number of pills not taken/total number prescribed) x100. Where 
adherence was found to be less than 80%, participants were excluded from further 
analyses. This method of adherence calculation has been shown to be an acceptable 
level of adherence (Winkler et al., 2002; Osterberg and Blaschke 2005; Mitri et al., 
2011).  
2.20 Statistical analyses 
Microsoft Excel was used to handle and maintain the data. All statistical analyses was 
performed using Statistics Package for Social Sciences (SPSS, version 20).   
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The population was characterised using descriptive statistics including mean, median, 
mode and range summary statistics for age, BMI and biological test results. Pill 
adherence was calculated as described in the previous section and compared between 
test groups by means of a one-way ANOVA. The Kolmogorov-Smirnov test was used 
to test the assumption that the clinical outcome measures are normally distributed. If 
necessary, appropriate transformations such as logarithms were used to normalise the 
data.   
To compare pre- and post-treatment variables, a multivariate approach is needed 
(Young 2007). An ANCOVA model was used to adjust the mean values of the 16-
week outcome measures by controlling for the within-subjects differences in the 
baseline measures, leading to precise estimates of the between-subjects effects of the 
treatments, taking in to account the interactions between covariates and treatment 
groups (Albert 1999; Raab et al., 2000; Pocock et al., 2002). The ANCOVA was based 
upon the General Linear Model (GLM) procedure, with statistical significance α<0.05. 
The GLM assumption of homogeneity of regression slopes (i.e. that the slopes of the 
lines of the outcome measures versus the baseline measures are equal for each test 
group) was tested by determining the significance of the interaction between covariates 
and the three treatment groups. A non-significant interaction at α=0.05 implies 
homogeneity of regression slopes (Rutherford 2001). The effect sizes were interpreted 
according to the criteria of Ferguson (2009) where eta squared < .04 = negligible; .041 
to .249 = low; .250 to .639 = moderate; .640 to 1.00 = high. 
Mixed ANOVA considers the number of times the dependent variable is measured per 
participant (Robert 2012). Two-way interaction is used to examine whether the effect 
of one factor depends on the level of another factor and vice versa (Robert 2012). In 
the present study, the effect of two different doses of vitamin D supplementation were 
compared against a placebo over time (pre-test and post-test). Mixed ANOVA was 
used to examine if there was an interaction within subject groups (pre-test and post-
test) and between subject groups (A, B and C) on the dependent variable.  
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Chapter 3. Patient Demographics 
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3.1 Introduction 
As with many diseases, certain traits and lifestyle factors can influence a person’s 
susceptibility to developing diabetes. There are many factors which confer a small 
amount of risk such as certain genetic polymorphisms, and others which confer a much 
larger risk such as obesity. Many studies have found that non-modifiable risk factors 
such as gender, age at onset of disease, duration of diabetes and the current age of the 
patient directly affect HbA1c (Verma et al., 2006).  
It is well documented that middle-aged and older adults are at highest risk of 
developing type 2 diabetes (CDC 2014). A wider age range of 18-60 years was 
selected in this study to enable comparisons with other similar studies (Mitri et al., 
2011; Al-Daghri et al., 2012). Several studies have shown a robust inverse 
relationship, especially in women, between T2DM prevalence and education level. The 
relationship between education level and health is, however, a complex one and is 
likely influenced by many factors, including lifestyle, access to health services and 
awareness of health promotion (Sacerdote et al., 2012). Lifestyle factors such as diet 
and smoking are considered to be strong risk factors for the development of diabetes. It 
is widely acknowledged that appropriate use of diet and exercise can increase insulin 
sensitivity, improve glycaemic control and reduce the need for intervention with oral 
medication or insulin (Ainsworth et al., 1993; Nielsen 1998a). 
It is well documented that having a family history of diabetes increases the risk of 
developing the disease, however the contribution of genetics to diabetes is not a simple 
topic (Valdez et al., 2007). There is considerable variation in the heredity of diabetes 
among different populations and in different environments. Studies have also shown 
that an increased duration of diabetes correlates with higher HbA1c levels (Verma et 
al., 2006).   
Obesity is one of the main non-genetic risk factors for diabetes (Hamman 1992). 
Weight gain has been shown to cause a decrease in insulin sensitivity, possibly as a 
mechanism to halt further weight gain (Hamman 1992). Increases in BMI amongst 
type 2 diabetics have been shown to be a strong indicator of changes in HbA1c as 
documented in longitudinal cohort studies. Similarly, patients who lose weight are far 
more likely to reach their target HbA1c than those whose weight remains stable or 
increases (Wilding 2014).  
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The risk factors that are linked to worse prognostic outcomes may confound results if 
they are unevenly distributed between groups (Practice Committee of American 
Society for Reproductive 2008). The aim of this study was to identify the relevant 
modifiable and non-modifiable risk factors and to control for their effects. As such, the 
following parameters were measured across the two groups (Group A: 4000 IU of 
vitamin D per day, and Group B: 2000 IU per day) and compared against the age-
matched control group:  
• Age, education level, smoking status, BMI and diet 
• Family history and duration of type 2 diabetes 
3.2 Materials & methods 
Ethical approval was granted by the Manchester Metropolitan University Ethics 
Committee as stated in section 2.2. This was a double-blind, randomized control trial 
of 156 female type 2 diabetics with HbA1c levels greater than 8.0 percent. All 
participants were recruited from Al-Noor hospital in Saudi Arabia and informed 
consent was obtained as detailed in sections 2.6 and 2.9. Subjects who met the 
inclusion criteria were randomly allocated to one of three test groups. These were as 
follows: 2000 IU vitamin D per day; 4000 IU vitamin D per day; or a placebo, as 
described in section 2.3. Participants were also asked to attend a meeting and complete 
a pre-study screening questionnaire at baseline, and a debriefing questionnaire at 16 
weeks as per sections 2.10 and 2.14.   
3.3 Results 
One hundred and fifty-six subjects were initially recruited, however, due to attrition 
between the baseline measurements and the final measurements (collected 16 weeks 
after the baseline), the total number of participants was n = 128: 42 in group A, 43 in 
group B and 43 in group C.  The reasons for the attrition of 10 individuals from Group 
A and nine individuals each from Groups B and C (based on the responses to the 
debriefing questionnaire) are listed in Table 3.1.  
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Table 3.1: Reasons for attrition 
Reason Group 
A 
Group 
B 
Group 
C 
Non-compliance with taking vitamin D supplements 1 2 2 
Contracted gastrointestinal malabsorption during the 
intervention  
1 1 0 
Changed diabetic medication during the intervention  4 3 2 
Did not return after 16 weeks 4 3 2 
Took additional vitamin D  0 0 3 
 
The demographic characteristics of the 128 participants, classified into groups A, B, 
and C, as reported in the Pre-Questionnaire, are summarized in Table 3.2. All of the 
participants were Saudi women.  The most frequent age-group, representing about half 
of the women in Group A, B, and C was 45 to 54 years. The next most frequent age-
group, representing about one third of the women in Group A, B, and C was 55 to 60 
years.  The most frequent levels of education of over half the women in each group 
were no schooling or primary school.  About 14 percent of the women in each group 
were employed, and over 70 percent in each group were unemployed. Consequently, in 
terms of their demographic characteristics, the women in groups A, B, and C appeared 
to be approximately equivalent.   
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Table 3.2: Demographic characteristics of participants at baseline (N = 128) 
Characteristic Category Group A Group B Group C 
n % n % n % 
Nationality Saudi 42 100.0 43 100.0 43 100.0 
Gender Female 42 100.0 43 100.0 43 100.0 
Age 25-34 1 2.4 1 2.3 0 0.0 
35-44 3 7.1 7 16.3 5 11.6 
45-54 24 57.1 21 48.8 21 48.8 
55-60 14 33.3 14 32.6 17 39.5 
Education No schooling 13 31.0 8 18.6 16 37.2 
Primary school 10 23.8 13 30.2 11 25.6 
Secondary school 11 26.2 7 16.3 5 11.6 
High school 1 2.4 4 9.3 4 9.3 
Diploma 3 7.1 2 4.7 2 4.7 
Bachelor’s degree 4 9.5 8 18.6 4 9.3 
Postgraduate degree 0 0.0 1 2.3 1 2.3 
Employment Employed 6 14.3 6 14.0 6 14.0 
Retired 2 4.8 6 14.0 3 7.0 
Unemployed 34 81.0 31 72.1 34 79.1 
 
The health-related characteristics of the 128 participants, classified into groups A, B, 
and C, as reported in the Pre-Questionnaire, are summarized in Table 3.3. Supplement 
compliance was very high (over 96%) and those who had taken less than 80% of the 
tablets were excluded from the study. The majority of the participants (81.0 % in group 
A, 86.0 % in group B, and 69.8 % in group C) were classified as obese (BMI > 30 
kg/m2). None of the women were pregnant. Only three or fewer women in each group 
were smokers or had a special diet. Over half of the participants in each group took 
vitamin supplements that did not contain vitamin D, before the study. The duration of 
diabetes of about two thirds or more of the participants in each group was over eight 
years. The family history of diabetes was very high in group A (95.2 %) and group B 
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(93.0 %) but relatively low in group C (18.6 %). All of the participants reported 
complications, of which the most frequent were neuropathy (about 80 % or more in 
groups A, B, and C); and cardiovascular disease (over 80 % in groups A, B, and C). 
Hypothyroidism was present in about one fifth of the patients in each group. 
Consequently, in terms of their health related characteristics, groups A, B, and C 
appeared to be approximately equivalent (with the exception of family history of 
diabetes).   
Table 3.3: Health-related characteristics of participants at baseline (N = 128) 
Characteristic Category Group A Group B Group C 
n % n % n % 
Overweight (BMI = 
25.1 to 30) 
8 19.0 6 14.0 13 30.2 
Obese (BMI > 30) 34 81.0 37 86.0 30 69.8 
Pregnancy Not pregnant 42 100.0 43 100.0 43 100.0 
Smoking Smoker 2 5.8 3 7.0 2 4.7 
Diet Special diet 3 7.1 3 7.0 1 2.3 
Supplements (not 
containing  
vitamin D).  
Yes 25 59.5 27 62.8 22 51.2 
Duration of diabetes 1-2 years 7 16.7 3 7.0 4 9.3 
3-5 years 2 4.8 10 23.3 5 11.6 
6-8 years 2 4.8 2 4.7 5 11.6 
> 8 years 31 73.8 28 65.1 29 67.4 
Family history of DM Yes 40 95.2 40 93.0 8 18.6 
Complications Yes 42 100.0 43 100.0 43 100.0 
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Nephropathy 0 0.0 0 0.0 1 2.3 
Neuropathy 37 88.1 35 81.4 34 79.1 
Diabetic Cataract 8 19.0 6 14.0 14 32.6 
Cardiovascular 
disease (e.g. coronary 
artery disease, 
hypertension, heart 
failure etc.)  
12 28.6 5 11.6 4 9.3 
Dyslipidaemia 37 88.1 39 90.7 36 83.7 
Retinopathy 12 28.6 18 41.9 9 20.9 
Comorbidities Hypothyroidism  10 23.8 8 18.6 9  20.9 
 
3.4 Discussion 
In this chapter the modifiable and non-modifiable risk factors and their effect on 
diabetes will be discussed.  
3.4.1 Age and duration of diabetes 
The mean age group across all study groups was 45-54 years. This is unsurprising 
given that older age is a well-documented risk factor for the development of type 2 
diabetes and the peak age of onset of type 2 diabetes is usually later than type 1 (CDC 
2014). In the 25-34 age group there were only 1.5 percent (n=2) of participants. Orwoll 
et al. (1994) has previously suggested that young patients with type 2 diabetes mellitus 
may confound outcomes due to the perceived lowered insulin secretion in diabetics of 
shorter duration. Therefore, despite low numbers of type 2 diabetics in Orwoll’s 1994 
study, it was important to take into account the duration of diabetes before analysis of 
the results.   
The average duration of diabetes was over eight years in two-thirds of the study 
population. Studies have shown that an increased duration of diabetes correlates with 
higher HbA1c levels (Verma et al., 2006). With increased age and duration of diabetes 
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the tendency is for the blood sugar level to increase, followed by an increase in the 
HbA1c and the fasting insulin level (Shera et al., 2004).  
3.4.2 Education level  
The mean education level of study participants was no schooling or primary school 
education (55.4 percent, n= 71). This supports what previous studies have found that 
lower levels of education are related to higher prevalence of type 2 diabetes amongst 
women (Robbins et al., 2001; Agardh et al., 2011; Sacerdote et al., 2012). Education 
level is not thought to directly influence the biology of type 2 diabetes; however its 
effect on the disease is mediated through other risk factors associated with low levels 
of education (smoking status, diet, exercise, BMI). Conversely, a higher level of 
education is thought to relate to positive health impacts (Winkleby et al., 1992; 
Berkman and Macintyre 1997). For example, those who are more educated are likely 
to be more amenable to health education and to have better access to healthcare, 
enabling them to exhibit more positive health practices. It is therefore perhaps 
unsurprising that the majority of the participants in this study had had little education. 
3.4.3 Smoking  
The incidence of smoking amongst participants in all groups was low (5.5 percent, 
n=7). This was surprising given that smoking is a well-documented risk factor for the 
development of type 2 diabetes (Eliasson 2003; Haire-Joshu et al., 2004). A systematic 
review by Willi et al., found that 24 of the 25 selected studies for their review showed 
a positive association between smoking and diabetes (Willi et al., 2007). A pooled 
analysis of these studies gave a relative risk for developing diabetes of 1.44 per cent 
for smokers compared to non-smokers. However, although there is a wealth of data to 
show that smoking is associated with diabetes, a causal relationship has yet to be 
established. Smoking is often associated with other risk factors such as lack of physical 
activity and poor diet, and so mechanisms for direct causality or indirect association 
must still be investigated. Similarly, the low prevalence of female smokers in this 
study may be explained by cultural factors. Studies have found gender disparities 
amongst young Arab smokers, with 65 percent of adolescent males claiming to be 
smokers, compared with just 11.1 percent of adolescent females (Abdalla et al., 2007). 
This is perhaps unsurprising given that Arab males are actively encouraged to spend 
time with friends and are not supervised as strictly as females. Arab females, however, 
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may consider smoking to affect their reputation and feminine Islamic image, 
consequently affecting their marriage prospects (Islam and Johnson 2003).  
3.4.4 Obesity  
Obesity has been shown to be a robust indicator for the development of type 2 diabetes 
with one study conducted in a cohort of over 110,000 women finding that for those 
with a BMI in the range of 23 to 23.9 kg/m2 the relative risk for development of type 2 
diabetes was 3.6 compared to women with a BMI of 22 kg/m2 or lower (Colditz et al., 
1990). The mean BMI across all study groups was above 30 kg/m2, highlighting that 
the majority of the study population were not just overweight (21 %, n= 27) but fell 
into the category of obese (79 %, n= 101) as per the WHO classification for BMI 
(WHO expert consultation 2004). Previous studies in Saudi Arabia have drawn similar 
conclusions. Al-Nozha et al. (2005) found 72.5 percent of his study population to be 
obese or overweight. Prevalence was also higher in females than males, with 44 
percent of Saudi females being obese compared to 26.4 percent of males. The reasons 
for this are plentiful. The Saudi population is experiencing a nutritional transition 
where traditional food is being substituted for high calorie, high fat, fast-food (Al-
Nozha et al., 1991). Alongside this, the lifestyle is predominantly sedentary, especially 
for females, who spend the majority of their time indoors. Physical activity such as 
sports is practiced by a very small percent of the population and socialising is instead 
predominantly around meals that are high in carbohydrates and fats, for example meals 
composed of rice with whole lamb. The hot climate discourages individuals from 
participating in physical activity and vehicles are used for even moderate distances of 
travel (Al-Othaimeen et al., 2007).  
3.4.5 Family history  
The family history of diabetes was very high in group A (95.2 %) and group B (93.0 
%) but relatively low in group C (18.6 %). It has been well-documented that first-
degree relatives of diabetic parents have an increased risk of developing type 2 
diabetes themselves (Midhet et al., 2010). There is strong evidence for hereditary 
aspects of diabetes, most notably because concordance rates are higher in monozygotic 
twins compared to dizygotic twins and sibling recurrence rates are higher than for the 
general population (O'Rahilly et al., 2005). However, roughly half of the risk of T2DM 
can be attributed to lifestyle, and half to genetics (Midhet et al., 2010). Whilst family 
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history is a good indicator of future development of type 2 diabetes, it is unlikely that 
having a positive or negative family history would affect the results of vitamin D 
supplementation (Krul-Poel et al., 2015). 
4.4.6 Summary 
All of the above measured modifiable and non-modifiable risk factors were roughly 
equal across all study groups. The only exception to this was the prevalence of a strong 
family history for diabetes amongst the subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
Chapter 4. Vitamin D3 Status 
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4.1 Introduction  
The Endocrine Society Clinical Practice Guidelines state that an optimal concentration 
of serum vitamin D is above 30 ng/ml (Holick et al, 2011). Vitamin D deficiency is 
defined as serum concentrations below 20 ng/ml, whilst insufficiency is defined as 
between 21 and 29 ng/ml (Bischoff-Ferrari et al., 2006; Lee et al., 2008; Holick et al, 
2011). A minimum daily dose of 400 IU of vitamin D is expected to raise serum 
concentrations by 2.8 ng/ml in deficient subjects and this dose has been also 
recommended by Public Health England to be taken daily in autumn and winter 
(Heaney et al., 2003; Public Health England, 2016). However, the rise in serum 
vitamin D is related to the baseline concentration, and a severely deficient patient is 
likely to require an even higher dose to normalise their status (Heaney et al., 2003). 
Multiple studies have found improvements in markers of diabetes in those involving 
vitamin D deficient subjects, whose vitamin D status is then normalised through 
supplementation (Norman et al., 1980; Cade and Norman 1986). Furthermore, it has 
been shown that where sufficient serum vitamin D concentrations were not achieved, 
despite similar doses of supplementation, the effect on diabetic markers is far less 
(Sugden et al., 2008). It is therefore important that this study measured serum vitamin 
D concentrations before and after supplementation.  
It has been proposed that high doses of vitamin D supplementation above 10,000 
IU/day may lead to toxic effects due to hypercalcaemia (Yiu al., 2013; Holick et al, 
2011). This can present with symptoms of anorexia, nausea, constipation and 
depression and can be life-threatening (Joshi et al., 2010). It was therefore important in 
this study to measure baseline and 16-week corrected calcium levels to ensure subject 
safety throughout the study. Vitamin D supplementation below 10,000 IU/day has not 
been found to have any adverse effects (Hathcock et al., 2007).  
Obesity has long been associated with an increased risk of developing type 2 diabetes 
(Kahn et al., 2006). The current literature highlights an inverse relationship between 
vitamin D and obesity (Dalgard et al., 2011; Salekzamani et al., 2011). Serum 
concentrations of 25(OH) D have been shown to be lower in obese subjects and obese 
subjects appear to have a lower vitamin D intake than those of a normal weight 
(Kamycheva et al., 2003; Jorde et al., 2010). One hypothesis is that vitamin D 
deficiency increases parathyroid hormone (PTH) which in turn increases the cytosolic 
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calcium level, preventing lipolysis and promoting expression of fatty acid synthase (Ni 
et al., 1994; Zemel et al., 2000; Xue et al., 2001). However, to date, the research has 
failed to demonstrate that supplementation with vitamin D in obese subjects aids 
weight loss (Sneve et al., 2008; Zittermann et al., 2009).  
This study aims to test the hypothesis that 16 weeks of vitamin D supplementation 
would lead to an improvement in serum vitamin D concentrations and BMI, with no 
adverse effect on the serum corrected calcium concentration.  
4.2 Methodology 
Blood samples were collected from all 128 participants at baseline and 16 weeks using 
the aseptic technique described in section 2.12. Vitamin D status was measured using 
the Roche electrochemiluminescent protein binding assay Cobas E601 as per section 
2.15.1. Serum corrected calcium levels were analysed using chemilumiescence as 
indicated in section 2.15.6. Anthropometric measurements were taken at baseline and 
16 weeks, and calculated using the BMI formula as described in section 2.11. 
4.3 Results 
4.3.1 Vitamin D Status 
The changes in the mean serum vitamin D of the participants (post-test minus pre-test) 
in the 4000 IU group (A), the 2000 IU/day group (B), and the placebo group (C) are 
compared in Table 4.1. The difference in mean serum vitamin D concentrations 
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 4.1.  
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Table 4.1: Post-hoc comparison of vitamin D status (ng/ml) between baseline (pre-
test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons  
 
 
 
The results of ANCOVA indicated that the mean serum vitamin D varied significantly 
between the three groups, (F (2, 124) 174.54, p <0.001) with a large effect size (eta 
squared = 0.738). Mixed ANOVA was used to test whether there was a statistically 
significant interaction between time (pre-test and post-test) and the three 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 10.52 ±7.04 32.92 ±7.81  22.40 ±7.37* < 0.001 
B 12.54 ±7.90 28.93 ±7.61  16.39 ±7.95* < 0.001 
C 11.55 ±9 10.87 ±7.25  -0.68 ±4.45 0.510 
Figure 4.1:  13: Mean Vitamin D status (ng/ml) across the three groups over 
time (pre-test and post-test) 
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supplementation groups (A, B and C). The results of mixed ANOVA showed that there 
was a significant interaction between time and the three groups (F (2,125) = 133.87, p 
< 0.001). One-way ANOVA was used to examine any significant difference between 
A, B and C, for pre-test and post-test. The results of one-way ANOVA indicated that 
for pre-test the mean serum vitamin D did not vary significantly between the three 
groups (F (2, 125) = 0.645, p = 0.527). In contrast, for post-test the mean serum 
vitamin D varied significantly between the three groups (F (2, 125) = 103.23, p < 
0.001). 
Using post-hoc test for pairwise comparison at post-test, mean serum vitamin D for 
group A was significantly higher than groups B (mean change = 3.99 ng/ml, p = 
0.016), and C (mean change = 22.05, p < 0.001), see Table 4.2. Mean serum vitamin D 
concentration for group B was significantly higher than C (mean change = 18.05 
ng/ml, p < 0.001).   
Table 4.2: Post-hoc test comparisons of vitamin D status (ng/ml) between the 
three groups for post-test 
*indicates a significant difference between two groups as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
Comparing pre- and post-test using post-hoc test, there was a significant difference in 
serum vitamin D concentration between the pre-test and post-test for group A (mean 
change = 22.40 ng/ml, p < 0.001), and B (mean change = 16.39 ng/ml, p < 0.001), 
where vitamin D status increased in the post-test, see Table 4.1. No significant 
difference was found for group C (p = 0.510).  
Time Group Group 
Mean 
change  
p-valueb 
16 weeks 
  A   B 3.996* 0.016 
 A   C 22.050* 0.001 
  B   C 18.054* 0.001 
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The frequencies of serum vitamin D concentrations of the three groups of participants 
(A, B, and C), as classified by The Endocrine Society (Holick et al, 2011), are 
presented in Figures 4.2 and 4.3.  
 
4.3.2 Corrected calcium (mg/dl) 
The changes in the mean corrected calcium of the participants (post-test minus pre-
test) in groups A, B, and C are compared in Table 4.3. The difference in mean 
corrected calcium between the post-test and the pre-test, as well as the differences 
across the three groups is shown in Figure 4.4.  
Table 4.3: Post-hoc comparisons of corrected calcium (mg/dl) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 9.66 ±0.33 9.77 ±0.35 0.11 ±0.40 0.060 
B 9.52 ±0.37 9.58 ±0.37 0.06 ±0.38 0.302 
C 9.79 ±0.25 9.76 ±0.27 -0.03 ±0.37 0.583 
Figure 4.2: Vitamin D status of participants at 
baseline (%) 
Figure 4.3: Vitamin D status of participants at 16 
weeks (%)  
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Figure 4.4: Mean corrected calcium (mg/dl)  across the three groups over time 
(pre-test and post-test) 
 
The results of ANCOVA indicated that the mean corrected calcium did not vary 
significantly between the three groups (F (2, 124) = 2.137, p = 0.122). In none of the 
three test groups did corrected calcium exceed the safety margin of 10.5 mg/dl. Mixed 
ANOVA testing revealed no significant interaction between time and the three groups 
(F (2,125) = 1.555, p = 0.215). Post- hoc test showed no significant difference in 
corrected calcium between pre-test and post for each group, see Table 4.3. 
4.3.3 BMI 
The changes in the mean BMI of the participants in groups A, B, and C (post-test 
minus pre-test) are compared in Table 4.4. The difference in mean BMI between the 
post-test and the pre-test, as well as the differences across the three groups is shown in 
Figure 4.5.  
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Table 4.4: Post-hoc comparisons of BMI (kg/m2) between baseline (pre-test) and 
after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
 
Figure 4.5:  Mean BMI (kg/m2) across the three groups over time (pre-test and 
post-test) 
 
 
The results of ANCOVA indicated that the mean BMI did not vary significantly 
between the three groups (F (2, 124) = 0.823, p = 0.442). Mixed ANOVA testing 
revealed no significant interaction between time and the three groups (F (2,125) = 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 34.79 ±5.17 34.80 ±5.30 0.01 ±1.34 0.970 
B 38.40 ±11.25 38.70 ±11.27 0.30 ±0.95 0.050 
C 34.94 ±6 .77 35.06 ±6.99 0.12 ±0.81 0.459 
M
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0.964, p = 0.384). Post- hoc test showed no significant difference in BMI between pre- 
and post test for each group, see Table 4.4. 
4.4 Discussion 
4.4.1 Vitamin D status 
This study found a significant improvement in vitamin D status in both of the 
supplemented groups. The doses used (4000 IU/day and 2000 IU/day) were found to 
be safe, as the results did not demonstrate an adverse effect on the serum corrected 
calcium concentration. 
The absence of any supporting evidence for a positive relationship between vitamin D 
and diabetes has often been accredited to suboptimal dosing and short study duration. 
Studies have found that normal serum concentrations of vitamin D can be achieved 
using supplementation doses of at least 1332 IU/day for one month to 50,000 
IU/month for six months in vitamin D deficient subjects (Borissova et al., 2003; Yiu et 
al., 2013; Al-Zahrani et al., 2014; Kampmann et al., 2014; Nasri et al., 2014; Al-
Sofiani et al., 2015; Krul-Poel et al., 2015; Mohamad et al., 2015; Sadiya et al., 2015). 
However, when doses of less than 1332 IU/ day were used, such as de Boer’s (2008) 
study of 2291 type 2 diabetic females using 400 IU/ day, sufficient serum 
concentrations of vitamin D were not achieved even with a study duration of seven 
years. Similarly, a study using 1000 IU vitamin D per day for 12 months was not 
adequate to raise serum vitamin D concentrations into the sufficient range (Breslavsky 
et al., 2013). Moreover, certain studies have highlighted how serum concentrations of 
vitamin D may be more important in improving markers of diabetes than 
supplementation alone. A systematic review of several studies found no improvement 
in diabetic outcomes in participants with already sufficient serum vitamin D 
concentrations (Pittas et al., 2007b). Whilst clear improvements have been 
demonstrated in the serum concentrations of vitamin D in both the supplemented 
groups in this study, neither dose was enough to ensure all participants had sufficient 
concentrations post intervention. Further work investigating the dose-response effect 
of vitamin D on serum status is warranted.  
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4.4.2 Corrected calcium  
In this study mean corrected calcium levels did not increase significantly in either of 
the supplemented groups. None of the participants exceeded the upper limit for normal 
safe calcium levels and no patient developed hypercalcaemia. This supports what other 
studies have concluded that using a safe dose of vitamin D supplements does not cause 
serum corrected calcium levels to increase beyond the normal range (Sugden et al., 
2008; Jorde and Figenschau 2009; Al-Sofiani et al., 2015). Although some studies 
found a significant increase in corrected calcium levels, which was attributed to the 
role of vitamin D in calcium homeostasis, this never exceeded the normal upper limit 
(Raghuramulu et al., 1992; Al-Daghri et al., 2012).    
4.4.3 BMI 
This study showed no significant change in BMI following 16 weeks of 
supplementation with either dose of vitamin D. This supports several other studies 
demonstrating vitamin D to have no significant impact on BMI in obese subjects with 
type 2 diabetes (Sugden et al., 2008; Jorde and Figenschau 2009; Al-Daghri et al., 
2012; Heshmat et al., 2012; Alkharfy et al., 2013; Breslavsky et al., 2013; Al-Zahrani 
et al., 2014; Kampmann et al., 2014; Ryu et al., 2014; Tabesh et al., 2014; Al-Sofiani 
et al., 2015).  
4.4.4 Summary 
In conclusion, this study demonstrates a significant improvement in serum vitamin D 
concentrations (p < 0.001) in both the 4000 IU/day and 2000 IU/day groups. The level 
of corrected calcium remained within normal parameters in all subjects and no side 
effects of vitamin D supplementation were demonstrated in any of the trial 
participants. Vitamin D supplementation of either 2000 IU/day or 4000 IU/day did not 
have an effect on BMI. 
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Chapter 5. Vitamin D3 and Markers of Glycaemia  
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5.1 Introduction 
HbA1c is the principle measure of glycaemia. One study reported that a fall in HbA1c 
of just one percent was associated with a 21 per cent decrease in diabetic 
complications and a 37 percent decrease in microvascular disease (Stratton et al., 
2000). Given that Asian populations develop type 2 diabetes at an earlier age than their 
Caucasian counterparts (Barnett et al., 2006), controlling glycaemia through the 
monitoring of HbA1c is even more pertinent. 
It has been established that high incidence of diabetes in the Middle East is strongly 
related to low vitamin D status (Zhang 2016). Several cross-sectional studies exist 
which demonstrate a relationship between low serum vitamin D concentrations and 
higher fasting blood glucose levels and insulin resistance (Saedisomeolia et al., 2013). 
Recent interventional studies exploring the effect of vitamin D supplementation on 
markers of glycaemia have, however, yielded inconsistent results and a definitive 
relationship between vitamin D and glucose metabolism is yet to be confidently 
established (Alvarez and Ashraf 2010). It has been proposed that vitamin D may affect 
glycaemia by binding to the vitamin D receptor (VDR) on pancreatic beta cells, 
resulting in increased transcription of the insulin gene and increased peripheral glucose 
uptake (Krul-Poel et al., 2014). Vitamin D may also facilitate glucose transport across 
target cells indirectly through the regulation of extra- and intra-cellular calcium (Krul-
Poel et al., 2014).  
This study aims to test the hypothesis that vitamin D supplementation improves insulin 
resistance and beta cell function, as reflected by a reduction in glycated haemoglobin 
and fasting blood glucose levels. 
 
5.2 Methodology 
Blood samples were taken from all 128 participants at baseline and 16 weeks using the 
aseptic technique described in section 2.12. Fasting insulin was measured using the 
Roche electrochemiluminescent immunoassay Cobas e601 as described in section 
2.15.2. Fasting glucose levels were determined using the Roche enzymatic reference 
method described in section 2.15.5. Beta cell function and insulin resistance were 
calculated according to the Homeostasis Assessment Model as described in section 
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2.16. Glycated haemoglobin levels were determined using the Roche turbidimetric 
inhibition immunoassay as per section 2.15.3.  
5.3 Results  
5.3.1 Fasting blood glucose 
The changes in the mean fasting blood glucose of the participants (post-test minus pre-
test) in groups A, B, and C are compared in Table 5.1. The difference in mean fasting 
blood glucose between the post-test and the pre-test, as well as the differences across 
the three groups is shown in Figure 5.1.  
Table 5.1: Post-hoc test comparisons of fasting blood glucose (mg/dl) between 
baseline (pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-value 
Mean ±SD 
A 215.21 ±70.67 175.14 ±73.31 -40.07 ±63.48* 0.001 
B 192.13 ±76.80 183.16 ±73.55 -8.97 ±72.54 0.435 
C 181.65 ±63.42 180.65 ±72.02 -1.00 ±87.09 0.931 
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Figure 5.1: Mean fasting blood glucose (mg/dl) across the three groups over time 
(pre-test and post-test) 
 
 
The results of ANCOVA indicated that the mean fasting blood glucose did not vary 
significantly between the three groups (F (2, 124) = 1.291, p = 0.279). Mixed ANOVA 
testing revealed a significant interaction between time and the three groups (F (2,125) 
= 13.87, p = 0.044). The results of one-way ANOVA for pre-test and post test 
indicated that the mean fasting blood glucose did not vary significantly between the 
three groups. Post- hoc test showed only a significant difference in fasting blood 
glucose between pre and post test for group A (mean change = -40.07 p-value < 
0.001), see Table 5.1. 
5.3.2 Fasting blood insulin 
The changes in the mean insulin of the participants (post-test minus pre-test) in groups 
A, B, and C are compared in Table 5.2. The difference in mean fasting blood insulin 
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 5.2.  
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Table 5.2: Post-hoc test comparisons of fasting insulin (μU/mL) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
Figure 5.2: Mean fasting insulin (μU/mL) across the three groups over time (pre-
test and post-test) 
 
The results of ANCOVA indicated that the mean fasting insulin did not vary 
significantly between the three groups, (F (2, 124) 0.776, p = 0.463). Mixed ANOVA 
testing revealed no significant interaction between time and the three groups (F (2,125) 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 15.34 ±10.40 17.80 ±12.64 2.46 ±10.05 0.213 
B 16.03 ±10.79 15.91 ±10.05 -0.11 ±12.20 0.954 
C 20.56 ±20.81 18.16 ±20.55 -2.40 ±15.28 0.218 
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= 1.55, p = 0.216). Post- hoc test showed no significant difference in fasting blood 
insulin between pre and post test for each group, see Table 5.2. 
5.3.3 Insulin resistance (HOMA-IR) 
The changes in the mean HOMA-IR of the participants (post-test minus pre-test) in 
groups A, B, and C are compared in Table 5.3. The difference in mean HOMA-IR 
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 5.3.  
Table 5.3: Post-hoc test comparisons of HOMA-IR (%) between baseline (pre-
test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
Figure 5.3: Mean HOMA-IR (%) across the three groups over time (pre-test and 
post-test) 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 8.69 ±8.43 8.05 ±7.50 -0.64 ±6.27 0.576 
B 7.62 ±5.27 7.15 ±5.20 -0.47 ±6.44 0.672 
C 11.32 ±20.13 9.08 ±14.46 -2.24 ±9.00 0.050 
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The results of ANCOVA indicated that the mean HOMA-IR did not vary significantly 
between the three groups (F (2, 124) = 0.136, p = 0.873). Mixed ANOVA testing 
revealed no significant interaction between time and the three groups (F (2,125) = 
0.753, p = 0.473). Post- hoc test showed no significant difference in HOMA-IR 
between pre and post test for each group, see Table 5.3. 
5.3.4 Beta cell function (HOMA-B) 
The changes in the mean HOMA-B of the participants (post-test minus pre-test) in 
groups A, B, and C are compared in Table 5.4. The difference in mean HOMA-B 
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 5.4.  
Table 5.4: Post-hoc test comparisons of HOMA-B (%) between baseline (pre-test) 
and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 42.45 ±26.53 82.57 ±76.49 40.12 ±73.92* < 0.001 
B 55.11 ±39.57 71.42 ±65.77 16.30 ±60.81 0.131 
C 65.00 ±73.40 72.95 ±73.55 7.95 ±75.27 0.460 
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Figure 5.4: Mean HOMA-B (%) across the three groups over time (pre-test and 
post-test) 
 
The results of ANCOVA indicated that the mean HOMA-B did not vary significantly 
between the three groups (F (2, 124) = 1.271, p = 0.284). Mixed ANOVA testing 
revealed no significant interaction between time and the three groups (F (2,125) = 
2.390, p = 0.096). Post- hoc test showed only a significant difference in HOMA-B 
between pre and post test for group A (mean change = 40.12%, p < 0.001), see Table 
5.4. 
5.3.5 Comparing the changes in HOMA-IR and HOMA-B with final vitamin D 
concentration 
To investigate the relationship between HOMA-IR and HOMA-B with changes in the 
serum vitamin D concentration, final serum vitamin D concentration was subdivided 
into three groups: < 30 ng/ml, 30-40 ng/ml, and > 40 ng/ml. The results are shown in 
Table 5.5. The baseline vitamin D concentration for the majority of participants across 
all three sample groups was less than 30 ng/ml. After 16 weeks, HOMA-IR for 
participants in group A decreased once a serum vitamin D concentration of more than 
30 ng/ml was achieved. Similar changes were noted for participants in group B, 
however the change in HOMA-IR was more pronounced once serum vitamin D 
concentrations were greater than 40 ng/ml.  
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Table 5.5: Changes in HOMA-IR at different serum vitamin D concentrations 
across the three groups (n = group size) 
   
Group 
Serum 
Vitamin D 
concentration 
(ng/ml) 
HOMA-IR   
Baseline After 16 week 
n Mean ±SD n Mean ±SD 
A 
< 30 42 8.68 ±8.43 16 9.71 ±7.93 
30 - 40 - - 16 6.54 ±5.25 
> 40 - - 10 7.81 ±9.84 
Total 42 8.68 ±8.43 42 8.05 ±7.50 
B 
< 30 41 7.83 ±5.31 23 8.27 ±5.82 
30 - 40 1 2.74 16 6.76 ±4.19 
> 40 1 3.94 4 2.23 ±0.39 
Total 43 7.62 ±5.27 43 7.14 ±5.20 
C 
< 30 40 11.69 ±20.81 41.00 8.81 ±14.47 
30 - 40 2 7.84 ±5.87 2.00 14.80 ±18.30 
> 40  1 3.20 - - 
Total 43 11.32 ±20.13 43.00 9.08 ±14.46 
 
Similarly, HOMA-B appeared to increase in participants in group A when serum 
vitamin D concentrations reached above 40 ng/ml as shown in Table 5.6. However, for 
participants in group B, HOMA-B appear to improve at serum vitamin D 
concentrations of between 30 and 40 ng/ml and less so at the higher concentration of 
greater than 40 ng/ml.   
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Table 5.6: Changes in HOMA-B at different serum vitamin D concentrations 
across the three groups (n = group size) 
 
Group 
Serum 
Vitamin D 
concentration 
(ng/ml) 
HOMA-B 
Baseline After 16 week 
n Mean ±SD n Mean ±SD 
A 
< 30 42 
42.45 ±26.54 
16 
81.26 ±55.95 
30 - 40 - 
- 
16 
65.62 ±61.68 
> 40 - - 10  111.78± 
116.75 
Total 42 42.45 ±26.54 42 
82.57 ±76.49 
B 
< 30 41 
56.85 ±39.57 
23 
58.68 ±42.46 
30 - 40 1 
34.92 
16 
94.96 ±90.60 
> 40 1 
4.19 
4 
50.55 ±38.86 
Total 43 
55.12 ±39.57 
43 
71.42 ±65.77 
C 
< 30 40 
67.46 ±75.44 
41.00 
71.98 ±75.23 
30 - 40 2 
34.37 ±29.75 
2.00 
92.80 ±4.75 
> 40 1 
27.74 
- 
 
Total 43 
65.00 ±73.41 
43.00 72.95 ±73.55 
5.3.6 Glycated haemoglobin (HbA1c)  
The changes in the mean HbA1c of the participants (post-test minus pre-test) in groups 
A, B, and C are compared in Table 5.7. The difference in mean HbA1c between the 
post-test and the pre-test, as well as the differences across the three groups is shown in 
Figure 5.5. 
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Table 5.7: Post-hoc test comparisons of HbA1c (%) between baseline (pre-test) 
and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons  
 
 
Figure 5.5: Mean HbA1c (%) across the three groups over time (pre-test and 
post-test) 
 
The results of ANCOVA indicated that the mean HbA1c varied significantly between 
the three groups, (F (2, 124) = 7.135, p = 0.001) although the effect size was relatively 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valueb 
Mean ±SD 
A 9.91 ±1.19 9.50 ±1.72 -0.41 ±1.08* 0.027 
B 9.57 ±1.15 9.27 ±1.44 -0.30 ±1.29 0.106 
C 9.70 ±1.29 10.19 ±1.39 0.48 ±1.18* 0.009 
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low (eta squared = 0.103). The results from mixed ANOVA showed that there was a 
significant interaction between time and the three groups (F (2,125) = 125, p = 0.001). 
The results of one-way ANOVA indicated that the mean HbA1c for pre-test did not 
vary significantly between the three groups, (F (2, 125) = 0.905, p = 0.407). In 
contrast, for post-test, the mean HbA1c varied significantly between the three groups 
(F (2, 125) = 4.169, p = 0.018). 
Post-hoc test for pairwise comparison at post-test indicated that the mean HbA1c for 
group A was significantly less than group C (mean change = -0.679 ng/ml, p = 0.042), 
see Table 5.8. In addition, group B was significantly less than group C (mean change = 
-0.914 ng/ml, p = 0.006) see Table 5.8.  
 
Table 5.8: Post-hoc test comparisons of HbA1 (%) between the three groups for 
post-test 
Time Group Group Mean change  p-valueb 
Post-test 
A B 0.235 0.478 
A C -0.679* 0.042 
B C -0.914* 0.006 
*indicates a significant difference between two groups as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
Comparing pre- and post-test using post-hoc test showed a significant difference in 
HbA1c for group A (mean change = -0.41 %, p = 0.027), where HbA1c decreased at 
post-test, see Table 5.7. There was also a significant difference for group C (mean 
change = 0.48 %, p = 0.009), where HbA1c increased at post-test, see Table 5.7. 
5.4 Discussion 
5.4.1 Fasting blood glucose level 
This study has found no significant change in fasting blood glucose level as a result of 
vitamin D supplementation of either 4000 IU or 2000 IU per day. These findings 
support previous studies that have found no relationship between vitamin D 
supplementation and improved fasting blood glucose levels (Patel et al., 2010; Al-
Zahrani 2013; Kampmann et al., 2014; Nasri et al., 2014; Ryu et al., 2014; Tabesh et 
al., 2014; Sadiya et al., 2015). Orwoll et al. (1994) recruited 20 type 2 diabetic subjects 
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in a double-blind, placebo-controlled trial with 200 IU vitamin D supplemented daily 
for four days. The study concluded that vitamin D supplementation had no effect on 
fasting blood glucose levels in type 2 diabetics, supporting the results of this study. A 
similar randomised, placebo-controlled study of 47 type 2 diabetics given a daily dose 
of 1000 IU vitamin D for a longer period of 12 months, still showed no improvement 
in fasting blood glucose levels (Breslavsky et al., 2013).  Even at higher doses and 
where sufficient serum concentrations have been achieved, vitamin D supplementation 
has not been found to improve fasting blood glucose levels. Jorde and Figenschau 
(2009) conducted a randomised control trial on 36 subjects with type 2 diabetes, 
supplemented with 40,000 IU per week of vitamin D.  At six months, the fasting blood 
glucose levels were not significantly different from the baseline values. Furthermore, 
there was no difference in fasting blood glucose levels between the vitamin D and the 
placebo group. This is consistent with the findings from a larger 2012 study involving 
100 type 2 diabetics randomised to either 5000 IU per day of vitamin D or a placebo 
for 12 weeks (Yiu et al., 2013). The study concluded that vitamin D supplementation 
had no effect on fasting blood glucose levels even at a higher dose. The results of this 
study suggest that vitamin D supplementation has no effect on fasting blood glucose 
levels. 
A 2014 systematic review of 25 randomised control trials evaluating the effect of 
vitamin D supplementation on subjects without diabetes, with pre-diabetes and with 
type 2 diabetes drew somewhat different conclusions (Seida et al., 2014). Whilst the 
participants with type 2 diabetes showed no improvement in fasting blood glucose 
levels following supplementation, those with pre-diabetes had a significantly lower 
increase in fasting blood glucose when compared to those randomised to a placebo. A 
similar observation was made by Pittas et al. (2007a) in a randomised control study of 
314 subjects given vitamin D for the treatment of osteoporosis (Pittas et al., 2007a). Of 
those studied, 92 exhibited an impaired fasting blood glucose level. After three years, 
those subjects allocated vitamin D supplements had a signiﬁcantly lower increase in 
their fasting blood glucose in comparison to those randomised to placebo (0.4 mg/dl 
compared to 6.12 mg/dl). Similarly, Boucher et al. (1995) highlighted improvements 
in glucose tolerance after vitamin D supplementation in vitamin D deficient subjects 
with impaired glucose tolerance.  
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This study appears to support the existing evidence that vitamin D supplementation has 
no effect on fasting blood glucose levels in those with type 2 diabetes. Interestingly, a 
review of the literature does, however, suggest a potential role for vitamin D in 
stabilising fasting blood glucose levels in those with pre-diabetes. 
5.4.2 Fasting insulin level, insulin resistance (HOMA-IR) and beta cell function 
(HOMA-B) 
This study found no change in the fasting insulin levels amongst subjects in any of the 
three groups. Previous studies have similarly found no significant improvement in 
insulin level following vitamin D supplementation (Raghuramulu et al., 1992; De Boer 
et al., 2008; Jorde and Figenschau 2009; Harris et al., 2012; Heshmat et al., 2012; 
Kampmann et al., 2014; Al-Sofiani et al., 2015). Conversely, a randomised control 
trial by von Hurst, (2010) concluded that there was a significant decrease in fasting 
insulin level amongst 81 pre-diabetic subjects, following supplementation of 4000 
IU/day for six months. Al-Daghri, (2012), however, found a significant increase in 
fasting insulin level, as well as an improvement in both insulin resistance and insulin 
secretion. Changes in fasting insulin levels can best be expressed as a measure of 
insulin resistance (HOMA-IR) and insulin secretion i.e. beta cell function (HOMA-B) 
(Laakso 1993).  
This study found no significant decrease in insulin resistance (HOMA-IR) at 
supplementation doses of either 4000 IU/day or 2000 IU/day vitamin D compared to 
placebo. These findings support those of a large 2008 randomised control trial of 2291 
type 2 diabetic females, supplemented with 400 IU per day vitamin D followed up for 
seven years (De Boer et al., 2008). A randomised control trial of shorter duration (four 
months) but with an increased supplementation of 100,000 IU and 200,000 IU vitamin 
D as a single stat dose in 61 type 2 diabetics concluded that there was still no 
improvement in HOMA-IR (Witham et al., 2010). These findings have been supported 
by several smaller studies using various supplement dosages and durations that also 
demonstrated vitamin D to have no effect on insulin resistance (Bonakdaran and 
Afkhami Zadeh 2011; Kampmann et al., 2014; Ryu et al., 2014; Yousefi Rad et al., 
2014; Al-Sofiani et al., 2015). Pittas (2007a) demonstrated that whilst insulin 
resistance and fasting blood glucose remained unchanged after three years of 
supplementation with 700 IU vitamin D per day, in the placebo group both markers 
had significantly increased. This could suggest that whilst vitamin D may not actually 
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improve insulin resistance and fasting blood glucose, it may slow the natural 
progression of diabetes.  
Other studies conducted in the Middle East have found vitamin D supplementation to 
have a significant effect on insulin resistance (Al-Daghri et al., 2012; Talaei et al., 
2013; Al-Shahwan et al., 2015). A 2015 randomised control trial of 45 Saudi type 2 
diabetics demonstrated a significant improvement in insulin resistance after one year of 
supplementation of 2000 IU vitamin D per day (Al-Shahwan et al., 2015). Von Hurst 
et al. (2010) not only highlighted how insulin resistance had significantly improved 
after six months of supplementation at 4000 IU/day, but that the improvement was 
most marked when serum 25(OH)D concentrations reached above 32 ng/ml. This 
suggests that achieving a certain serum vitamin D concentration may be of greater 
importance than the dose of supplement given. Similarly, Talaei (2013) reported 
improvements in insulin resistance only when serum vitamin D concentrations reached 
40-60 ng/ml and found no effect when lower serum vitamin D concentrations were 
achieved. This corroborates what the present study found with regards to HOMA-IR 
and vitamin D concentration. Whilst these changes were descriptive and not 
statistically significant, the findings do suggest that the serum vitamin D concentration 
is more important than the dose of supplementation given. This suggests there is scope 
for further research on the role of vitamin D in insulin resistance when higher serum 
vitamin D concentrations have been achieved.  
This study demonstrates an improvement in pancreatic beta cell function (HOMA-B) 
as a result of vitamin D supplementation, however this was not found to be significant. 
A growing body of evidence suggests that vitamin D plays a role in improving beta 
cell function (Borissova et al., 2003; Harris et al., 2012; Al-Sofiani et al., 2015), 
however this study did not support these findings. An 18 month prospective 
interventional study of 34 males and 58 females with type 2 diabetes in Saudi Arabia, 
supplemented with 2000 IU/day vitamin D, further showed that this improvement was 
more marked in females than in males (Al-Daghri et al., 2012). Harris et al. (2012) in a 
randomized control trial of 89 pre-diabetics and type 2 diabetics supplemented with 
4000 IU/day vitamin D saw a significant improvement in beta cell function after 12 
weeks.   
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Other studies, however, have found vitamin D to play no role in improving pancreatic 
beta cell function (Orwoll et al., 1994; Jorde and Figenschau 2009; von Hurst et al., 
2010). A cross-sectional analyses of the National Health & Nutrition Examination 
Survey 1989-1994 (NHANES III) found serum 25(OH)D concentrations to be 
inversely related to diabetes risk and insulin resistance. However, no relationship was 
found between serum 25(OH)D concentrations and beta-cell function (Scragg et al., 
2004). This discrepancy in the evidence may be related to insufficient doses of 
supplementation used, the duration of supplementation given and the validity of the 
study. Orwoll et al. (1994) found no relationship between vitamin D and improved 
beta cell secretion, however as previously mentioned the very small sample size used 
(n=20), small supplement dosage (400 IU/day) and short duration of trial (four days) 
made drawing any valid conclusions difficult. Sufficient serum vitamin D 
concentrations were also not achieved following intervention. Similarly, it is hard to 
draw reliable conclusions from the cross-sectional analyses of the NHANES III as it 
was an observational rather than an interventional study and therefore it is difficultly to 
demonstrate causality. In contrast to this, Jorde and Figenschau (2009) and von Hurst 
et al. (2010) both used supplementation doses of 40,000 IU/ week and 4000 IU/day 
respectively and both for a duration of six months, yet still found no relationship 
between vitamin D and beta cell function.  
In conclusion, this study has demonstrated no significant improvements in either beta 
cell function or insulin resistance following four months of supplementation with 
vitamin D. This is likely due to not achieving a serum vitamin D concentration above 
40 ng/ml as previous studies have demonstrated. Furthermore, vitamin D has been 
shown to delay the progression of insulin resistance and beta cell dysfunction in those 
with impaired fasting glucose. As a result it may be the case that whilst vitamin D does 
not necessarily improve these two markers, it has a role in delaying the progression of 
diabetic complications.  
5.4.3 Glycated haemoglobin 
This study found a significant improvement in glycated haemoglobin in those 
supplemented with vitamin D. After 16 weeks of vitamin D supplementation, 62% of 
patients had a lower HbA1c level compared to baseline. Of those patients that received 
4000 IU vitamin D per day this figure was even higher at 72%, compared to 51% of 
those that received the lower dose of 2000 IU per day. In comparison, 67% of those 
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patients given the placebo had an increase in their HbA1c from baseline after 16 
weeks. These findings are consistent with several cross-sectional analyses also finding 
vitamin D to be inversely associated with HbA1c (Schwalfenberg 2008; Sabherwal et 
al., 2010; Dalgard et al., 2011; Zoppini et al., 2013; Sebekova et al., 2015). A 2012 
cross-sectional analysis of 158 vitamin D deficient, type 2 diabetics demonstrated that 
as serum vitamin D concentrations improved, so too did glycated haemoglobin 
(Dalgard et al., 2011). Similarly, a 2013 cross-sectional study of 715 type 2 diabetics 
with known serum 25(OH)D concentrations concluded that serum vitamin D 
concentration was inversely associated with HbA1c (Zoppini et al., 2013). 
Furthermore, Sabherwal et al. (2010) found the greater the increase in serum vitamin D 
concentrations following supplementation, the greater the decrease in HbA1c in a 
retrospective study of 52 South Asians with both type 2 diabetes and vitamin D 
deficiency.  
Discrepancies continue to exist within the current literature as to whether vitamin D 
supplementation improves HbA1c levels. Several interventional studies from the 
Middle East and North Africa have demonstrated a causal link between improved 
serum vitamin D concentrations and a decrease in HbA1c levels (Labban 2014; Nasri 
et al., 2014; Yousefi Rad et al., 2014; Mohamad et al., 2015). A 2014 randomised 
control trial of 722 Moroccan type 2 diabetics supplemented with 2000 IU/day vitamin 
D demonstrated a 21.0% improvement in HbA1c levels after three months (Labban 
2014). Similarly, Nasri (2014) demonstrated a significant improvement in the HbA1c 
levels of 60 Iranian type 2 diabetic participants following supplementation with 50,000 
IU vitamin D per week for three months. A 2008 case report of two female type 2 
diabetics receiving 3000 IU/day and 2000 IU/day vitamin D respectively, found a 
substantial decrease in HbA1c level of 13.5 percent and 9.0 percent respectively after 
nine months (Schwalfenberg 2008).  
Conversely, several large-scale interventional studies have demonstrated no causal 
relationship between vitamin D and HbA1c (Sugden et al., 2008; Jorde and Figenschau 
2009; Patel et al., 2010; Witham et al., 2010; Heshmat et al., 2012; Al-Zahrani et al., 
2014; Kampmann et al., 2014; Ryu et al., 2014; Al-Sofiani et al., 2015; Krul-Poel et 
al., 2015). A 2012 randomised double-blind control trial on 42 Iranian type 2 diabetic 
patients supplemented with a single intramuscular injection of 300,000 IU vitamin D 
found there to have been no change in HbA1c levels after three months (Heshmat et 
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al., 2012). The researcher concluded that in this case the sample size was likely too 
small to see significant improvements. Similarly, Sugden et al. (2008), Jorde and 
Figenschau (2009), Patel et al. (2010), Kampmann et al. (2014) and Al-Sofiani et al. 
(2015) all used sample sizes likely too small to demonstrate a significant effect of 
vitamin D therapy on glucose metabolism. Furthermore, a 2010 pilot prospective 
randomised trial of 24 type 2 diabetics with serum concentrations of vitamin D below 
25 ng/ml, were supplemented with either 400 IU/ day or 1200 IU/ day of vitamin D, 
well below the 2000 IU required to achieve significant results (Patel et al., 2010). 
Therefore, this discrepancy in the evidence may be related to the different doses of 
supplementation used, the sample size and the ethnic background of the study 
population.  
This study appears to support the existing evidence that vitamin D supplementation has 
a significant effect on glycated haemoglobin in participants from the Middle East and 
North Africa with type 2 diabetes. Interestingly, improvements were seen when 
vitamin D supplements of 2000 IU/day or higher were used and sample sizes ranged 
from between 58 to 722 participants.  
5.4.4 Summary  
In conclusion, this study demonstrates no significant relationship between vitamin D 
supplementation of either 2000 IU/day or 4000 IU/day on fasting insulin and glucose 
levels, insulin resistance and beta cell function. However, a significant improvement in 
glycated haemoglobin (p = 0.001) was demonstrated in both groups supplemented with 
vitamin D, with the higher dose proving to be the more effective of the two. This 
suggests vitamin D may play a positive role in diabetic control and prevention of 
diabetic complications, particularly in Middle Eastern countries. Further human studies 
at higher doses of vitamin D supplementation, achieving serum concentrations of 40-
60 ng/ml, will be useful in cementing the role of vitamin D in the long-term 
management of type 2 diabetes.  
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Chapter 6. Vitamin D3 and Lipidaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
6.1 Introduction 
A review of the literature indicates that the relationship between vitamin D and 
dyslipidaemia remains controversial. Observational studies have, however, shown low 
serum concentrations of vitamin D are associated with unfavourable lipid profiles and 
it has been suggested that vitamin D may affect serum lipid levels in a number of ways 
(Kendrick et al., 2009; Wang et al., 2012). Vitamin D increases absorption of intestinal 
calcium, which in turn affects the amount of fat absorbed in the gut. The calcium binds 
to fatty acids and bile acids, forming calcium-fatty acid soaps, which are excreted in 
the faeces (Boon et al., 2007). This decreases the absorption of fat from the gut, 
reducing serum total and LDL-cholesterol, as well as triglyceride concentrations 
(Saunders et al., 1988; Grundy and Denke 1990; Van der meer et al., 1990; Vaskonen 
et al., 2002; Vaskonen 2003; Cho et al., 2005; Zittermann et al., 2009). In addition, the 
action of vitamin D on serum parathyroid hormone (PTH) concentrations may inhibit 
dyslipidaemia (Jorde and Grimnes 2011). Raised serum PTH levels are associated with 
an increased risk of obesity and have been shown to reduce lipolysis in vitro 
(Kamycheva et al., 2004a; Kamycheva et al., 2004b; Jorde et al., 2005; Hagstrom et 
al., 2009). It has therefore been proposed that vitamin D may lower serum lipid 
concentrations through the suppression of PTH secretion from the parathyroid glands 
(Zemel et al., 2000).  
 
Apolipoprotein A1 has been shown to persistently correlate with vitamin D 
concentrations (Satin 2000; Gagnon et al., 2012; Salum et al., 2012; Vacek et al., 
2012). Elevations in serum apolipoprotein A1 concentrations lead to a direct increase 
in HDL particle formation and increase reverse cholesterol transport (Vacek et al., 
2012). To date, the effects of vitamin D on apolipoprotein gene expression and 
cholesterol levels remains controversial and further research is required.  
The aim of this study was to test the hypothesis that vitamin D supplementation 
improved markers of dyslipidaemia in poorly controlled type 2 diabetic females within 
the Saudi Arabian population.  
6.2 Methodology 
Blood samples were taken from all 128 participants to determine the lipid profile, 
including high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides 
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(TG) and total cholesterol (TC) using the Roche enzymatic colorimetric assay system 
as described in section 2.15.4.  
6.3 Results 
6.3.1 High density lipoprotein (HDL) 
The changes in the mean HDL of the participants (post-test minus pre-test) in groups 
A, B, and C are compared in Table 6.1. The difference in mean HDL between the post-
test and the pre-test, as well as the differences across the three groups is shown in 
Figure 6.1.  
Table 6.1: Post-hoc test comparisons of HDL cholesterol (mg/dl) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
Figure 6.1: Mean HDL cholesterol (mg/dl) across the three groups over time (pre-
test and post-test) 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 48.31 ±12.04 48.12 ±12.49 0.22 ±8.67 0.850 
B 49.21 ±9.64 47.70 ±10.94 -1.51 ±6.61 0.184 
C 46.74 ±9.66 46.18 ±10.46 -0.56 ±6.88  0.623 
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The results of ANCOVA indicated, however, that the HDL did not vary significantly 
between the three groups (F (2, 123) = 0.468, p = 0.628). Mixed ANOVA testing 
revealed no significant interaction between time and the three groups (F (2,125) = 573, 
p = 0.565). Post- hoc test showed no significant difference in HDL between pre and 
post test for each group, see Table 6.1. 
6.3.2 Low density lipoprotein (LDL)  
The changes in the mean LDL of the participants (post-test minus pre-test) in groups 
A, B, and C are compared in Table 6.2. The difference in mean LDL between the post-
test and the pre-test, as well as the differences across the three groups is shown in 
Figure 6.2. 
Table 6.2: : Post-hoc comparisons of LDL cholesterol (mg/dl) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 105.45 ±36.25 103.71 ±39.84 -1.74 ±37.16 0.949 
B 105.91 ±34.21 100.44 ±25.41 -5.47 ±32.06 0.282 
C 102.79 ±32.53 115.30 ±36.37 12.51 ±30.18* 0.015 
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Figure 6.2: Mean LDL cholesterol (mg/dl) across the three groups over time (pre-
test and post-test) 
 
The results of ANCOVA indicated that the mean LDL varied significantly between the 
three groups (F (2, 123) = 3.684, p = 0.028) although the effect size was relatively low 
(eta squared = 0.057). The results of mixed ANOVA showed that there was a 
significant interaction between time and the three groups (F (2,125) = 3.342, p = 
0.039). The results of one-way ANOVA indicated that at both pre and post test the 
mean LDL did not vary significantly between the three groups. 
Using post-hoc test for pairwise comparison at post-test, mean LDL cholesterol in  
group B was significantly lower than group C (mean change = -14.86, p = 0.043), see 
Table 6.3. Comparing pre and post test using post-hoc test, the only significant 
difference in LDL was for group C (mean change = 12.51, p = 0.015), see Table 6.2.    
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Table 6.3: Post-hoc test comparisons of LDL cholesterol (mg/dl) between the 
three groups for post-test 
Time Group Group Mean change  p-valueb 
Post-test 
A B 4.86 0.526 
A C -10.18 0.169 
B C -14.86* 0.043 
*indicates a significant difference between two groups as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
6.3.3 Triglycerides  
The changes in the mean triglycerides of the participants (post-test minus pre-test) in 
groups A, B, and C are compared in Table 6.4. The difference in mean triglycerides 
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 6.3.  
Table 6.4: Post-hoc comparisons of triglycerides levels (mg/dl) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
 
 
 
 
 
 
 
 
 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-
test) 
p-valuep 
Mean ±SD 
A 146.52 ±85.29 155.97 ±96.19 9.46 ±69.36 0.350 
B 126.77 ±80.34 123.09 ±53.88 -3.67 ±54.42 0.713 
C 142.91 ±64.54 151.22 ±96.28 8.32 ±70.96 0.405 
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Figure 6.3: Mean triglyceride levels (mg/dl) across the three groups over time 
(pre-test and post-test) 
 
The results of ANCOVA indicated, however, that the mean triglycerides did not vary 
significantly between the three groups (F (2, 124) 1.068, p = 0.347). Mixed ANOVA 
testing revealed no significant interaction between time and the three groups (F (2, 
124) = 0.531, p = 0.589). Post- hoc test showed no significant difference in 
triglycerides between pre and post test for each group, see Table 6.4. 
6.3.4 Total cholesterol  
The changes in the mean total cholesterol of the participants (post-test minus pre-test) 
in groups A, B, and C are compared in Table 6.5. The difference in mean total 
cholesterol between the post-test and the pre-test, as well as the differences across the 
three groups is shown in Figure 6.4. 
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Table 6.5: Post-hoc comparisons of total cholesterol levels (mg/dl) between 
baseline (pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
 
  
Figure 6.4: Mean total cholesterol levels (mg/dl) across the three groups over time 
(pre-test and post-test) 
 
The results of ANCOVA indicated that the mean total cholesterol varied significantly 
between the three groups, (F (2, 124) = 2.685, p = 0.049) although the effect size was 
low (eta squared = 0.042). The results of mixed ANOVA showed that there was a 
significant interaction between time and the three groups (F (2,125) = 4.43, p = 0.037). 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 177.91 ±39.39 170.52 ±44.94 -7.38 ±38.50 0.209 
B 176.00 ±41.47 160.84 ±31.50 -15.16 ±40.44* 0.010 
C 176.70 ±34.82 178.07 ±41.44 1.37 ±34.56 0.813 
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The results of one-way ANOVA indicated that for pre and post test the mean total 
cholesterol did not vary significantly between the three groups. 
Using post-hoc test for pairwise comparison at post-test, there was a significant 
difference in total cholesterol levels between groups B and C (mean change = -14.86, p 
= 0.046), with group B having a lower mean total cholesterol than group C, see table 
6.6. Comparing pre and post test using post-hoc test, the mean total cholesterol was 
significantly lower (mean change = -15.16, p = 0.010) in group B, see Table 6.5.  
Table 6.6: Post- hoc test comparisons of total cholesterol levels (mg/dl) between 
the three groups for post-test 
*indicates a significant difference between two groups as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
6.4. Discussion  
6.4.1 HDL cholesterol 
This study found no significant relationship between vitamin D supplementation and 
changes in serum HDL cholesterol concentrations. This supports the existing literature 
base that vitamin D supplementation does not improve HDL cholesterol significantly 
(Jorde and Figenschau 2009; Patel et al., 2010; Al-Daghri et al., 2012; Breslavsky et 
al., 2013; Eftekhari et al., 2013; Talaei et al., 2013; Yiu et al., 2013; Al-Daghri et al., 
2014; Kampmann et al., 2014; Ryu et al., 2014; Al-Sofiani et al., 2015; Sadiya et al., 
2015). A 2015 randomised double blind control trial of 87 vitamin D-deficient obese, 
type 2 diabetics supplemented with 6000 IU/day vitamin D for three months, and 3000 
IU/day for a further three months showed no effect on serum HDL concentrations 
(Sadiya et al., 2015). Similarly, a 2015 Saudi study of 20 diabetic subjects found no 
significant change in HDL cholesterol concentration following supplementation of 
5000 IU/day for three months (Al-Sofiani et al., 2015). Even when a larger sample size 
and greater dose was used, such as in Talaei’s (2013) study of 100 type 2 diabetics 
Time Group Group 
Mean change 
between two 
groups 
p-valueb 
Post-test 
A B 9.69 0.263 
A C -7.54 0.382 
B C -14.86* 0.046 
113 
 
supplemented with 50,000 IU/ week for two months, no significant improvements 
were demonstrated in serum HDL cholesterol concentrations.  
To the best of the researcher’s knowledge only two studies from the Middle East exist 
that demonstrate a significant improvement in HDL cholesterol following vitamin D 
supplementation (Yousefi Rad et al., 2014; Mohamad et al., 2015). Yousefi Rad 
(2014) conducted a randomised control trial of 58 type 2 diabetics, the majority of 
which were female, supplemented with 4000 IU/day for two months (Yousefi Rad et 
al., 2014). Despite the small sample size and short duration of the study, a significant 
improvement in HDL cholesterol was demonstrated following vitamin D 
supplementation. The reasons behind this are unclear. Interestingly, a 2015 study of 
100 type 2 diabetics given 4500 IU/ day of vitamin D for two months demonstrated 
significantly higher HDL cholesterol levels in those subjects with double the sufficient 
concentration of serum vitamin D (> 61 ng/ml) post supplementation (Mohamad et al., 
2015). This suggests further work on the dose response of vitamin D is warranted and 
achieving serum vitamin D concentrations greater than 61 ng/ml may show significant 
improvements in HDL cholesterol. 
6.4.2 LDL cholesterol 
This study demonstrates a significant decrease in LDL cholesterol in the vitamin D 
supplemented groups. Interestingly, LDL cholesterol levels increased in the placebo 
group after 16 weeks. These findings have been supported by similar Middle Eastern 
studies by Al-Daghri et al., (2012), Eftekhari (2013), Bonakdaran and Afkhami Zadeh 
(2011) and Mohamad (2015) who also demonstrated a significant improvement in 
LDL cholesterol following vitamin D supplementation of varying doses and durations. 
Despite the improvements in LDL cholesterol demonstrated by Eftekhari (2013) and 
Bonakdaran and Afkhami Zadeh (2011), it is hard to draw definite conclusions from 
these two studies. Both used lower doses (< 2000 IU/day) of vitamin D than the two 
other studies as well as the present study and did not measure serum concentrations of 
25(OH)D. Al-Daghri’s 2012 study of 92 Saudi type 2 diabetics supplemented with 
2000 IU/day for 18 months demonstrated a significant decrease in LDL cholesterol, 
more marked in females than males, when serum vitamin D concentrations also 
increased significantly. Similarly, Mohamad (2015) demonstrated a significant 
decrease in LDL cholesterol in subjects with greater than double the sufficient serum 
level of vitamin D (> 61 ng/ml) when compared to those with lower serum levels post 
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supplementation. This suggests that higher serum 25(OH)D concentrations may be 
required in order to achieve favourable effects on the lipid profile. This supports the 
findings of the present study; 61.9 percent of participants in the 4000 IU/day group 
achieved sufficient serum vitamin D concentrations post supplementation compared to 
just 41.9 percent of participants in the 2000 IU/day group.  
Conversely, the bulk of literature conducted from the rest of the world to date appears 
to suggest vitamin D plays no significant role in improving LDL cholesterol (Patel et 
al., 2010; Breslavsky et al., 2013; Talaei et al., 2013; Yiu et al., 2013; Kampmann et 
al., 2014; Ryu et al., 2014; Yousefi Rad et al., 2014; Al-Sofiani et al., 2015; Sadiya et 
al., 2015). This may be explained partly by the sample sizes of the studies, all of which 
used a much smaller number of participants than the present study. To some extent, 
short study duration may also explain the inconsistency in the findings; only three of 
the cited trials had study durations equal to or greater than the present study 
(Breslavsky et al., 2013; Ryu et al., 2014; Sadiya et al., 2015). The majority of the 
studies that did not find any correlation between vitamin D supplementation and 
improved LDL cholesterol levels did not achieve sufficient post-supplementation 
serum vitamin D concentrations (> 30 ng/ml). Furthermore, only two studies (Talaei et 
al., 2013; Yiu et al., 2013) achieved close to the 61 ng/ml demonstrated in Mohamad’s 
(2015) study to be the optimal serum level for reduced LDL-cholesterol levels. The 
reliability of Talaei’s (2013) study may be questionable given that it was only a single 
blinded study. Similarly, Yiu et al., 2013 study was not conducted in the Middle East 
and therefore the reproducibilty of the results in the Saudi population is dubious.    
The evidence base suggests that significant improvements in LDL cholesterol levels 
have been achieved in Middle Eastern countries where a dose of at least 2000 IU/day 
vitamin D is used. Those studies that achieved serum concentrations of vitamin D 
above 61 ng/ml appeared to produce the most significant decrease on LDL cholesterol.  
6.4.3 Triglycerides 
This study found no significant relationship between serum triglycerides and improved 
vitamin D status. These findings are supported by the current body of literature which 
suggests there is no relationship between vitamin D supplementation and triglyceride 
levels (Jorde and Figenschau 2009; Talaei et al., 2013; Ryu et al., 2014; Yousefi Rad 
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et al., 2014; Al-Sofiani et al., 2015; Sadiya et al., 2015; (Bonakdaran and Afkhami 
Zadeh 2011; (Patel et al., 2010).  
To the best of the researcher’s knowledge, only three studies conducted to date, all of 
which have been in the Middle East, have demonstrated a significant reduction in 
triglyceride levels following supplementation with vitamin D (Alkharfy et al., 2013; 
Eftekhari et al., 2013; Mohamad et al., 2015). Of note, is Alkharfy’s (2013) study of 
499 Saudi participants supplemented with 2000 IU/day for 12 months. It is likely the 
large sample size and long study duration contributed to the finding of a significant 
relationship between vitamin D and improved triglyceride levels. In contrast to the 
current findings, a 1998 case study of three vitamin D–deficient subjects with type 2 
diabetes receiving a single intramuscular dose of 300,000 IU of vitamin D, 
demonstrated a significant increase in serum triglycerides after three months. This 
suggests that too high a dose of vitamin D supplementation may in fact have negative 
effects on triglycerides (Taylor and Wise 1998). Once again, more research is 
warranted to assess the most appropriate dose of vitamin D supplementation in 
reducing triglyceride concentrations in 12 months.  
6.4.4 Total cholesterol 
This study demonstrates a significant decrease in total cholesterol in the vitamin D 
supplemented groups. In contrast, the placebo had a significant increase in total 
cholesterol after 16 weeks. To a certain extent, these findings can be explained by the 
parallel decrease in LDL cholesterol as total cholesterol is a sum of serum LDL-, 
HDL- cholesterol and triglyceride levels. These findings have echoed similar studies 
conducted in the Middle East that demonstrated significant decreases in serum total 
cholesterol following supplementation with vitamin D (Al-Daghri et al., 2012; 
Alkharfy et al., 2013; Eftekhari et al., 2013). However, the effect of vitamin D on total 
cholesterol in the current literature remains controversial and many studies have 
demonstrated no relationship between the two variables (Jorde and Figenschau 2009; 
Patel et al., 2010; Witham et al., 2010; Breslavsky et al., 2013; Talaei et al., 2013; Yiu 
et al., 2013; Kampmann et al., 2014; Ryu et al., 2014; Yousefi Rad et al., 2014; Al-
Sofiani et al., 2015; Sadiya et al., 2015). This may be explained by ethnic background, 
sample size and short study duration of less than three months. It has been suggested 
that significant improvements in total cholesterol can be achieved in Middle Eastern 
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countries where studies include at least 70 participants and use a study duration of four 
months of greater (Alkharfy et al., 2013).  
6.4.5 Summary 
In conclusion, this study demonstrates no significant relationship between vitamin D 
supplementation of either 2000 IU/day or 4000 IU/day on serum HDL cholesterol and 
triglyceride levels. A significant improvement in serum LDL cholesterol (p = 0.028) 
and total cholesterol levels (p = 0.049) was demonstrated in both groups supplemented 
with vitamin D. Further interventional studies are clearly required using higher doses 
of vitamin D supplementation in order to achieve serum concentrations of greater than 
61 ng/ml and to replicate these positive findings on the lipid profile of type 2 diabetics. 
It is worth mentioning that the majority of the participants in the present study were 
already taking statins (87.5%, n = 112) prior to enrolment and thus a large percentage 
had a lipid profile within normal parameters at baseline. Statins have a considerable 
anti-inflammatory effect (Pickup 2004), that may have masked the anti-inflammatory 
effect of vitamin D. Alternatively, the extent of inflammation may already be so 
established in type 2 diabetics that four months of vitamin D supplementation had no 
effect. To the best of the researcher’s knowledge, no study to date has analysed the 
effect of vitamin D supplementation on the lipid profile of type 2 diabetic patients who 
are not already taking statins. This indicates there is scope for future work to assess the 
effect of vitamin D in deficient, type 2 diabetics with uncontrolled lipid profile.  
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Chapter 7. Vitamin D3 and Oxidative Stress  
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7.1 Introduction  
Oxidative stress is considered to be a vital component in the pathogenesis and 
development of diabetic vascular complications (Ceriello et al., 2002). Sustained 
hyperglycaemia is associated with heightened production of reactive oxygen species 
(ROS) as well as a reduction in the intrinsic antioxidant defence mechanisms, 
rendering diabetic individuals more susceptible to oxidative damage (Tsai et al., 1994; 
Kakkar et al., 1998). Type 2 diabetics have consistently been shown to have far lower 
total antioxidant capacities (TAC) than their healthy counterparts (Illing et al., 1951; 
Sundaram et al., 1996; Maxwell et al., 1997; Opara et al., 1999; Serafini and Del Rio 
2004). This imbalance between oxidant and antioxidant levels leads to both functional 
and morphological damage to blood vessels and results in the development of micro- 
and macrovascular complications (Baynes 1991). Oxidative reactions also increase the 
formation of advanced glycation endproducts (AGEs) and their accumulation in 
cardiovascular tissues (Smith and Thornalley 1992).  
Advanced glycation endproducts are a group of compounds formed non-enzymatically 
by glycation and oxidation of proteins. In type 2 diabetics, the formation of AGEs is 
increased as a result of hyperglycaemia and an abundance of free radicals (Singh et al., 
2001). The accumulation of AGEs in the skin has been shown to be a strong indicator 
for the development of both micro- and macrovascular complications (Gerrits et al., 
2008a; Meerwaldt et al., 2008). AGEs bind to the RAGE receptor in endothelial cells, 
resulting in further oxidative stress, superoxide radical generation and cell apoptosis 
(Vincent et al., 2007).  
 
Vitamin D has been shown to enhance antioxidant defences and reduce the damage 
caused by both oxidative stress and AGEs, and may be of benefit in the treatment of 
diabetic vascular complications (Codoner-Franch et al., 2012; Gradinaru et al., 2012; 
Jain et al., 2013). Recent animal studies have shown vitamin D to upregulate the 
activity of certain antioxidant enzymes, such as catalase, superoxide dismutase (SOD) 
and glutathione peroxidase (GSH-px) in diabetic rats (Noyan et al., 2005). 
Furthermore, vitamin D may improve vascular endothelium function through the 
modulation of radical generation and RAGE expression, averting the overproduction of 
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ROS and AGE formation (Dong et al., 2012). Despite these positive findings, research 
on the antioxidant properties of vitamin D for use in type 2 diabetes remains scarce.  
 
The aims of this study were to test the hypothesis that vitamin D supplementation 
improved markers of oxidative stress, including advanced glycation endproducts 
(AGEs), in poorly controlled type 2 diabetic females within the Saudi Arabian 
population. 
7.2 Methodology  
Blood samples were taken from all 128 participants at baseline and 16 weeks using the 
aseptic technique described in section 2.12. Total antioxidant capacity was measured 
using the colorimetric method with the commercially available Cell Biolabs’ 
OXiSelect TAC assay kit as described in section 2.15.7. Skin AGE levels were 
assessed using a skin autofluorescence AGE reader as described in section 2.17.  
7.3 Results  
7.3.1 Total antioxidant capacity  
The changes in the mean total antioxidant capacity of the participants (post-test minus 
pre-test) in groups A, B, and C are compared in Table 7.1. The difference in mean total 
antioxidant capacity between the post-test and the pre-test, as well as the differences 
across the three groups is shown in Figure 7.1. 
Table 7.1: Post-hoc comparisons of total antioxidant capacity (mM) between 
baseline (pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 0.62 ±0.32 0.42 ±0.10 -0.20 ±0.31* < 0.001 
B 0.80 ±0.27 0.40 ±0.09 -0.40 ±0.29* < 0.001 
C 0.47 ±0.13 0.37 ±0.07 -0.10 ±0.13* 0.013 
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Figure 7.1: Mean total antioxidant capacity (mM) across the three groups over 
time (pre-test and post-test) 
 
 
The results of ANCOVA indicated, however, that the mean total antioxidant did not 
vary significantly between the three groups (F (2, 124) 1.981, p = 0.142). Mixed 
ANOVA testing revealed no significant interaction between time and the three groups 
(F (2,125) = 2.83, p = 0.063). Post- hoc test showed a significant decrease in total 
antioxidant capacity between pre and post test for each group, for group A (p < 0.001), 
group B (p < 0.001), and group C (p = 0.013), see Table 7.1. 
7.3.2 Skin Advanced glycation endproducts (AGEs) 
The changes in the mean skin AGEs of the participants (post-test minus pre-test) in 
groups A, B, and C are compared in Table 7.2. The difference in mean skin AGEs   
between the post-test and the pre-test, as well as the differences across the three groups 
is shown in Figure 7.2. 
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Table 7.2: Post-hoc comparisons of skin AGEs (arbitrary units) between baseline 
(pre-test) and after 16 weeks (post-test) 
*indicates a significant difference between pre-test and post-test as per p < 0.05  
b indicates adjustment for multiple comparisons 
 
 
Figure 7.2: Mean skin AGEs (arbitrary units) across the three groups over time 
(pre-test and post-test) 
 
The results of ANCOVA indicated that the mean AGEs did not vary significantly 
between the three groups (F (2, 124) = 1.478, p = 0.232). Mixed ANOVA testing 
revealed no significant interaction between time and the three groups (F (2,125) = 
Group Baseline 
(pre-test) 
After 16 weeks 
(post-test) 
Mean change 
(post-test minus pre-test) 
p-valueb 
Mean ±SD 
A 3.13 ±0.87 3.12 ±0.81 -0.01 ±0.59 0.971 
B 2.98 ±0.65 2.86 ±0.57 -0.13 ±0.64 0.524 
C 3.17 ±2.82 2.94 ±1.18 -0.23 ±2.05 0.234 
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0.332, p = 0.718). Post- hoc test showed no significant difference in AGEs between pre 
and post test for each group, see Table 7.2. 
7.4 Discussion  
7.4.1 Total Antioxidant Capacity 
This study found no significant improvement in TAC following supplementation with 
either 2000 IU/day or 4000 IU/day vitamin D. To the best of the researcher’s 
knowledge this is only the second interventional study to assess the role of vitamin D 
on TAC in type 2 diabetics. The first, a 2015 study of 100 type 2 diabetics 
supplemented with a fortified yoghurt drink containing 1000 IU vitamin D, 
demonstrated a significant improvement in TAC after three months (Shab-Bidar et al., 
2015). A 2013 cross-sectional analyses of 100 type 2 diabetics also demonstrated a 
positive correlation between serum vitamin D concentrations and TAC when compared 
to healthy individuals, although given the nature of the study it was difficult to 
establish causality (Saedisomeolia et al., 2013). Two further interventional studies 
have also shown vitamin D supplementation to significantly increase TAC in non-
diabetic subjects (Asemi et al., 2013; de Medeiros Cavalcante et al., 2015). Whilst the 
present study has shown no relationship between vitamin D and TAC this appears to 
be in contrast with the, albeit limited, existing evidence base.  
There appears to be some discrepancy in the literature concerning the most appropriate 
parameter by which to measure an individual’s oxidative stress (Argüelles et al., 2004; 
Serafini and Del Rio 2004). Other studies have used alternative markers to determine 
the effect of vitamin D supplementation on oxidative stress. Nikooyeh et al. (2014) 
demonstrated a significant improvement in the antioxidant superoxide dismutase 
(SOD) and a reduction in the pro-oxidants protein carbonyl (PCO) and 
myeloperoxidase (MPO) in 90 type 2 diabetics supplemented with a 1000 IU fortified 
vitamin D yoghurt drink daily for four months. Conversely, Yiu et al. (2013) 
demonstrated no significant change in SOD levels following administration of 5000 
IU/day vitamin D for three months. Both Eftekhari et al. (2013) and Tayebinejad et al. 
(2012) failed to demonstrate any improvements in oxidised LDL (ox-LDL) or 
malondialdehyde (MDA) following supplementation with vitamin D for three months. 
Once again, these studies had shorter durations than the present study which may 
explain the discrepancy in findings. Regardless of the marker used, the existing 
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literature base provides inconsistent evidence for the role of vitamin D in ameliorating 
oxidative stress in diabetic individuals. It is suggested that intervention studies on a 
larger scale are warranted. These should use greater doses of vitamin D 
supplementation and have a study duration longer than the present study, using a 
variety of different markers to measure oxidative stress.  
7.4.2 Skin Advanced Glycation Endproducts 
This study found no significant relationship between vitamin D supplementation and 
reduced levels of advanced glycation end products. These findings are supported by a 
2015 randomised control trial of 245 type 2 diabetics given 50,000 IU/month vitamin 
D for six months (Krul-Poel et al., 2015). Whilst skin autofluorescence (as a measure 
of AGE accumulation) was found to be significantly higher in those with a serum 
25(OH)D concentration of less than 20 ng/ml, compared to patients with serum 
concentrations above 30 ng/ml, there was no reduction in AGE levels after six months 
of intervention. This is likely due to the fact that skin AGEs have a mean half life of 10 
to 15 years (Gerrits et al., 2008b) and therefore the length of the intervention may be 
too short to demonstrate any perceivable outcomes. Furthermore, using an AGE-reader 
to measure the accumulated AGEs in the skin may not be sufficient to record all AGE 
types, for example circulating AGEs and AGEs without fluorescent properties (Krul-
Poel et al., 2015). Similarly, a 2015 cross-sectional study of 233 type 2 diabetics, 
concluded that vitamin D deficiency did not enhance the skin autofluorescence or 
plasma AGE levels (Sebekova et al., 2015).  
In contrast, studies performed on diabetic rats have shown vitamin D supplementation 
to reduce AGE deposition within the vasculature and to downregulate the effects of the 
RAGE receptor (Salum et al., 2013; Lee et al., 2014). AGEs have been shown to bind 
to the RAGE receptor in endothelial cells, resulting in further oxidative stress, 
superoxide radical generation and cell inflammation (Vincent et al., 2007). Two recent 
in vitro studies demonstrated a reduction in endothelial inflammation following 
supplementation with vitamin D. It has been suggested that vitamin D may act as a 
vascular protective agent, offsetting the harmful effects of AGEs on endothelial cells 
(Talmor et al., 2008; Salum et al., 2013; Krul-Poel et al., 2015). Similar findings have 
also been demonstrated in human studies. Two recent randomised control trials of 60 
and 90 type 2 diabetics respectively found significant decreases in serum AGEs 
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following supplementation with two 500 IU fortified yoghurt drinks a day 
(Tayebinejad et al., 2012; Nikooyeh et al., 2014). It is worth noting that this 
improvement was in serum AGEs, corresponding with our observations in Chapter 5. 
Whilst this study has demonstrated no relationship between vitamin D and skin AGE 
accumulation, the positive findings from both in vitro and in vivo studies suggests 
further work within this field is warranted with longer study durations for both serum 
and skin AGE concentrations. 
7.4.3 Summary 
In conclusion, this study has demonstrated no significant relationship between markers 
of oxidative stress and vitamin D in type 2 diabetic Saudi females. Current evidence, 
whilst limited, is inconsistent and more research within this field is required to assess 
the role for vitamin D, if any, in ameliorating oxidative stress. These studies should 
use longer durations and supplement doses, as well as assessing AGE response in both 
skin and serum.  
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Chapter 8. Discussion 
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8.1 General Discussion   
Diabetes Mellitus represents a condition that is characterised by chronic 
hyperglycaemia, resulting from deficits in insulin secretion and sensitivity (WHO 
2016). Saudi Arabia has amongst the highest incidence of type 2 diabetes in the world, 
with nearly 20 percent of adults suffering from the condition (International Diabetes 
Federation 2012). Mortality rates amongst diabetics are nearly twice that of healthy 
individuals and are largely due to microvascular and macrovascular complications that 
arise from the disease (Roglic et al., 2005).  
Biological processes within the body produce reactive oxygen species (ROS) that harm 
tissues and cells (Skrha 2003). In healthy individuals this process is limited by 
exogenous and endogenous antioxidant defences (Betteridge 2000). In type 2 diabetes 
high concentrations of intracellular glucose increase the production of ROS (Lorenzi 
2007). This is compounded by significantly reduced antioxidant levels and accelerated 
formation of advanced glycation endproducts (AGEs). This imbalance between 
oxidant and antioxidant defences results in functional and morphological damage to 
the vasculature and the initiation of diabetic angiopathy (Baynes 1991).  AGEs are a 
group of compounds formed non-enzymatically via the glycation and oxidation of 
proteins. Their formation is accelerated in type 2 diabetics as a result of 
hyperglycaemia and an increased number of free radicals (Singh et al., 2001). The 
accumulation of AGEs in the skin has been shown to cause the development of 
diabetic vascular complications (Gerrits et al., 2008a; Meerwaldt et al., 2008).  
Vitamin D has been shown to enhance antioxidant defences and limit the harm caused 
by both oxidative stress and AGEs and therefore may be of benefit in the treatment of 
diabetic complications (Codoner-Franch et al., 2012; Gradinaru et al., 2012; Jain et al., 
2013). The prevalence of vitamin D deficiency in type 2 diabetics has repeatedly been 
shown to be nearly twice that of non-diabetic individuals; within the Saudi Arabian 
population it is estimated that somewhere between 30 and 85% of females are vitamin 
D deficient (Scragg et al., 1995; Isaia et al., 2001; Scragg et al., 2004; Al-Zahrani 
2013). Despite a number of recent interventional studies on vitamin D and diabetes in 
Saudi Arabia, none to date have considered the effect of vitamin D supplementation on 
markers of oxidative stress. Whilst being the first study of this kind, unfortunately the 
present study has demonstrated no significant effect on total antioxidant capacity or 
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skin autofluroscence (AGEs) in the type 2 diabetic Saudi population. There have been 
few previous studies on vitamin D, diabetes and oxidative stress in any population and 
all have provided conflicting results. This study concludes that vitamin D has limited, 
if any effect, antioxidant properties.  
Administration of vitamin D supplementation has differed between studies, with daily 
doses proving to be more effective in raising serum concentrations than weekly or 
monthly doses (Von Hurst et al., 2010). This is likely to be due to more consistent 
absorption in the gut (Chel et al., 2008). Recent meta-analysis of 51 randomised 
control trials using doses of vitamin equivalent to 1000 IU per day has failed to 
demonstrate any beneficial effects of vitamin D on diabetic outcomes (Elamin et al., 
2011). However, for studies using higher doses of vitamin D the results have proved 
more inconclusive.  
In the present study, the therapeutic effect of daily oral supplementation of vitamin D 
in 128 female patients with type 2 diabetes mellitus and hypovitaminosis D was 
investigated. The results demonstrate that daily oral supplementation with doses of 
2000 IU and 4000 IU was both safe and effective in significantly (p < 0.001) 
improving vitamin D status in patients with type 2 diabetes. The majority of Saudi 
studies have used a supplement dose of 2000 IU for varying durations, yet this is the 
first to consider the effect of a higher dose of 4000 IU on diabetic parameters. Serum 
vitamin D concentrations increased by 212% in the 4000 IU group and 131% in the 
2000 IU group (compared to a 5% decrease in the placebo group). However, only 61.9 
% of the 4000 IU group and 41.9 % of the 2000 IU group had achieved sufficient (>30 
ng/ml) vitamin D concentrations post supplementation. No patients developed either 
clinically or biochemically significant hypercalcaemia.  
These findings confirm that greater doses of vitamin D supplementation are likely to 
be required in order to achieve sufficient serum concentrations amongst female type 2 
diabetics. This may in part be due to the baseline BMIs of participants; one of the 
inclusion criteria was for subjects to have a BMI greater than 25. Wortsman et al. 
(2003) reported that obese patients were able to raise their serum vitamin D 
concentrations by no more than 50 percent when compared to their non-obese 
counterparts and hence this may be accountable for the suboptimal increase in many of 
the participants. However, this study demonstrated no relationship between BMI and 
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vitamin D. Other similar studies have demonstrated that using 6000 IU vitamin D per 
day for three months was effective in safely increasing serum concentrations from 
deficient to sufficient (Sadiya et al., 2015; Al-Zahrani et al., 2014). However, it was 
noted that this dose may still be inadequate to achieve optimum vitamin D function.  
Whilst the effects of vitamin D on oxidative stress have been somewhat disappointing, 
the present study has demonstrated significant improvements (p = 0.001) in the 
glycaemic profile of participants. After 16 weeks, subjects who had taken vitamin D 
supplements had a significantly lower HbA1c level than at baseline. HbA1c is a 
marker of average serum glucose concentrations over the previous three months and 
therefore is indicative of glucose homeostasis (Woerle et al., 2004). The UK 
Prospective Diabetes Study (UKPDS) demonstrated a one percent reduction in HbA1c 
to be associated with a 21 percent decrease in diabetic complications and a further 37 
percent reduction in microvascular disease (Stratton et al., 2000). The findings of this 
study suggest that vitamin D supplementation may therefore produce a significant 
reduction in diabetes-related morbidity and mortality, and may be used as an adjuvant 
to regular anti-hyperglycaemic agents.  
It has been further suggested that improvements in HbA1c are more likely to be seen in 
vitamin D-deficient female type 2 diabetics than in their insufficient and sufficient 
counterparts. Sabherwal’s 2010 study demonstrated a 0.70% improvement in HbA1c 
levels amongst vitamin D-deficient type 2 diabetics compared to a 0.21% improvement 
in those who were vitamin D insufficient (Sabherwal et al., 2010). Similarly, Jorde and 
Figenschau (2009) and Krul-Poel et al. (2015) found that vitamin D replacement 
therapy had no effect on HbA1c in type 2 diabetics with sufficient serum vitamin D 
concentrations. Due to the similar numbers of deficient and insufficient subjects across 
all of the intervention groups, it is impossible to either prove or disprove this theory in 
the present study. It was found that giving a higher dose of 4000 IU vitamin D per day 
improved HbA1c levels more than a dose of 2000 IU per day. Of the 37 female 
subjects found to be vitamin D deficient at baseline who received the higher dose, 80% 
of them elevated their vitamin D status after 16 weeks. This was in comparison to 76% 
of those in the lower supplementation group and therefore suggests a higher dose may 
not be that beneficial.   
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After 16 weeks of supplementation with vitamin D, no improvements were found in 
pancreatic beta cell function and insulin resistance. Fasting blood glucose did not show 
an improvement at all. A recent study similarly demonstrated that after three years of 
supplementation with 700 IU vitamin D per day, insulin resistance and fasting blood 
glucose remained unchanged (Pittas et al., 2007a). Interestingly however, in the 
placebo group both markers had significantly increased after three years. This suggests 
that whilst vitamin D may not actually improve insulin resistance and fasting blood 
glucose, it may slow the natural progression of the disease. The majority of vitamin D 
interventional studies to date all have durations between one and six months and few 
have considered the long-term effect of supplementation on diabetic outcomes.  
Dyslipidaemia is one of the leading causes of cardiovascular disease in type 2 diabetics 
(Mooradian 2009). Diabetes mellitus is associated with increased small-dense low- 
density lipoprotein (sdLDL) and triglyceride concentrations, alongside low 
concentrations of cardio-protective high-density lipoprotein (HDL) (American 
Diabetes Association 2003). The exact mechanism behind the pathogenesis of diabetic 
dyslipidaemia remains uncertain, however evidence has shown insulin resistance to be 
critical in the development of the condition (Mooradian 2009).  
Many observational studies have demonstrated high serum vitamin D concentrations to 
be associated with more favourable lipid profiles (Jorde and Grimnes 2011). 
Unfortunately, interventional studies to date have provided inconsistent results. These 
studies have been limited by comparatively small sample sizes, short study durations 
and supplement doses not sufficient to achieve optimal serum 25(OH)D 
concentrations, as well as study locations outside the Middle East (Ponda et al., 2012). 
In the present study, significant reductions in LDL- and total cholesterol (p = 0.028 
and p = 0.049 respectively) have been demonstrated, following 16 weeks of 
supplementation with vitamin D. Furthermore, both LDL- and total-cholesterol 
increased in the placebo group after 16 weeks. No significant changes were noted in 
HDL cholesterol and triglyceride concentrations.  
Mohamad et al. (2015) demonstrated that diabetic subjects with high serum vitamin D 
concentrations (> 61 ng/ml) had significantly lower levels of total and LDL 
cholesterol, compared to those with sufficient or insufficient serum concentrations. As 
such, higher serum concentrations than what are currently considered to be sufficient 
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may be required in order to produce auspicious gains on the lipid profile. None of the 
participants in the present study achieved final serum vitamin D concentrations above 
47.28 ng/ml. Supplementation doses were selected on the basis of recommendations 
from the Endocrine Society Clinical Guidelines (Holick et al, 2011), however these 
have been derived from interventional studies centred on skeletal outcomes. To date, 
there has been little consideration as to the effective supplementation doses required 
for the non-skeletal properties of vitamin D and further research in this area is clearly 
warranted (Jorde and Grimnes 2011).  
It is presumable that if vitamin D supplementation were to effect serum lipid levels, 
this would be most evident in individuals with both hypovitaminosis D and 
dyslipidaemia. Unfortunately, the majority of participants in the present study were all 
taking statins prior to enrolment and therefore very few had unfavourable lipid profiles 
at baseline (14% in group A, 14% group B, 4% in group C). As it is a recommendation 
(Grundy, 2006) that all newly diagnosed type 2 diabetics be commenced on a statin, it 
was impossible to find a population in which the lipid profile had not already been 
controlled for. However, until such studies are performed the effect of vitamin D 
supplementation on the serum lipid profile will remain controversial.  
8.2 Limitations 
The results of this study may have been affected by a number of limitations: 
• Not all participants in both supplemented groups achieved sufficient (> 30 
ng/ml) serum concentrations of vitamin D following intervention 
• All subjects were taking statins at the time of enrolment and therefore very few 
had unfavourable lipid profiles at baseline 
• Insulin resistance and beta cell function were calculated using the HOMA 
model which is less invasive and time-consuming but not as accurate as the 
glucose clamp method 
• The study duration of 16 weeks was relatively short and it is likely that to elicit 
any tangible effects on insulin resistance, beta cell function and oxidative stress 
warrants longer durations of supplementation  
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8.3 Scope for future work 
To date, recommendations for vitamin D supplementation doses have been based 
solely on its calcaemic properties. Further research is currently warranted into the dose 
of vitamin D that is not only adequate for bone health but for its potential non-
calcaemic actions. It is recommended that these studies use doses starting at 6000 IU 
per day aiming to achieve serum concentrations of greater than 60 ng/ml. Longer study 
durations of 18 months or greater are warranted to assess the long-term effect of 
vitamin D supplementation on insulin resistance, beta cell function and using different 
markers to measure oxidative stress. Furthermore, further work is warranted to assess 
the different accumulation of AGEs in serum and skin for longer study durations as 
well to demonstrate which marker is the most effective measurement of oxidative 
stress. This study has highlighted the need for further investigation in newly diagnosed 
female type 2 diabetics who have not yet been commenced on statins in order to 
accurately assess the effect of vitamin D on the lipid profile.  
8.4 Overall conclusion  
In conclusion, the results from the present study indicate that HbA1c levels 
significantly decreased following 16 weeks of supplementation with vitamin D. These 
findings were most evident at the greater dose of 4000 IU day (p < 0.001), however 
this was still not adequate to achieve sufficient serum vitamin D concentrations in all 
participants. Similar improvements were noted in LDL- and total cholesterol. No 
significant improvements in oxidative stress were demonstrated. This study adds to a 
growing body of evidence that vitamin D supplementation may be beneficial not only 
in bone-related conditions, but as an adjuvant therapy in female type 2 diabetes 
management in the Middle Eastern diabetic population.  
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Screening Questionnaire for recruiting participants  
 
Name:…………..……………………………………           Today’s date: ____/_____/_____ 
Address:…………………………………………………………………………………............
....... 
Telephone:………………………………………………………………………………………
…... 
Patient’s file number……………………………………………  
Patient’s next appointment ……………………………….. 
1- Age? 
(1)  Less than 18      (2) 18 - 24       (3) 25 -34           (4) 35 - 44           (5) 45 - 5        (6) 
55-60                        (7) 61 and over     
Date of birth: ------/-------/-------- 
2- Does the patient have type 2 diabetes? 
(1) Yes          (2) No                 
• Current HbA1c           ________________%  
• Calculated BMI         ________________m2 
• Participant’s Height?    ________________cm 
• Participant’s Weight?  ________________kg 
• Calcium level  ________________mmol/l  
3- Does the patient have any of the following medical conditions?  
(1) Renal failure                    
(2) Gastrointestinal Malabsorption (e.g. Crohn’s disease, Colitis) 
(3) Thyroid and parathyroid disease          
(4) Hypercalcaemia                
(5) Liver disease  
4- Does the patient take vitamin supplements? 
(1) Yes                                  (2) No  
If yes, please specify type and brand 
............................................................................................ 
5- Is the patient taking vitamin D?  
(1) No                          (2) Yes 
If yes, please specify type and brand 
…………………………………………………………… 
 
Eligible                                               Not eligible Participant number………… 
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INFORMATION SHEET 
Project title:- Effect of vitamin D3 supplementation on markers of glycaemia and 
oxidative stress in Saudi women with Type 2 Diabetes Mellitus 
 
Dear Participant, 
This information sheet is to provide you with information about a project being 
conducted as a PhD in Nutritional Physiology at Manchester Metropolitan University. 
This study will provide valuable information about whether vitamin D supplements may 
help control type two diabetes.  
Study requirements:-  
• Questionnaires 
This study will involve two questionnaires, one at the start and one after 16 weeks which 
should take approximately 5-10 minutes to be completed.  
 
• Anthropometric data 
For the purpose of the study, your weight, height and waist circumference will be 
measured at the start of the study and after 16 weeks. 
 
• Blood samples 
As part of the research blood will be taken at pre-screening, the start of the study and 
after 16 weeks. 
 
• Vitamin D Supplements 
This study requires participants to take one tablet on a daily basis for 16 weeks. You 
will also need to record the days in which supplements were taken and whether any 
supplements were missed. 
Confidentiality and data protection 
You may decide not to answer some or any of the questions provided.  You may also 
decide to withdraw from this study at any time. The information you provide will be 
considered confidential, except that with your permission anonymised quotations may 
be used. If you request confidentiality, beyond anonymised quotations, the information 
you provide will be treated only as a source of background research, alongside books 
and web-based research and the information presented by others. All the information 
you provide will be handled in line with the Data Protection Act and will not be used for 
anything other than this research study. Your name and any other personal identifying 
information will not appear in the course project paper resulting from this study; neither 
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will there be anything to identify your address. Only the study team will have access to 
the data itself.  
If you have any questions regarding this study or would like additional information 
please contact the email below. Thank you for your assistance in this project.  
Alaa Hatim Qadhi  
E-mail  10997250@stu.mmu.ac.uk 
 
Consent form 
 
Have you read the information sheet?  
  
Do you understand what the project is about?  
 
Are you aware that you will be asked to complete a medical background questionnaire? 
 
Are you aware that four blood samples will be taken? 
 
Are you aware that these blood samples will be analysed? 
 
Are you aware that you need to consume a tablet on a daily basis? 
 
Are you aware that you can stop participating in the study at any time?  
 
Are you willing for your blood to be used for further analysis? 
 
If you are willing to participate please sign your name below.  
 
I ................................................................ agree to take part in the above research study. 
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I am aware that all information will be kept confidential in line with the Data Protection 
Act and that I can withdraw at any time. 
 
Signed...................................................................... 
Date..........................................................................        
 
Should you have any questions about this research project please contact Alaa Qadhi on 
this E-mail 10997250@stu.mmu.ac.uk 
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Pre-study Screening Questionnaire 
A. Participant Section: 
Background  
Name:…………..……………………………………           Today’s date: ____/_____/_____ 
Address:…………………………………………………………………………………............ 
Telephone:……………………………………………………………………………………… 
1- Are you male or female?  
(1) Male      (2) Female  
 
2- How old are you? 
(1)  Less than 18      (2) 18 - 24       (3) 25 -34           (4) 35 - 44           (5) 45 - 5        (6) 
55-60                        (7) 61 and over             
Date of birth: ------/-------/-------- 
 
3- Are you currently? 
(1) Single     (2) Married   (3) Divorced   (4) Widowed 
 
4- What is your ethnicity? 
(1) Arab   (2) Caucasian    (3) African   
             (4) Indian subcontinent  (5) Other. Please 
specify…………………………….  
 
5- Please circle the highest year of school completed: 
(1) No schooling  (2) Primary school              (3) Secondary school  (4) High 
school          (5) Diploma            (6) Bachelor’s degree               (7) Post-graduate degree
  
  
6- Are you currently? 
(1) Student             (2) Employed               (3) Unemployed              (4) Retired 
    
7- Are you pregnant? 
(1) Yes   (2) No 
 
8- Do you currently smoke cigarettes or any other tobacco products on a daily basis?  
(1) Yes   (2) No    
 
9- Are you on a special diet? 
(1) Yes    (2) No     If Yes Please specify:. . . . . . . . . . . . . . . . .  
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Medications  
10- How long have you been diagnosed with type 2 diabetes? 
(1) 1-2 years          (2) 3-5 years                  (3) 6-8 years          (4) over 8 years 
 
11- Has either of your parents, or any of your brothers or sisters been diagnosed with 
diabetes? 
(1) Yes              (2) No 
 
12- Do you have any diabetic complications?  
(1) Yes        (2) No    (3) Don’t know 
 
If yes please give details of relevant diabetic complications: 
(1) Nephropathy   (2) Neuropathy              (3) Diabetic 
cateract              
(4) Cardiovascular disease    (5) Dyslipidemia              (6) Retinopathy 
Other:……………………………………………………………………………………… 
 
13- Do you have any of the following medical conditions? Circle every relevant condition. 
(1) Renal failure                    (2) Gastrointestinal Malabsorption (e.g. Crohn’s disease, 
Colitis) 
(3) Parathyroid disease         (4) Hypercalcaemia               (5) Liver disease  
 
14- Are you currently taking prescribed medications? 
Name of Drug Dose How many times a day? 
e.g. Metformin 1 tablet of 1g 2 times with meals 
   
   
   
   
   
   
 
15- Do you take vitamin supplements? 
(1) Yes                                  (2) No  
If yes, please specify type and brand 
............................................................................................ 
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16- Have you taken vitamin supplements 3 months prior to today’s date?  
(1) No                          (2) Yes 
If yes, please specify type and brand 
…………………………………………………………… 
 
B. Researcher Section - Anthropometric Measurements 
• Participant’s Height?    ________________cm 
• Participant’s Weight?  ________________kg 
• Calculated BMI         ________________m2 
• Current HbA1c           ________________%  
• Calcium level  ________________mmol/l                                
• Date tested ____/_____/_____ 
 
 
Eligible                                               Not eligible
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Debriefing Questionnaire 
C. Participant Section: 
Background  
Name: …………..……………………………………           Today’s date: 
____/_____/_____ 
Address: 
…………………………………………………………………………………................... 
Telephone: 
…………………………………………………………………………………………... 
 
1- I know it must be difficult to take medications regularly. How often did you miss 
taking the vitamin tablet? 
(1) Once a week         (2) twice a week          (3) three or more times a week         (4) never 
took them       
 
2- How many times did you forget to record your pill taking on the calendar? 
(1) Once a week         (2) twice a week          (3) three or more times a week         (4) never 
recorded 
 
3- Have you been prescribed any new medications since you started taking the 
vitamin supplements, if so please specify? 
(1) No        (2) Yes 
If yes, please specify  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
4- Have you stopped taking any prescribed medications since you started taking the 
tablets? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
5- Have the doses of your medications changed since you started taking the tablets? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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6- Have you taken vitamin supplements other than those supplied during the study? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
  
 
7- Did you suffer from any of the following medical conditions in the last 16 weeks? 
Circle every relevant condition. 
(1) Renal failure       (2) Gastrointestinal Malabsorption (e.g. Crohn’s disease, Colitis)   (3) 
Parathyroid disease (4) Hypercalcaemia    (5) other, please specify . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
8- Are you pregnant? 
(1) No       (2) Yes   
 
9- Did you start any special diets? 
(1) No      (2) Yes              
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . .  
 
10- Overall, how would you say the control of your diabetes has been over the last 16 
weeks? 
(1) Better than before     (2) Worse than before          (3) No change          
 
11- Have you been diagnosed with any other conditions? 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
D. Researcher Section - Anthropometric Measurements 
• Participant’s Height?    ________________cm 
• Participant’s Weight?  ________________kg 
• Calculated BMI         ________________m2  
• AGE reading                        ________________units  
    
Participant number……………………………. 
 
 
Checklist: 
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Questionnaire complete                         
 
Tablets returned 
 
Calendar returned 
 
Anthropometric measures  
 
Blood sample taken 
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Pill Record 
Name …………………………………………… 
Participant number ……………………………. 
 
 
 
If you took the pill on a particular day please mark the appropriate box with a tick. If 
you did not take a pill on a certain day please mark this with a cross.  
 
Week Sunday Monday Tuesday Wednesday Thursday Friday Saturday 
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
16        
 681
 
 
 مشاركة 042استبيان لمرحلة المسح ل 
 
 ...................................................................   الاسم:
 .......................        رقم الملف:
 ......................................................................................................... العنوان:
  ..............................................................  الهاتف:
 ___/___/_____ تاريخ اليوم:
 ........................................ تاريخ الموعد:
 
 العمر؟ -1
 16) أكثر من 7( 06-55) 6( 45 – 54) بين 5(44-53) بين 4( 43-52) بين 3سنة ( 42-81) بين 2( سنة 81) دون 1(
 ---/----/----تاريخ الميلاد: 
 
 هل تعاني المريضة من السكري النوع الثاني؟-2
 ) لا  2) نعم                        (1(
 
 %________ الحالية السكري  الهيموغلوبيننسبة 
     2م ________ مؤشر كتلة الجسم؟
     سم________________ طول المشاركة؟
    كجم ________________ لمشاركة؟وزن ا
 Ld/gm ___________ مستوى الكالسيوم
                            
  التالية؟ الطبية الحالات من أي تعاني المريضة من هل-3
  الكلوي  الفشل )1(
 )القولون  والتهاب كرون  مرض مثل(المعوي  متصاصالا سوء )2(
 والجار درقية الدرقية الغدة مرض )3(
 الدم كالسيوم فرط )4(
 الكبد أمراض  )5(
 
 ومن أي تاريخ بدأت تناولها؟ هل تتناول المريضة مكملات الفيتامينات؟ -4
  لا) 2( نعم) 1(
 تحديد يرجى بنعم، الإجابة كانت إذا
 الفيتامين....................... نوع 
 ية له..................التجار  والعلامة 
 
  هل تتناول المريضة فيتامين د؟ -5
  لا) 2( عمن) 1(
 تاريخ بدأ تناوله .................................. تحديد يرجى بنعم، الإجابة كانت إذا
  
 رقم المشاركة .............                          غير مناسبة   مناسبة
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 ورقة معلومات
هاد الأكسدة لدى النساء على مستويات السكر في الدم وإج 3عنوان المشروع: أثر مكملات فيتامين د
 النوع الثاني السعوديات اللاتي تعانين من من داء السكري 
 
 عزيزتنا المشاركة
بجامعة  التغذية فسيولوجيايقصد بهذه الورقة التي بين أيدينا موافِاتك بمعلومات عن المشروع المنفذ في إطار رسالة دكتوراة في مجال 
معلومات قيمة عما إذا كانت مكملات فيتامين د تساعد في التحكم في النمط الثاني من داء  مانشستر متروبوليتان؛ حيث تطرح الدراسة
 السكري أم لا.
 أدوات الدراسة:
 استبيانات •
  أسبوًعا من بدايتها، ويستغرق كل استبيان منهما  61تشمل هذه الدراسة إجراء استبيانين؛ أحدهما في بداية الدراسة والآخر بعد مرور 
 دقائق لاستكماله. 01-5حوالي 
 
 بيانات ذات صلة بالجسم •
 .بدايتها أسبوًعا من 61لأغراض الدراسة ستخضعين لقياس وزنك وطولك ومحيط الورك في بداية الدراسة وكذلك بعد مرور 
 
 عينات الدم •
 أسبوًعا من بدئها. 61يجرى فحص للدم قبل بدء الدراسة كجزء من البحث ويجرى نفس الفحص مجدًدا بعد مرور 
 
 مكملات فيتامين د •
لتدوين الأيام التي  أسبوًعا، ومن ثم فإنِك ستحتاجين 61هذه الدراسة من المشاركات تناول قرًصا واحًدا يومًيا لمدة  تتطلب
 تتناولين فيها المكملات وما إذا انقطعِت عن استخدام أي مكملات أخرى أم لا.
 السرية وحماية البيانات
عن إجابة بعض الأسئلة المطروحة أو الانسحاب من الدراسة كلية في أي وقت كان نضمن لك سرية في حالة رغبِتك في الامتناع 
معلوماِتك، فيما عدا بعض الاقتباسات التي يمكن استخدامها بتصريح منك دون الإفصاح عن هوية قائلها، فإذا كنِت راغبة في الاحتفاظ 
يها عن هويتك، فسوف تعامل المعلومات التي تدلي بها لنا معاملة مصادر بسرية معلوماتك، دون هذه الاقتباسات التي لا نفصح ف
البحث الأساسية التي تضاف للكتب وأبحاث الشبكة والمعلومات التي يقدمها الآخرون، فكافة المعلومات التي تدلين بها يجري التعامل 
هذه الدراسة، ولا يظهر اسمك أو أي معلومات تعريف معها وفًقا لقانون حماية البيانات ولا تستخدم لأي أغراض أخرى غير أغراض 
شخصية أخرى في ورقة المشروع التي تطرحها هذه الدراسة، كما أنها لن تشمل أي بيانات للتعريف بعنوانك؛ حيث أنه من المسموح 
 لفريق البحث وحده دون غيره الإطلاع على البيانات.
عبر  ذا كنت ترغبين في الحصول على أي معلومات إضافية بشأنها يرجى التواصلإذا كانت لديِك أي استفسارات تتصل بالدراسة أو إ
 البريد الإلكتروني الموضح أسفله، نشكر لك تعاونك معنا في هذا المشروع.
 
 ku.ca.umm.uts@05279901الاء حاتم قاضي         البريد الإلكتروني: 
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 نموذج الموافقة
 
         
  هل اطلعت على ورقة المعلومات؟
  
  هل تشعرين أنِك ملمة بموضوع المشروع؟
  
  هل تعلمين أنه سيطلب منِك تعبئة استبيان عن تاريخك الطبي؟
  
  هل تعرفين أنه سيؤخذ منك أربعة عينات دم؟
  
  هل تعرفين أن هذه العينات ستخضع للتحليل؟
  
  رفين أنه سيكون عليك تناول قرًصا واحًدا يومًيا؟هل تع
  
  هل تعلمين أنه بإمكانك الانسحاب من الدراسة في أي وقت ترغبين في ذلك؟
  
  هل ترحبين باستخدام عينة الدم الخاصة بك في مزيد من التحاليل؟
  
  إذا كنِت ترغبين في المشاركة يرجى التوقيع باسمك أدناه.
 
 ............................. على المشاركة في الدراسة البحثية المذكورة أعلاه.أوافق أنا 
وأقر بعلمي بالحفاظ على سرية كافة البيانات وفًقا لقانون حماية البيانات وبأنه بوسعي الانسحاب من الدراسة في 
 أي وقت أرغب فيه في ذلك.
 ..................التوقيع: ........................................
 التاريخ: ..........................................................
إذا كانت لديِك أي استفسارات بشأن مشروع هذا البحث يرجى التواصل مع الاء قاضي عبر البريد الإلكتروني: 
  ku.ca.umm.uts@05279901
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 استبيان المقابلة الأولى 
 خاص بالمشارك: -أ
 معلومات أساسية:  
العنوان: .......  رقم المشاركة:.......الاسم: ............................................................
 .........................................................................................................
 تاريخ اليوم: ___/___/_____ الهاتف: .............................................................. 
 ) أنثى2(   ذكر )1(هل أنت ذكر أم أنثى؟             -1
 كم عمرك؟ -2
 06-55) 6( 45 – 54) بين 5(44-53) بين 4( 43-52) بين 3سنة ( 42-81) بين 2( سنة 81) دون 1(
 16) أكثر من 7(
 ---/----/----تاريخ الميلاد: 
 هل أنت؟ -3
 ) أرملة4( ) مطلقة3( ) متزوجة2( ) عزباء1(
 ما هي الجنسية التي تحملينها؟  -4
  ) غير سعودية2( ) سعودية1(
 برجاء وضع دائرة على أعلى شهادة دراسية حصلت عليها؟ -5
) 5( ) شهادة الثانوية4) شهادة المتوسطة  (3ة الابتدائية      () الشهاد2( ) لم التحق بالمدرسة1(
  شهادة الدبلوم
 ) دراسات عليا7( ) شهادة البكالوريوس6(
 هل أنت؟ -6
 ) متقاعدة4( ) لا تعملين 3( ) موظفة2( ) طالبة1(
 هل أنِت حامل؟ -7
 ) لا2(  ) نعم1(
 التبغ يومًيا؟ هل تدخنين في الوقت الحالي أو تستخدمين أحد منتجات -8
 ) لا2(  ) نعم1(
 هل تتبعين حمية غذائية خاصة؟ -9
إذا كانت الإجابة بنعم يرجى تحديد الحمية الغذائية المتبعة    ) لا2(  ) نعم1(
 ........................
 أسئلة طبية ودوائية 
 منذ متى جرى تشخيص حالتك على أنها حالة داء السكري النوع الثاني؟ -01
 8) أكثر من 4(        سنوات 8-6) 3( سنوات    5-3) 2( سنتين       –واحدة  ) سنة1(
 سنوات
 هل أصيب أحد والديك أو أحد إخوتك أو أخواتك بداء السكري؟ -11
 ) لا2(  ) نعم1(
 091
 
 هل تعانين من أي مضاعفات لداء السكري؟ -21
 ) لا أعلم3(  ) لا2(  ) نعم1(
 م تفاصيل عن مضاعفات داء السكري التي تعاني منها:إذا كانت الإجابة بنعم برجاء تقدي
) إعتام عدسة العين الناتج عن الإصابة 3( ) الاعتلال العصبي2(   ) اعتلال الكلى1(
 بداء السكري 
 ) اعتلال الشبكية6(  (ارتفاع نسبة الدهون) دسليبيدميا) 5( ) أمراض القلب والأوعية الدموية4(
مضاعفات أخرى: 
 ....................................................................................................
 بصفة عامة، كيف تصفين حالة داء السكري لديك؟ -31
 ) لم تتغير3( ) أسوأ من ذي قبل2( ) أفضل من ذي قبل1(
  ي منها:تعان حالة كل على دائرةضع  التالية؟ الطبية الحالات من أي تعانين من هل -41
 )القولون  والتهاب كرون  مرض مثل( المعوي  متصاصالا سوء) 2  الكلوي  الفشل) 1(
والجار  الدرقية الغدة مرض) 3(
 درقية
 الكبد أمراض) 5( الدم كالسيوم فرط) 4(
 
 هل تتناول حالًيا أي أدوية موصوفة لك؟ يمكنك استخدام هذه الصور للتعرف على الأدوية -51
 كم مرة في اليوم؟ ةالجرع اسم الدواء
 الطعام وجبات مع مرتين ، جرام1واحد،  قرص الميتفورمين ،المثال سبيل على
   
 
  الفيتامينات؟هل تتناولين مكملات  -61
  لا) 2( نعم) 1(
 ية لهالتجار  والعلامةالفيتامين  نوع تحديد يرجى بنعم، الإجابة كانت إذا
 
 ؟اليوم تاريخ من أشهر 3 قبل الفيتامينات تناولت هل -71
  نعم) 2( لا) 1(
 ية لهالتجار  والعلامةالفيتامين  نوع تحديد يرجى بنعم، الإجابة كانت إذا
 الجسم قياسات  –ة خاص بالباحث -ب
                                   سم________________طول المشاركة؟  •
                                     2م ________حساب مؤشر كتلة الجسم  •
                                                                 %________الحالية  السكري  الهيموغلوبيننسبة  •
 
 تاريخ الاختبار ____/_____/______
 
 رقم المشاركة .............        غير مناسبة  مناسبة
 ________________ ؟ةوزن المشارك •
 كجم
 Ld/gm ___________مستوى الكالسيوم  •
 
 
 
 
 
 
 ________________ ؟ةوزن المشارك •
 كجم
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 استبيان المعلومات للمرحلة الثانية
 (المقابلة الثانية)
 خاص بالمشاركة: -أ
 معلومات أساسية
 رقم المشاركة:................ الاسم:........................................................
 ....................العنوان:......................................................................................................
 الهاتف:............................................................ تاريخ اليوم: ....../....../..........
 
ات التي لم تتناولين فيها أقراص مر عدد ال كم ،بانتظام الأدوية تناول الصعب من نحن نعلم أنه -1
 الفيتامين؟ 
مرات أو أكثر في  3) 3( رتان في الأسبوع) م2( ) مرة في الأسبوع1(
 الأسبوع
 ) لم أتناولها مطلًقا4(
  كم عدد المرات التي لم تتذكرين فيها تسجيل تناول أقراص الدواء الخاص بك في المفكرة؟ -2
مرات أو أكثر في  3) 3( ) مرتان في الأسبوع2( ) مرة في الأسبوع1(
 الأسبوع
 ) لم أسجلها مطلًقا4(
 ،كذلك الأمر كان وإذا الفيتامينات، في تناول مكملات بدأت أن منذلك  جديدة أدوية أي وصف تم هل -3
 ؟الأدوية الموصوفة تحديد يرجى
 ) نعم2( ) لا 1( 
  تحديدال يرجى بنعم، الإجابة كانت إذا
.............................................................................................................
.............................................................................................................
 ..........................................
 هل توقفتين عن تناول أية أدوية موصوفة منذ أن بدأتين  في تناول الأقراص؟ -4
 ) نعم2(  ) لا1(
 إذا كانت الإجابة نعم، يرجى التوضيح 
.............................................................................................................
.............................................................................................................
 ..........................................
 هل تغيرت جرعات الأدوية التي تتناوليها منذ أن بدأتين في تناول الأقراص؟ -6
 ) نعم2(  ) لا1(
 إذا كانت الإجابة نعم، يرجى التوضيح 
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.............................................................................................................
.............................................................................................................
 ..........................................
 هل تناولتين مكملات فيتامين بخلاف تلك المقَدمة أثناء الدراسة؟ -6
 ) نعم2(  ) لا1(
 إذا كانت الإجابة نعم، يرجى التوضيح
.............................................................................................................
.............................................................................................................
 ..........................................
الأخيرة؟ ضعي دائرة حول أي حالة تعاني  61هل عانيتي من أي من الحالات الطبية التالية في الأسابيع الـ -7
 منها.
) مرض الغدة الدرقية 3) سوء الامتصاص المعوي (مثل مرض كرون، والتهاب القولون)  (2) الفشل الكلوي (1(
) أمراض أخرى، يرجى 5وم الدم () فرط كالسي4(
تحديدها......................................................................................................
.............................................................................................................
 ................................  .........
 هل أنِت حامل؟ -8
 ) نعم2(  ) لا1(
 هل بدأتي أية ِحميات غذائية خاصة؟ -9
 (نعم)  ) لا1(
 إذا كانت الإجابة نعم، يرجى التوضيح
.............................................................................................................
.............................................................................................................
 ..........................................
بصفة عامة، كيف تصفين حالة داء السكري خلال  -01
 الأخيرة؟ 61الأسابيع الـ
من ذي قبل) أسوأ 2( ) أفضل من ذي قبل1(
 ) لم تتغير3( 
 هل هناك تشخيص لأي حالات أخرى لديكي؟ -11
..........................................................
 ...................................................
..........................................................
 ...................................................
 
 قياسات الجسم -خاص بالباحث -ب
 كجم ________________ ؟ةوزن المشارك •
 
 
 كجم ________________ ؟ةوزن المشارك •
 
 
 كجم ________________ ؟ةوزن المشارك •
 
 
 كجم ________________ ؟ةوزن المشارك •
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                                   سم________________طول المشاركة؟  •
  2م ________حساب مؤشر كتلة الجسم  •
 _____________ sEGA ال معدل •
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